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Summary / Resumen 
  
  
SUMMARY 
Testicular cancer is a frequently occurring disease among adult males, and it accounts for 
1-2% of all male tumors. It can be classified into different types of cancer: germ cell tumors (GCT), 
which represent 98% of all cases, and tumors involving the gonadal stromal tumors and secondary 
tumors of the testes. The incidence of Testicular Germ Cell Tumors (TGCTs) has been increasing 
for the past decades, although the etiology of the disease and the reasons of its increased incidence 
remain unknown. Environmental factors, in particular exposure to endocrine disruptors during 
embryogenesis and perinatal life are suspected culprits. It is likely that genetic factors also play an 
important role in TGCT formation, as the estimated heritability, 48.9%, is the third highest among 
all cancers, and the Familial Testicular Germ Cell Tumor (FTGCT) risk is 2-fold higher than what 
is typical for more common cancers such as breast, colorectal and prostate cancer.  
Several candidate gene approaches failed to identify high susceptibility genes. In fact, in 
the last years scientists have come to believe that a polygenic model fits better with the genetic 
landscape of the disease, although the idea of polygenic susceptibility does not fit in with a history 
of familial aggregations in a disease. Due to the absence of information about the genetic basis of 
this disease, our objective was to identify high/moderate or low susceptibility genes using whole 
exome sequencing (WES) and case-control studies considering both monogenic and polygenic 
models of inheritance. These studies will help to increase our knowledge about the genetic basis of 
the disease and may have a significant impact on its prevention, early diagnosis and a possible 
treatment. 
The hypothesis of the monogenic model was tested using a pipeline previously described 
by our group, while the polygenic model was studied by performing family-based association tests 
in which we evaluated the level of additive and cumulative effects our variants could have in the 
familial aggregation of the disease. DNA of a group of 19 families (71 individuals) was sequenced 
with an Illumina HiSeq 2000 sequencer. Based on the analysis assuming both patterns of 
inheritance, a total of 120 candidate variants were evaluated in the case-control study performed in 
391 sporadic cases and 382 healthy Spanish controls. In order to increase the size sample, we used 
data from the public database of the Spanish Center for Biomedical Research on Rare Diseases 
(CIBERER), which contains WES data of 788 unaffected individuals, and to perform statistical 
analysis. In this discovery analysis, 27 variants gave significant results and two of them (located in 
the VNN1 and SLC22A16 genes, which are both involved in spermatogenesis) were later on 
replicated in a large series studied in the English population. Moreover, the variant of the SLC22A16 
gene appears to be specifically associated with the development of Seminoma germ cell tumors. 
 In summary, our results present two new susceptibility risk genes whose variants are 
potential candidates for being associated with the development of familial testicular cancer. 
 
 
  
RESUMEN  
El cáncer de testículo es una enfermedad frecuente en hombres adultos, representa en torno 
al 1-2% de todos los tumores masculinos. Existen diferentes tipos de cáncer testicular: los tumores 
germinales que representan el 98% de todos los casos, los tumores estromales y secundarios. La 
incidencia de tumores germinales de testículo se ha incrementado en las últimas décadas, aunque 
su etiología y causas son desconocidas. Los factores ambientales, y en particular la exposición a 
factores endocrinos durante el proceso de embriogénesis en la etapa perinatal, son los más señalados 
como responsables. Además, es probable que los factores genéticos, desempeñen también un papel 
importante en la formación de este tipo de tumores, ya que la herencia estimada es del 48.9%, la 
tercera más alta de todos los canceres, y el riesgo de los casos familiares, es 2 veces superior al de 
los canceres más comunes, como mama, colon o próstata. 
 Varios estudios de aproximación a genes candidatos han fracasado en la identificación de 
genes de alta susceptibilidad. De hecho, durante los últimos años se ha fomentado la idea de que un 
modelo poligénico sería el que mejor se ajustaría para explicar el entorno genético de la enfermedad, 
aunque este modelo en principio no contempla una posible agregación familiar. La carencia de 
información acerca de las bases genéticas de esta enfermedad, es la razón por la que nos planteamos 
el estudio para la identificación de genes de alta, moderada y baja susceptibilidad mediante la 
técnica de secuenciación masiva de exoma y estudios de asociación de caso control, para ambos 
modelos de herencia monogénico y poligénico. Estos estudios nos ayudaran a mejorar nuestro 
conocimiento acerca de las bases genéticas de la enfermedad, así como para la prevención, 
diagnóstico temprano y posible tratamiento de los pacientes. 
 La hipótesis del modelo monogénico fue analizada mediante un sistema de filtrado descrito 
previamente por nuestro grupo, mientras que, para el estudio del modelo poligénico, se utilizaron 
estudios de asociación basados en patrones familiares, en los que evaluamos el efecto aditivo y 
acumulativo que nuestras variantes podían tener sobre la agregación familiar. Un grupo de 19 
familias (71 individuos) fue secuenciado con el HiSeq2000. Del análisis de ambos patrones de 
herencia se obtuvieron un total de 120 variantes candidatas que se estudiaron en el ensayo de caso 
control realizado en 391 casos esporádicos y 382 controles sanos españoles. Con el fin de 
incrementar nuestro tamaño muestral, decidimos utilizar la información de la base de datos pública 
española del Centro de Investigación Biomédica en Red Enfermedades raras (CIBERER,) que 
contiene datos de secuenciación de exoma de 788 individuos, y llevar acabo los análisis estadísticos. 
De este primer estudio, 27 variantes resultaron significativas, pero de estas, solo de dos se replicaron 
los resultados en población inglesa. Las dos variantes, se encuentran en los genes VNN1 y 
SLC22A16, ambos implicados en el proceso de espermatogénesis, y una de ellas asociada 
específicamente al diagnóstico clínico de tumor germinal seminomatoso. 
 En conclusión, nuestro estudio demuestra que existen dos nuevos genes de susceptibilidad 
cuyas variantes son posibles candidatas de conferir riesgo al desarrollo del cáncer familiar testicular 
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1. DEVELOPMENT OF THE TESTES 
 
Sexual reproduction in mammals involves two sexes, each of which is characterized by sex-
specific anatomical and genetic features determined by an individual’s chromosome complement 
(specifically the presence or absence of the Y chromosome). Once gonads are formed, they start 
producing sex-specific hormones, androgens in male and estrogens in female individuals, to 
determine the development of secondary sexual characteristics. In addition, the structure of these 
two distinct organs, as well as the type of sex hormones produced, influences the production and 
maturation of germ cells (sperm and oocytes) (Eggers et al., 2014). 
1.1 Gonadal development  
Embryonic development of the gonads is controlled by a complex network of gene 
products, both in time and space, in which two phases can be distinguished. The initial phase is 
characterized by the emergence of the so-called indifferent, bipotential gonad, or genital ridge, 
which is identical in males and females (Wilhelm et al., 2007). The second phase is the development 
of the organs, a testis or an ovary, which is triggered solely by the expression and proper function 
of the testis-determining gene SRY (sex-determining region Y). 
The primordial germ cells (PGCs) represent the initial manifestation of the germ line in 
both sexes (Figure 1). They are the only cells in the body that can exchange and transfer hereditary 
information as gametes, and can undergo both types of cell division (mitosis and meiosis), which 
require different and strict regulation of the cell cycle and the DNA repair system. The regulation 
of gene expression differs as well, including waves of epigenetic activation and silencing, and a 
final selective chromosomal condensation specifically during the process of spermiogenesis 
(Rajpert-De Meyts et al., 2006). 
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Figure 1. Schematic representation of normal embryonic development and origin of the 
germ-cell lineage. The primordial germ cells (PGCs) originate in the epiblast, migrate to the 
genital ridge, and it is there where they are referred to as gonocytes. They differentiate either to 
pre-spermatogonia or oocytes. Embryonic stem cells (ESCs) are derived from the inner cell mass, 
whereas embryonic germ cells (EGCs) can be isolated from PGCs until day 12.5 of development. 
The ESCs show a biparental pattern of genomic imprinting, whereas in EGCs this is erased. During 
spermatogenesis, the paternal pattern of genomic imprinting is established, whereas the maternal 
pattern is formed during oogenesis. The timing of meiotic I arrest is different between male and 
female germ cells. (Oosterhuis et al., 2005) 
1.2 Genetic differentiation program 
Approximately during the third week of embryonic development in humans, the PGCs 
migrate from the yolk sac along the hindgut to the genital ridge (Molyneaux et al., 2004) (Figure 
2). These cells are characterized by their morphology and their protein profile, including alkaline 
phosphatase, OCT3/4 (Octamer binding transcription factor 3/4) , NANOG (Nanog Homeobox), 
and LIN28 (Protein Lin 28) (Schöler et al., 1990) (Millán et al., 1995). Around the fifth week of 
development they arrive at the genital ridge, where they start to interact with the developing 
supportive cells. The survival, movement and proliferation along the midline of the body is 
supported by and dependent upon an interaction between the tyrosine kinase receptor KILG (Kit 
Ligand), which is present on the surface of PGCs, and its ligand c-kit (KIT proto-oncogene receptor 
tyrosine kinase) and the stem cell factor (SCF), which is produced by the surrounding tissues. 
Once inside the genital ridge, the PGCs lose their motility and begin to aggregate with one 
another, but they continue to proliferate within the indifferent gonad and maintain their 
bipotentiality until 13 days post coitum (Wilhelm et al., 2007), when sex chromosome 
determination starts.  
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Figure 2. A. Schematic drawing of a 3-week-old embryo showing the PGCs in the wall of 
the yolk sac, close to the attachment of the allantois. B. Migration path of the PGCs along the wall 
of the hindgut and the dorsal mesentery into the genital ridge. (Reproduced with permission from 
Langman J, Sadler TW. Langman's Medical Embryology. 8th ed. Lippincott Williams & Wilkins; 
2000.) 
Testis development is initiated by expression of the SRY gene (Sinclair et al., 1990) (Figure 
3). At this stage, the primordia of the gonads, adrenals, kidneys and reproductive tract are formed 
by  the expression of several genes which are considered crucial for subsequent development and 
normal sexual dimorphism (Morais da Silva et al., 1996)(Sekido et al., 2009).  
 
 
 
Figure 3. Determination of sexual organ development. Generally, SRY activates SOX9 
(SRY-related HMG box gene 9) through binding to its enhancer TES (Tesin LIM domain). SOX9 
can also self-activate through binding to TES. It then triggers the secretion of FGF9 (Fibroblast 
growth factor 9) and PGDS (Prostaglandin D synthase), which leads to testis formation. FGF9 and 
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PGDS, in turn, upregulate SOX9 expression. RSPO1(R-spondin1) and WNT4 (Wnt family member 
4) are both ligands for canonical Wnt signaling. RSPO1 synergizes with WNT4 to activate CTNNB1 
and promote ovary development. CTNNB1can inhibit SOX9 signaling to prevent testis formation. 
The antagonists DKK1(dickkopf WNT signaling pathway inhibitor 1), DMRT1 (Doublesex and mab 
related transcription factor 1) and SFRP can inhibit the RSPO1/WNT4/CTNNB1 pathway and 
promote testis determination (Dong et al., 2015). 
Expression of both SRY and its related downstream target SOX9 is restricted to somatic cell 
precursors that give rise to the epithelial Sertoli cell lineage. Sertoli cells are thus the first testis-
specific cell lineage to arise in the XY gonad. Establishment of the Sertoli cell lineage is critical for 
testis morphogenesis, as it is considered capable of regulating all subsequent events in testis 
development such as morphogenesis by organizing testis cord formation, establishing testis 
vasculature, and inducing differentiation of other male-specific lineages including peritubular 
myoid cells and fetal Leydig cells (Svingen et al., 2013).  
1.3 Differentiation during testis organogenesis  
The undifferentiated male gonad develops into the testis toward week 7 of development, 
due to the XY genetic constitution. This process is schematically shown in Figure 4. 
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Figure 4. Testis differentiation process. The primary sex cords, proliferating from the coelomic 
epithelium, condense and extend into the medulla of the gonad. There, the cords branch, their deep 
ends anastomose, and form the rete testis. The prominent sex cords become the seminiferous cords 
which soon lose their connections with the germinal epithelium because of the development of a 
thick fibrous capsule, the tunica albuginea. This is a layer of connective tissue that is interposed 
early between the coelomic epithelium and the rest of the gland. This compartmentalizes the gland 
and closes off the seminiferous ducts into testes cords. The seminiferous cords then develop into the 
seminiferous tubules, whose deep portions narrow to form the tubuli recti, which converge on the 
rete testis. They become separated by mesenchyme, which gives rise to the interstitial cells of 
Leydig. Here, the androgenic hormones are secreted and help in the differentiation of the genital 
tract and the external genital organs. The walls of the seminiferous tubules, as a result of their 
cellular duality of origin, are composed of 2 types of cells: supporting cells of Sertoli, derived from 
the germinal epithelium, and the spermatogonia, derived from the PGCs. In later development, the 
germinal epithelium flattens to form the mesothelium on the surface of the testis and the rete testis 
becomes continuous with the 15 to 20 adjacent persistent mesonephric tubules. The persistent 
mesonephric tubules, after regression of the mesonephric (Wolffian) body, participate in the 
formation of the excretory tracts of the testis, forming the efferent ductules that open into the 
adjacent mesonephric duct which finally becomes the ductus epididymidis. 
http://discovery.lifemapsc.com/library/review-of-medical-embryology/chapter-99-development-
of-the-testis. 
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1.4 Functions 
1.4.1 Reproductive system 
Shortly after the initial differentiation of the testis in the male fetus, PGCs differentiate into 
gonocytes. Next, they are transformed into fetal spermatogonia from 10 to 22 weeks post 
conception, and these fetal spermatogonia give rise to prospermatogonia which, after birth, give 
rise to spermatogonial stem cells (SSCs) in the seminiferous epithelium of the adult testis 
(Vlajković et al., 2012). SSCs are the specific PGCs that undergo the differentiation process which 
leads to the formation of sperm (Sutton, 2000) (S. R. Singh et al., 2010) (Vlajković et al., 2012).  
The process of spermatogenesis is outlined in Figure 5. The Sertoli cells that participate in 
this process are specialized cells that provide the nutritional and architectural support required for 
adult germ cell development. They play an important role in the formation of the SSC niches by the 
secretion of specific growth factors, and inducing output of secreted factors from Leydig cells and 
other interstitial cell populations (Oatley et al., 2011). 
 
 
Figure 5. Spermatogenesis Process. The developmental process includes mitotic, meiotic and 
postmeiotic phases. Two cell divisions occur between the meiotic and the post-meiotic phases 
without chromosomal replication, resulting in spermatid nuclei that contain a haploid amount of 
DNA (Eddy, 1998). 
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1.4.2 Endrocrine system 
The importance of these organs in the endocrine system derives from the production of two 
principal hormones, testosterone and follicle stimulating hormone (FSH), which are considered to 
be the primary hormonal regulators of spermatogenesis, by controlling the generation of the 
gametes and the production and controlled release of sex steroids (Schlatt et al., 1997) (Sikka et al., 
2008). 
Testosterone is the classical hormone responsible for the androgen-dependent functions in 
the entire organism. It is secreted by the Leydig cells between the seminiferous tubules and 
stimulated by luteinizing hormone (LH) in the anterior pituitary (Henderson et al., 1988) (Figure 
6). FSH is a peptide hormone produced in the anterior lobe of the pituitary. It binds to receptors on 
the Sertoli cell surface to activate signal transduction processes. Moreover, it influences Sertoli cell 
replication during fetal and neonatal life, and supports the capacity of spermatogenesis by 
establishing the Sertoli cell population, while androgens (mostly testosterone) affect the functional 
completion of meiosis and postmeiotic sperm differentiation and maturation (Sutton, 2000). 
 
Figure 6. Regulation of Testosterone Production. Gonadotropin-releasing hormone (GnRH) 
activates the anterior pituitary to produce LH and FSH, which in turn stimulate Leydig cells and 
Sertoli cells, respectively. The system is a negative feedback loop because the end products of the 
pathway, testosterone and inhibin, interact with the activity of GnRH to inhibit their own production 
(Schlatt et al., 1997). 
 
The hypothalamus and the pituitary gland in the brain integrate external and internal signals 
to control testosterone synthesis and secretion. The regulation begins in the hypothalamus. Pulsatile 
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release of a hormone called Gonadotropin-releasing hormone (GnRH) from the hypothalamus 
stimulates the endocrine release of hormones from the pituitary gland. Binding of GnRH to its 
receptors on the anterior pituitary gland stimulates release of the two gonadotropins: LH and FSH. 
These two hormones are critical for reproductive function in both men and women. In men, FSH 
binds predominantly to the Sertoli cells within the seminiferous tubules to promote spermatogenesis 
and also stimulates the Sertoli cells to produce hormones called inhibins, whose function is to inhibit 
FSH release from the pituitary, thus reducing testosterone secretion. These polypeptide hormones 
correlate directly with Sertoli cell function and sperm number (Schlatt et al., 1997)(Svingen et al., 
2013). In men, LH binds to receptors on Leydig cells and upregulates the production of testosterone 
(Omole et al., 2006), which in consequence promotes spermatogenesis indirectly through the 
androgen receptors located on the surface of the Sertoli and peritubular cells (Walker, 2011). 
 
2. TESTICULAR CANCER 
 
2.1 Testicular germ cell tumors (TGCT).  
The complexity of these tumors derives from the characteristics of the germ cell tumors 
(GCTs) (Figure 7). The clinical course of testicular GCTs (TGCTs) depends on factors such as sex 
and age of the patient, anatomical site, spread of the tumor and histological type. However, their 
histological heterogeneity and seemingly unlimited ability to differentiate into all somatic tissues 
(totipotency) makes their classification extremely difficult (Rajpert-De Meyts et al., 2006). 
Figure 7. The genomic features of TGCTs, summarized using a timeline approach. CNV (copy 
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number variation); FRR (familial relative risk); i(12p) (12p isochromosome); ITGCNU 
(intratubular germ cell neoplasia, unclassified); m (mutant); wt (wild-type) (Litchfield et al., 
2016b). 
Evidence supports the idea that TGCT develops from PGCs or gonocytes (Figure 8), with 
tumor initiation described in utero, via a preinvasive stage termed ITGCNU (intratubular germ cell 
neoplasia, unclassified) or CIS (carcinoma in situ) that is located in the spermatogonial niche of the 
seminiferous tubule of the adult human testis (Litchfield et al., 2016b).  
Figure 8. Schematic illustration of normal male germ cell development and its possible 
transformation to CIS. ESCs are derived from the inner cell mass of a blastocyst. Prolonged 
culturing often leads to an accumulation of chromosomal aberrations, especially gain of material 
from chromosomes 12p and 17q. During early development, PGCs migrate to the gonadal ridge 
and develop along the germ cell lineage (gonocytes). CIS cells are proposed to arise when 
gonocytes fail to differentiate to pre-spermatogonia and fail to undergo apoptosis. These 
gonocytes or pre-CIS cells lie dormant in the testis through infancy, while genomic aberrations 
may occur; at puberty, when testosterone levels increase, they start to proliferate and genomic 
aberrations accumulate, especially of chromosome 12p and 17, eventually resulting in the 
formation of an overt tumor (Rajpert-De Meyts et al., 2006). 
 ITGCNU transforms into the two main TGCT histological subtypes: seminomas and non-
seminomas (Litchfield et al., 2016b). The fact that the microenvironment plays a defining role in 
the genomic instability of the ESC could indicate that the same is happening during the formation 
of CIS cells. It is quite possible that a disturbance or disruption of the original niche of gonocytes 
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may have led to an imbalance between proliferation and differentiation, resulting in genetic 
instability and neoplastic transformation. As time passes, the CIS cells also develop through 
selection, eventually resulting in the progression to a malignant seminoma or non-seminoma 
(Kristensen et al., 2008).  
2.2 Types of TGCT 
TGCT is a histologically heterogeneous disease due to the pluripotency of its origin in the 
germ cell line at a period of time in which oncogenic mutations could be generated and accumulated 
before a rapid invasive growth after or during puberty (Pyle et al., 2016). TGCT can be divided into 
two major classes: seminomas and non-seminomas. Seminomas retain a CIS-like phenotype and 
germ cell features; they are homogenous tumors that resemble undifferentiated gonocytes and 
account for 55% of TGCTs with a peak incidence between ages 35 to 39. On the other hand, the 
more pluripotent embryonic stem cell (ESC)-like non-seminomas or non-seminoma germ cell 
tumors (NSGCTs) are heterogeneous tumors resembling embryonic (e.g., embryonal carcinomas 
and teratomas) as well as extraembryonic tissues (e.g., choriocarcinomas and yolk sac tumors), and 
make up around 44% of TGCTs. They are generally more aggressive and present a younger age at 
diagnosis of 25-29 years. This is reflected in their dysregulated differentiation into embryonal 
carcinomas, teratomas, choriocarcinomas, and yolk sac tumors. Tumors containing both NSGCTs 
and seminomas are known as mixed tumors and are classified as a subtype of NSGCTs (Reuter et 
al., 2005) (Kristensen et al., 2008). 
As it is suggested that germ cell neoplasia has a fetal origin, it would give rise to all 
seminomas and non-seminomas of adolescents and young adults (Skakkebaek, 1972), but not to 
infantile non-seminomas or spermatocytic seminomas (Oosterhuis et al., 2005). In contrast to the 
tumors of adolescents and young adults, infantile non-seminomas appear to arise from either 
embryonic stem cells or early PGCs  (Kristian Almstrup et al., 2006). Spermatocytic seminomas, 
in comparison, arise from pre-meiotic germ cells during the expansion of the spermatogonium 
(Waheeb et al., 2011). Both infantile non-seminomas and spermatocytic seminomas are thought to 
be etiologically distinct from the more common TGCTs that occur in young men and adolescents.  
2.3 Epidemiology 
The occurrence of TGCT presents a peak incidence in young adulthood: 84% of TGCTs 
occur among men between the ages of 15 and 44 years, 15% occurs in men aged 45 years and older, 
while only 1% occurs in boys less than 15 years of age. The latest estimations indicate that 
Testicular Cancer (TC) survival is >95% in the most affluent populations; corresponding mortality 
rates are <0.2 per 100,000, suggesting that TC deaths are almost completely avoidable (Znaor et 
al., 2014). 
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Figure 9. International variation in estimates of national age-standardized TC incidence rates 
(Znaor et al., 2014). 
As we mentioned before TC is relatively rare, with >52,000 new cases and almost 10,000 
deaths estimated worldwide for 2008; the disease makes up approximately 1% of all new male 
cancer cases globally. 
Based on the cancer registry data, the highest incidence rates were observed in Norway (9.9 
per 100,000), Denmark (9.4 per 100,000), and Switzerland (9.2 per 100,000), but also in Slovenia 
(8.5 per 100,000) and in Southern Europe (Figure 9). In the United States, a greater than fivefold 
difference was observed between whites (6.2 per 100,000) and blacks (1.2 per 100,000). Threefold 
variations were observed among the populations of Central America and South America (1.2–4.4 
per 100,000), while the incidence rates across Asia were more homogeneous (0.5–1.3 per 100,000). 
The exception is Israel, with substantially higher incidence rates (4.0 per 100,000) than its 
geographic counterparts. 
 
Figure 10. International variation in estimates of national age-standardized TC mortality 
rates, all ages (Znaor et al., 2014). 
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TC mortality shows a different global pattern, with higher rates estimated in low- and 
middle-income countries (0.5 per 100,000) than in high-income countries (Figure 10). The highest 
mortality rates were observed in Chile (1.1 per 100,000), Latvia (0.9 per 100,000), and Central 
European and Eastern European countries (0.5–0.9 per 100,000). The lowest mortality rates were 
observed in Asia. Mortality rates were also very low (0.2 per 100,000) in some higher-incidence 
areas, such as Australia, the United States, and some Northern European countries (United 
Kingdom, England and Wales; Sweden; Finland; and Iceland). 
The incidence to mortality ratios ranged from 26 to 1 in Northern Europe to approximately 
2 to 1 in south-eastern Asia, south-central Asia, and Africa. In almost all populations studied, the 
increase in incidence has been found to be more consistent with a birth-cohort effect than with a 
calendar-period effect (Bergstrom et al., 1996)(Ekbom et al., 1998)(McGlynn et al., 2003). Overall, 
the pattern of increasing incidence only among specific ethnic and/or racial groups argues that there 
has either been an ethnic-specific change in a risk factor or that there has been a global change in a 
risk factor that only affects genetically susceptible men. However, it is a fact that during the past 
few decades there has been a significantly increasing trend in germ cell tumors all over the world, 
and the changes in incidence have occurred so fast that only environmental factors can explain this 
development (Skakkebaek et al., 2016). 
2.4 Risk factors 
Molecular and clinical observations are consistent with the first oncogenic transformation 
step occurring during fetal development (Figure 11). But, despite extensive epidemiological studies 
including maternal gestational or environmental exposures, to date no exogenous risk factors have 
been consistently associated with TGCT. Most studies have been negative (non-genitourinary organ 
malformations and dysmorphology), or not consistently repeatable (history of orchitis), while others 
identified cryptorchidism, subfertility, testicular microlithiasis, hydrocele, and increased adult 
height to be consistently associated with TGCT risk (McGlynn et al., 2012). In contrast, twin and 
family studies provided the most robust evidence for inherited genetic susceptibility risk (Litchfield 
et al., 2015f). 
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Figure 11. Hypothesis of how both genetic and environmental factors may cause dysgenesis of 
the fetal testis and result in a range of symptoms, including germ cell neoplasia and Testicular 
Germ Cell Cancer (TGCC) in adult males and gonadoblastomas in children with disorder of 
sexual development (DSD), cryptorchidism, hypospadias and infertility. It may also lead to 
reduced anogenital distance (Skakkebaek et al., 2016). 
 Both genetic (SRY-SOX9) and hormonal (androgens) regulation is necessary in mammals 
for the development and organization of the male reproductive tract. If this delicate process is 
disturbed, either by genetic abnormalities or by chemical exposure, reproductive tract disorders can 
result in cryptorchidism, hypospadias, impaired spermatogenesis, microlithiasis or TC 
(Skakkebaek, et al., 2001). The increased incidence of these abnormalities has led to a theory of 
testicular dysgenesis syndrome (TDS). Cryptorchidism and hypospadias are fairly frequent 
congenital abnormalities that may occur as isolated disorders or may be associated with other 
congenital syndromes. Cryptorchidism results from undescended testis, meaning that 1 or both 
testicles do not move down into the scrotum before birth. Men with this condition have an increased 
risk of developing TC, associated with approximately 10% of TGCT (Møller et al., 1998)(Ferguson 
et al., 2013). Hypospadias is a birth defect (congenital condition) in which the opening of the urethra 
is on the underside of the penis instead of at the tip. The urethra is the tube through which urine 
drains from the bladder and exits the body (Welsh et al., 2008). Moreover, impaired 
spermatogenesis is an alteration that produces male infertility and involves some of the semen 
parameters (Wohlfahrt-Veje et al., 2009)(Rajpert-De Meyts et al., 2006). Finally, microlithiasis, 
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which is a relatively common condition that represents the deposition of multiple tiny calcifications 
throughout both testes, is seen in up to 0.6% of patients undergoing scrotal ultrasound (Reuter et 
al., 2005)(Ye et al., 2012). 
 In addition, several other congenital disorders have been studied with an eye to the etiology 
of disease states: congenital adrenal hyperplasia, androgen insensitivity syndrome (Västermark et 
al., 2011), Klinefelter syndrome, and hypothalamic hypogonadism may also result from 
chromosomal or genetic abnormalities or may be induced by chemical exposure during fetal 
development (Omole et al., 2006) (Sikka et al., 2008). 
 
3. GENETIC LANDSCAPE 
 
3.1 Family and Twin Studies  
Family history is one of the strongest known risk factors for TGCT, and relatively high as 
compared to other cancer types. As documented across multiple populations, sons of men with 
TGCT have a four- to six fold risk of TGCT (versus generally threefold or below in other cancer 
types), and brothers an eight- to tenfold risk of TGCT (versus sixfold or below in other types) 
(Hemminki et al., 2004). The higher rate in brother vs brother than in father vs son may reflect a 
complex genetic and shared environmental risk, or an X-linked or autosomal recessive component 
of complex inheritance. TGCT has an estimated heritability that ranks as the 3rd highest among all 
cancers (Czene et al., 2002). Compared with most malignancies which have familial relative risks 
between 1.5-2.5,  retrospective cohort studies with various designs have also demonstrated that sons 
of men with TGCT have a 4 to 6-fold increased risk of TGCT versus the general population, while 
brothers of affected men have an 8 to 14-fold increased risk (Pathak et al., 2015). These risks 
increase to 37-fold and 76-fold in dizygotic and monozygotic twins, respectively (Swerdlow et al., 
1997). The heritability of TGCT recently was estimated to be 48.9% using the Swedish population 
family-cancer database (over 15 million individuals born in Sweden after 1937), and 38% using 
genomic estimates drawn from 1,000 UK patients previously included in genome-wide association 
studies (GWAS) (McGlynn et al., 2012)(Litchfield et al., 2015f) (Mucci et al., 2016). Altogether, 
it can be concluded that the heritability of TGCT is estimated to be 35%–50%, with the higher 
population-based estimate reflecting multiple components beyond the genetic, or the “missing 
heritability”, that includes unmeasured environmental factors, epigenetic effects, or other factors 
such as imperfect linkage disequilibrium between genotypes, single-nucleotide polymorphisms 
(SNPs), and casual variants.  
The currently known TGCT risk loci collectively explain ~25% of the excess sibling risk 
of TGCT. Accordingly, multiple additional TGCT susceptibility loci are likely to exist and remain 
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to be identified (Litchfield et al., 2016b). It is supported by a genome-wide complex trait analysis 
conducted for TGCT, that at least 50 additional risk SNPs with an odds ratio of ~1.2 are likely to 
exist, or, more plausibly, with a trailing set of effect sizes (OR = 1.01–1.20) the undiscovered set 
could be considerably larger (Litchfield et al., 2015b)(Litchfield et al., 2015f). Thus, the prevailing 
evidence supports a genomic architecture of TGCT predisposition dominated by multiple common 
risk loci perturbing a consistent set of biological pathways.  
3.2 Approaches to find out the genetic predisposition to TGCT  
Attempts to elucidate the genetic risk factors initially involved linkage studies, but this 
essentially yielded no results, indicating that a single high-penetrance risk locus was unlikely to 
exist (Rapley et al., 2000)(Crockford et al., 2006). The only locus identified through linkage 
analysis was at Xq27, found through linkage studies of 134 families with a family history 
compatible with an X-linked inheritance pattern (Rapley et al., 2000). However, a larger 
independent follow-up analysis (237 families) did not confirm the association (Crockford et al., 
2006), and it has not been further pursued. The first independently validated candidate locus was  a 
1.6 Mb deletion in chromosome Y (designated gr/gr), which confers a twofold elevation in TGCT 
risk and was based on the co-occurrence of TGCT and subfertility (Nathanson et al., 2005). 
However, the frequency of the gr/gr deletion was quite low, present only in 3.0% of familial TGCT 
cases (13/431), versus 2% of TGCT without a family history (28/1376), and 1.3% of unaffected 
males (33/2599), meaning that it accounts for only ~0.5% of the total genetic (excess familial) risk 
of TGCT development (Nathanson et al., 2005). The gr/gr region, within the AZFc (azoospermia 
factor) region, contains genes of the BPY2 (Nathanson et al., 2005), CDY1, and DAZ families (Kratz 
et al., 2010), all of which are relevant to germ cell maturation and development, underscoring the 
common genetic links tying TGCT to germ cell development (Pyle et al., 2016). Two candidate 
genes in which inactivating mutations were found in association with TGCT predisposition, similar 
to those found in other hormonal neoplasms, have been identified: PDE11A (Horvath et al., 
2009)(Azevedo et al., 2013) and DND1(Linger et al., 2008).  
Afterwards, GWAS revolutionized the knowledge of the role of genetic variation in TGCT 
predisposition. Currently, ten GWAS studies of TGCT have been published, including meta 
analyses of previously published and unpublished populations (Rapley et al., 2009) (Kanetsky et 
al., 2009a) (Turnbull et al., 2010)(Kanetsky et al., 2011)(Schumacher et al., 2013) (Ruark et al., 
2013a) (Chung et al., 2013)( Litchfield et al., 2015a) (Litchfield et al., 2015d) (Kristiansen et al., 
2015). These studies identified 25 independent loci or genomic regions with specific alleles 
associated with TGCT. The strength of these associations is greater than for other cancers, with all 
odds ratios over 1.2, including the strongest GWAS signal thus far reported in any cancer (KITLG 
locus, per allele odds ratio [OR] >2.5) (Greene et al., 2011).  
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GWAS of TGCT has revealed multiple variants, many of which are in introns or in close 
proximity to genes with strong biological plausibility to be associated with the disease. Genes 
involved in TGCT as suggested by GWAS fall into multiple pathways. Some of the genes and 
pathways involved have been associated with other cancer types (e.g., DNA damage response and 
telomere length) (Horwich et al., 2006), while other ones are unique to germ cell tumors (sex 
determination and microtubule assembly) (Wilhelm et al., 2007)(Ruark et al., 2013a). All of these 
pathways also regulate important components of male germ cell development, and therefore can be 
organized within that framework (Pyle et al., 2016). 
The incorporation of whole exome sequencing (WES) into clinical practice for both 
diagnosis and research has opened an important window for the study of familial cases in order to 
look for high/moderate-risk susceptibility genes that explain their tumors. This technique has been 
used with success in the identification of genes responsible for some infrequent genetic diseases  
such as  type I gastric neuroendocrine tumor (Calvete et al., 2015b) or cardiac angiosarcoma 
(Calvete et al., 2015a) in familial pancreatic cancer (Jones et al., 2009) and in TGCT ( Litchfield et 
al., 2015e) (Litchfield et al., 2016b).  
WES was performed in 328 TGCT cases from 153 families, 634 sporadic TGCT cases and 
50 TGCT tumor tissues with different histology, but analysis failed to identify high-risk TGCT 
predisposition genes of significant frequency (Litchfield et al., 2015e)(Cutcutache et al., 2015) 
(Litchfield et al., 2016a). To examine the predictive potential of the TGCT-predisposition variants, 
polygenic risk scores (PRS) were constructed by calculating the combined effects on overall TC 
risk of thus far identified loci (Litchfield et al., 2015c). Taking all this information into account, 
only the polygenic model of inheritance can explain the diversity of the development of the disease, 
not only regarding the genetic aspects but also regarding its morphological and molecular landscape 
(Litchfield et al., 2015b) (Litchfield et al., 2015f). 
3.3 Mutational spectrum 
As explained above, genetic factors play an important role in the development of this 
disease, however, only variants with low susceptibility risk alleles have been described as yet (Table 
1). These variants are involved in some of the most important pathways that require a tight 
regulation, such as the establishment of the germline linage, the regulation of the epigenetic 
program or the process of sex determination. First of all, the ability of germ cells to switch from 
mitotic cell division to meiotic division requires an exquisite regulation of the cell cycle to maintain 
the balance between proliferation and differentiation, since disturbance of this balance may lead to 
cancer development or cell death (Rajpert-De Meyts et al., 2006). Closely related to cell cycle 
regulation are the mechanisms of DNA repair and microtubule and kinetochore assembly; these last 
ones are extremely important during the last stage of germ cell development. The DNA repair 
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pathway is essential to prevent cell death or neoplastic transformation, especially in cells subjected 
to adverse environmental effects. The processes of DNA repair is regulated differently in 
mitotically dividing immature germ cells during testicular development, and different mechanisms 
are specifically triggered when meiotic division starts at puberty, because the meiotic crossover 
requires double-strand DNA breaks (Litchfield et al., 2015c). Moreover, the KITLG/KIT system 
has been shown to regulate the survival, proliferation and migration of germ cells (Boldajipour & 
Raz, 2007), and alterations in these genes lead to a dysregulation of the migration process of the 
PGCs to the genital ridge. Finally, the involvement of telomere function and telomerase in 
carcinogenesis is supported by a number of previous observations: they are hallmarks for the self-
renewal potential in cancer, such as inducing pluripotent stem cells (iPS) and male germ cells. 
However, functionally it remains unclear exactly how telomere regulation influences in cancer risk; 
a recent study of TERT genotype and telomere length in 53,000 breast/ovarian cancer cases 
demonstrated that both shorter and longer telomere lengths can increase cancer risk, indicating that 
multiple complex mechanisms exist (Qi et al., 2011)(Bojesen SE et al., 2013).  
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Table 1. Overview of TGCT predisposition loci identified to date. 
SNPs Loci Candidate genes Pathway Risk allele frequency Allelic OR References 
rs3782181 12q21.32 KITLG 
KIT–KITLG signaling 
0.8 2,55 
Kanetsky et al.; Rapley et al.  2009 
rs210138 6p21.31 BAK1 0.2 1,5 
Apoptosis 
rs4624820 5q31.3 SPRY4 KIT–KITLG signaling 0.54 1,37 Rapley et al. 2009 
rs4635969 
5p15.33 
TERT 
Telomerase function 
0.2 1,54 
Turnbull et al. 2010 rs2736100 CLPTM1L 0.2 1,33 
rs755383 
9p24.3 DMRT1 Sex determination 
0.62 1,37 
rs7040024 0.62 1.48 Kanetsky et al. 2011 
rs2900333 12p13.1 ATF7IP Telomerase function 0.62 1,27 Turnbull et al. 2010; Kanetsky et al. 2011 
rs8046148 16q12.1 HEATR3 DNA damage 0.79 1,32 
Ruark et al. 2013 
rs2839243 21q22.3 Noncoding Unknown or other 
0.47 
1,26 
rs3805663 5q31.1 
CATSPER3 
Telomerase function 1,25 
PITX1 0.63 
rs10510452 3p24.3 DAZL 
Male germ cell 
development 
0.7 1,24 
Ruark et al. 2013 rs2720460 4q24 CENPE Centrosome cycle 0.62 1,24 
rs7010162 8q13.3 PRDM14 
Male germ cell 
development 
0.62 1,22 
rs9905704 17q22 RAD51C DNA Repair 0.68 1,21 Chung et al. 2013 
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PPM1E Unknown or other 
TEX14 Centrosome cycle 
rs3790672 1q24.1 Noncoding Unknown or other 0.28 1,2 
Ruark et al.; Schumacher et al. 2013 
rs2072499 1q22 PMF1 Centrosome cycle 0.35 1,23 
rs4888262 16q23.1 RFWD3 DNA Repair 0.46 1,19 
Chung et al. 2013 
rs12699477 7p22.3 MAD1L1 Centrosome cycle 0.38 1,16 
rs17021463 4q22.3 HPGDS 
Male germ cell 
development 
0.42 1,15 
rs1510272 3q25.31 
SSR3 
Unknown or other 
0.73 
1,16 Litchfield et al. 2014 
TIPARP 0.73 
rs7501939 17q12 HNF1B 0.39 0,78 
Kristiansen et al. 2015 
rs2195987 19p12 Noncoding 0.22 0,76 
rs11705932 3q23 
TFDP2 
0.80 1,22 
Litchfield et al. 2015d 
ATP1B3 
rs7107174 11q14.1 
GAB2 KIT–KITLG signalling 
0.15 1,26 
USP35 
Unknown or other 
rs4561483 16p13.13 
BCAR4 
0.35 1,22 
RSL1D1 
GSPT1 Apoptosis 
TNFRSF17 Unknown or other 
rs55637647 16q24.2 ZFPM1 Sex determination 0.37 1,21 
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 Variants located at the loci 12q21 (encompassing KITLG), 5q31 (SPRY4), 6p21 (BAK1), 
5p15 (TERT and CLPTM1L), 12p13 (ATF7IP) and 9p24 (DMRT1) account together for >11% of 
the genetic risk of TGCT (Rapley et al., 2009) (Kanetsky et al., 2009a)(Turnbull et al., 
2010)(Kanetsky et al., 2011) (Turnbull et al., 2011). Each variant individually only makes a modest 
contribution to the genetic risk of TGCT (Chanock, 2009), but collectively the risks of the identified 
loci have some of the highest effect sizes reported for any cancer, although they can only explain 
approximately ~25% of the excess familial risk (Litchfield et al., 2016a). 
 Because it is clear that genetics play an important role in the inheritance of FTGCT, coding 
variants conferring intermediate-to-high risk of TGCT might still exist, but they are more likely to 
each account for only a small proportion of cases of multiple occurrence TGCT families. 
Nevertheless, a number of additional strands of evidence also support an alternative, highly 
polygenic model of TGCT susceptibility, in which disease risk is determined by the co-inheritance 
of multiple risk variants, many of which are common (Pathak et al., 2015) (Litchfield et al., 2016a). 
 
 
  
 
 
 
 
Objectives 
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 Therefore, the aim of this thesis is the identification of high-/moderate or low risk 
susceptibility genes responsible for FTGCTs by WES in Spanish Population that could contribute 
to the knowledge of the genetic basis of the disease. The main objectives that have being carry out 
in this thesis are: 
1. Selection of families with at least two (first-degree) family members 
affected by TGCT, or two members, one of them with a bilateral affection. 
Recruitment of samples from the patients characterize by the absence of 
family history of TGCT to bring up the cohort of sporadic cases (500 cases). 
2. To analyze both models of inheritance, monogenic and polygenic, by using 
specific bioinformatics programs. To investigate the meaning of the 
candidate variants found from both models of inheritance we compare their 
frequency in healthy males and sporadic cases. For this task, we will carry 
out a case control association study with the Open array Genotyping 
platform. 
3. To replicate the candidate variants in bigger cohorts from the CIBERER 
public database, and replicate the results in a large English cohort.  
  
 
 
 
Materials and Methods 
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1. PATIENTS & SAMPLES 
 
1.1 Procurement of samples and ethics statement 
To realize this project, the first step was to obtain collaborative agreements with oncological 
and urological services from different institutions in our country that deal with TC patients, from 
whom we could obtain samples and clinical information. We achieved collaborations with: 
Grupo español de tumores Germinales; Centro Integral Oncológico Clara Campal-HM 
Madrid; Hospital General Universitario Morales de Messeguer; Complejo Hospitalario 
Universitario de Albacete; Hospital Alvaro Cunquerio de Vigo; Hospital Clinic de Barcelona; 
Hospital Clínico Lozano Blesa; Hospital Clínico San Carlos; Hospital del Mar; Hospital Infanta 
Sofía; Hospital Universitario Gregorio Marañón; Hospital Universitario La Paz; Hospital 
Universitario Ramon y Cajal; Hospital Universitari Sant Joan de Reus; Hospital Universitari Sant 
Joan de Deu; Hospital Universitario Vall d´Hebron; Instituto Catalán de Oncología (Badalona); 
Instituto Catalán de Oncología (Bellvitge); Instituto Valenciano de Oncología; Hospital 
Universitario de Fuenlabrada; Clínica Rotger de Baleares; Hospital Son Dureta; Hospital de Cruces; 
Instituto Oncológico Rosell; Hospital Virgen del Rocío; Fundación Jiménez Díaz; Hospital Virgen 
de la Arrixaca; Hospital Son Espases; Hospital Universitario de Pontevedra; and Hospital de 
Toledo. 
We prepared specific informed consent forms for each type of patient (familial and sporadic 
cases; Supplementary Material 1.1 and 1.2, respectively) that were filled in by every individual; we 
also made a questionnaire for affected patients only. 
Cuestionario sobre antecedentes familiares en Cáncer de Testículos (para evaluación en el 
CNIO). 
Este cuestionario tiene como única finalidad recoger información sobre los antecedentes familiares 
de cáncer de testículo y patologías asociadas. Si en su familia hay o ha habido casos de cáncer 
testicular podría estar indicado realizar una consulta de consejo genético para tratar de estimar el 
riesgo de todos los miembros de la familia y facilitar el acceso a medidas de detección precoz y/o 
prevención. 
DATOS DEL PACIENTE 
Nombre:  
Fecha de nacimiento:  
Diagnóstico clínico:  
Otras patologías y factores de riesgo asociados: 
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Marcadores tumorales (β –hCG ó AFP y LDH): 
Año Dx:  
Tratamiento: 
Médico responsable /Servicio/ Hospital/Ciudad: 
___________________________________________________________________ 
FACTORES DE RIESGO A DESTACAR 
-Criptorquidia   -Bilateralidad (presencia de tumor en ambos testículos) 
-Hidrocele    - Micro litiasis 
-Infertilidad    - Anorquia 
-OT: otro tipo de tumor  - OC: otra característica 
____________________________________________________________________ 
DATOS FAMILIARES 
1.- ¿Cuántos hijos tiene? Indique por favor las edades y el sexo (H/M): 
2.- ¿Alguno ha sido diagnosticado con Cáncer de testículos u otro tipo de cáncer? Indique cuál de 
ellos, a qué edad fue diagnosticado y presencia de marcadores tumorales (β –hCG ó AFP y LDH): 
3.- ¿Cuántos hermanos tiene? Indique por favor las edades y el sexo (H/M). 
4.- ¿Alguno ha sido diagnosticado con Cáncer de testículos u otro cáncer? Indique cuál de ellos, a 
qué edad fue diagnosticado y presencia de marcadores tumorales (β –hCG ó AFP y LDH): 
5.- Indique la edad actual o la del fallecimiento, de sus padres. Si alguno ha fallecido indique la 
edad y la causa. ¿Alguno ha sido o fue diagnosticado con Cáncer de testículos u otro cáncer? Indique 
la edad del diagnóstico 
     MADRE    PADRE 
 Edad                                                                               
 Edad y causa fallecimiento 
 Origen 
Consanguinidad 
Patología 
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 Edad diagnóstico 
 Marcadores tumorales (β –hCG ó AFP y LDH) 
6.- Otros antecedentes familiares por vía materna o paterna? (tíos, primos, sobrinos). Especificar  
10.- ¿Ha recibido Ud. consejo genético por el Cáncer de testículos?  
11- Incluir un árbol genealógico con todos los miembros de 2-3 generaciones, vivos o fallecidos, 
indicando no solo los pacientes con cáncer testicular y su edad Dx, sino también los miembros con 
otros cánceres. 
We intended to obtain as much information as possible from each individual, to enable us 
to explain not only the possible role of the genetic background of the diseases, but also to gain 
insight into the possible differences that might explain the origin of each type of TC. The study was 
approved by the ethics committees of all institutions mentioned above. 
1.2 Selection criteria of the sample cohorts 
During the elaboration of this thesis, 2 different studies were performed that included 
different numbers of samples. 
First study: candidate families with TGCTs fulfilling the criteria of having at least 2 
affected members who were available for sequencing studies. The families were recruited by our 
genetic counseling unit for familial cancer, and several oncology and urology services from the 
different hospitals mentioned above. We recruited a total of 19 candidate families based on clinical 
criteria and family history (Figure 12).  
Most of the selected families have 2-3 brothers affected with TC and in some occasion’s 1-
2 additional affected second-degree relatives of the same generation. Thus, we performed WES for 
at least 2 affected brothers together with both parents, whenever possible. DNA from a total of 71 
individuals from the 19 families was sequenced. Additionally, we tried to get more samples from 
different members of the families for segregation analysis (Supplementary Table S1). 
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Figure 12. Pedigrees of families selected to perform WES. Circles, female; squares, male. 
Individuals whose exomes were sequenced are boxed in blue. * indicates family members of whom 
DNA and RNA samples were available. T indicates paraffin-embedded tumor tissue available. dx: 
refers to age at diagnosis of TGCT. 
Of the 19 families collected, 3 presented three individuals affected with TGCT: family 1 
with three affected brothers, and families 3 and 12 with two affected brothers and one affected 
cousin. Interestingly, the affected individuals of the latter two families did not share the most 
probable inheritance pattern because in family 12 a paternal cousin was involved, whereas in family 
3 a maternal cousin was involved. The other 16 families each include two affected cases: 11 families 
contain two affected brothers, but in two of these families (families 4 and 7) there was another 
healthy brother, who did present some of the most important risk factors. In family 4, the healthy 
brother suffers from hydrocele, and in family 7 the healthy brother suffers from microlithiasis, so it 
is possible that, given their ages, they will develop the disease in a near future. Furthermore, family 
10 presents a couple of affected twins, and two families (families 11 and 14) show an affected father 
and son. In both cases they share the histopathology diagnosis: in family 11 both are affected with 
a seminoma and family 14 both are affected with a non-seminoma (Supplementary Table S1). 
Finally, families 15 and 16 present two affected cousins, involving the maternal line or both lines, 
respectively. 
Second study: in addition to the samples of the candidate families, a cohort of 500 sporadic 
cases was recruited following the same workflow that we used to collect the family cases. For these 
patients the principal selection criterion was the absence of a family history of the disease. Finally, 
control samples were obtained from a control cohort of 525 unaffected men from the Bar association 
in Madrid. 
The three cohorts from the 1st and 2nd study were used to perform case-control association 
studies of the variants identified by WES.  
1.3 DNA extraction and quantification 
We requested 15cm3 of peripheral blood from each individual to isolate DNA and RNA. It 
is important to point out that RNA could only be isolated when the blood sample was drawn at most 
48 hours before starting the isolation process, since otherwise the RNA degrades. For that reason, 
we did not obtain an RNA sample from every individual. 
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Peripheral blood was centrifuged at 3000 rpm for 15 minutes at room temperature in order 
to separate the nucleated cells (lymphocytes, platelets and leucocytes) from which DNA was 
isolated using the MagNA Pure LC DNA isolation Kit I (Roche). DNA concentration was 
determined using the Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies).  
In addition, tumor DNA was extracted from paraffin tumor tissue obtained from the 
available samples. Formalin-fixed, paraffin-embedded (FFPE) tissue samples were stained by 
hematoxylin and eosin and examined by a pathologist (Dr. Manuel Morente). The tumor area was 
identified and macro dissected from three 30 μm thick sections for subsequent DNA extraction. 
Each section was dissolved in 1 ml of Xilol at room temperature for 30 minutes, followed by 5 
minutes at 55º and a centrifugation at 14,000 rpm for 10 minutes in order to liquefy and remove the 
paraffin. The sample was washed twice with 1 ml of 100% ethanol and centrifuged, and the samples 
were left overnight at 37º. Finally DNA was isolated using the Maxwell® RSC DNA FFPE kit 
(Promega). Quality and quantity was assessed by NanoDrop Spectrophotometer (NanoDrop 
technologies, Wilmington, DE, USA). 
1.4 RNA extraction and quantification 
To isolate the RNA from peripheral blood samples, we mixed the peripheral blood with 
7ml of Ficoll and centrifuged for 25 minutes at 3,000 rpm without brake to separate the different 
components of the blood. The lymphocytes were collected and washed with PBS. RNA was 
extracted using the FlexiGen Trizol kit. The samples were extracted with chloroform and RNA was 
precipitated with isopropanol. RNA quality and quantity was assessed using a NanoDrop 
Spectrophotometer (NanoDrop technologies, Wilmington, DE, USA). 
2. WHOLE EXOME SEQUENCING (WES) 
 
2.1 Workflow of WES 
DNA was prepared at a concentration of 6µg/µl. The samples, together with data regarding 
the quality of the DNA and a pedigree of each family, were sent to Sistemas Genómicos (Valencia, 
Spain) for WES analysis. WES was performed using the latest version of the Illumina HiSeq 2000© 
sequencing platform and the Agilent SureSelect Target Enrichment kit for 51Mb. Afterwards, a 
quality assessment, similar to Sanger sequencing, was carried out because next-generation 
sequencing (NGS) platforms generate errors. These errors are known as quality values (probability 
values per base) and were evaluated using the FastQC tool. Quality values are provided using a 
Phred-like quality score (Ewing, B et al. 1998, a, b). The global study of the quality scores provides 
information about the sequencing quality. Read alignment was performed against the human 
reference genome version hg19 using the BWA software package and ‘in-house’ scripts. From the 
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BAM-formatted file obtained after alignment, low-quality reads and sequences flagged as PCR 
duplicates were removed. In addition, the overall sample coverage and the efficiency of the 
combination of the selected strategies (target enrichment system + NGS platform) were evaluated 
at this point. Three different parameters were evaluated for this purpose: the coverage distribution 
along targeted regions; the percentage of target bases covered at 1x, 10x and 20x for each 
chromosome; and the percentage of reads on target against the total number of mapped reads. 
Filtering was performed using Picard-tools (http://picard.sourceforge.net/) and SAMtools (Li, H et 
al., 2009). Coverage metrics and evaluation of the target enrichment was performed using custom 
scripts. Next, variant calling was performed using a combination of two different algorithms: 
VarScan (Koboldt, D et al., 2009) and GATK (McKenna, A et al. 2010). Finally, identified variants 
were annotated using the Ensembl database version GRCh37 (Flicek, P et al., 2012). This database 
contains information from the most relevant human variation resources such as dbSNP, the HapMap 
project, the 1000 Genomes project, and COSMIC [www.ensembl.org], which can be exported in an 
excel document.  
2.2 Data analysis for the monogenic model of inheritance 
The data was analyzed according to the specific pipeline previously described by our group 
(Calvete et al., 2015b) based on different filters for nucleotide location (canonical isoform, intron 
or exon), minor allele frequency (MAF) ≤0.1, and pattern of inheritance (recessive model, dominant 
model or compound heterozygotes). Filtering is based on the frequency of the variant allele with 
respect to the total number of sequences ( ≤ 0.2 homozygous for the reference allele;  > 0.2 and < 
0.7 heterozygous;  ≥ 0.7 homozygous for the variant), pathogenicity (SIFT, Condel and Polyphen 
should indicate deleterious for exonic variants and Alamut v.3 to study the possible role of intronic 
variants), functional impact (missense, frameshift, stop lost/gained and splice sites) and pathway 
involvement (Gracia-Aznares et al, 2013), (Calvete O, et al., 2015a). However, since the model of 
inheritance of the disease has not been described, we extended the analysis by taking siblings into 
account or by studying the cases individually, to study all the possibilities. After applying the 
principal filters, we confirmed the MAFs by consulting several databases (See section 3.4). 
Moreover, the pathogenicity was also confirmed by our own analysis using the same pathogenicity 
predictors as WES used and compared it with other ones (See section 3.2), to bring up a consensus. 
Once variants were characterized by their genetic features, we assessed their molecular function 
and if they took part in any of the biological pathways that have been previously described to be 
involved in the development of the disease. 
2.3 Data analysis for the polygenic model of inheritance 
Sequence kernel associations tests (SKATs) have been used to study the cumulative effects 
of multiple variants in a genomic region, using the raw data obtained from the WES. Due to the 
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absence of information about the kind of variants involved in the development of the disease, we 
studied both common and rare variants. To carry out our objective we based our first analysis on 
the family-based association test (FBAT) that takes into account parental origin effects and allowed 
us to study the family structure, including nuclear families and sibships. Two different tests were 
used, the FB-Burden test which is powerful in collapsing or summarizing rare variants within a 
region by a single value, followed by a test for association with the trait of interest. However, the 
Burden test assumes that all rare variants influence the phenotype in the same direction and with 
the same magnitude of effect. However, we expect some variants to be protective and others to 
confer risk. The magnitude of each variant effect is also likely to vary, and we therefore also used 
the variance component test FB-SKAT that uses a regression approach that tests for association 
between variants in a region (both common and rare) and dichotomous phenotype, while adjusting 
for covariates. 
Both types of analysis test the null hypothesis that no genetic variant in the region is 
associated with the disease. However, they make different assumptions on the distribution of effect 
sizes, and therefore their performance depends on the underlying disease model. In particular, the 
Burden test tends to be more powerful when a large proportion of the genetic variants in the region 
are associated with the disease and have a low MAF, such as rare variants, while the variance 
component test tends to be more powerful when the proportion of disease-associated variants (both 
risk and protective variants) in a region is small; the latter test has no restrictions regarding MAF, 
and both common and rare variants in the region are tested (Ionita-Laza et al., 2013). 
Furthermore, although our main goal was to study the genetic pattern of inheritance for 
family cases, we also wanted to extend our analysis and assess the possible role the variants 
obtained from the WES, or their interactions, could have on the development of the disease without 
the inheritance factor as a covariable. For this analysis we considered only affected and healthy 
individuals. We used as healthy individuals the members of the family who did not suffer the 
disease and who did not present any of its risk factors. To this end, we performed a Sequencing 
Kernel Association Test, which, as mentioned above, is based on a multiple regression model that 
directly regresses the phenotype on genetic variants in a region and on covariates, which allows 
different variants to have different directions and magnitudes of effects, including no effects, and 
avoids the selection of thresholds. 
Taking all this information into account, the selection of the candidate genes was based on 
a pipeline designed according to our own criteria. First of all, we selected the genes depending on 
their function and their involvement in the main pathways described as causing the disease. We 
studied their function in several databases (See section 3.1) and performed an enrichment analysis 
in the Enrich program and the DAVID annotation tools, to classify the genes not only by molecular 
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function, or pathway, but also taking into consideration the biological process in which they were 
classified by the Gene ontology database.  
Since we were searching for low, moderate and high susceptibility genes, we next used 
Venny 2.1 to select variants common to both FBATs. Although we had already searched for their 
function/pathways, we decided to study them in more detail. We considered the variants of each 
gene individually, because, even though the method considers each gene under the condition that it 
must present at least 3 variants, our hypothesis of a polygenic model does not require this condition 
to be fulfilled, since only 1 variant is necessary. Thus, we removed those variants from the WES 
data that were present only in healthy members, and continued only with risk variants. Moreover, 
as not much information is available regarding the genetic basis of the disease, we decided to 
consider most variants: missense variants, frameshifts, in frame deletions and insertions, 
synonymous variants, since they can have an effect on splicing, and finally intronic variants with a 
predicted effect on splicing. These splicing errors not only involve canonical splice sites located at 
the end (splice donor site) or at the beginning (splice acceptor site) of each exon, but may also occur 
along the entire sequence – not only as missense variants, which are the most common ones, but 
also as synonymous variants.  
Once we finished filtering by effect and function, we looked at the behavior of each variant 
in the WES data, as a quality assesment. The ones that presented low reads or var/depth numbers 
in disagreement with the results or either they present uncover region values, were ruled out. 
Finally, we evaluated the impact of the effect using online predictors (See section 3.2) for 
pathogenicity and Alamut v3.1 for splicing effects. 
3. SELECTION OF CANDIDATE VARIANTS 
 
3.1 Functional role and involvement in pathways 
As mentioned above, the selection of the variants finally depended on the function of the 
gene in which they appear. We therefore queried the curated databases Genecards, Gene atlas, and 
DisGeNET, and consulted the literature using the PubMed online library. Moreover, we checked if 
those variants took part in any of the principal biological pathways described to be involved in the 
development of the disease. To attain this objective, we used the Reactome and Enrichr databases, 
Ingenuity pathway analysis, the DAVID Bioinformatics Resources 6.7 programs (Nathanson KL et 
al 2005, Chung CC et al. 2013, Litchfield K et al 2015d, Pathak A et al. 2015), STRING tools to 
search for interactions between them, and the Quick Go platform of the European Bioinformatics 
institute (EMBL-EBI) to analyze their involvement in Biological processes in depth. 
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3.2 Evaluation of the results of the pathogenicity predictors  
We confirmed the results of the pathogenicity predictions with the Predict SNP tool that 
contains several pathogenicity predictors (MAPP, Phd-SNP, Polyphen-1, Polyphen-2, SIFT, SNP, 
nsSNPAnalyzer and Panther). We employed Condel, Polyphen-2, and SIFT predictions 
individually. 
The Condel score involves the scores of different methods which are weighted using the 
complementary cumulative distributions of approximately 20,000 missense SNPs, both deleterious 
and neutral. The probability that a predicted deleterious mutation is not a false positive of the 
method and the probability that a predicted neutral mutation is not a false negative are employed as 
weights, ranging from 0.0 =Neutral, to 1.0 =Deleterious. 
PolyPhen-2 calculates the Naive Bayes posterior probability that this mutation is damaging 
and reports estimates of the prediction sensitivity (True Positive Rate, the chance that a mutation is 
classified as damaging when it is indeed damaging) and specificity (1 – False Positive Rate, the 
chance that a benign mutation is correctly classified as benign). A mutation is also appraised 
qualitatively as benign, possibly damaging, or probably damaging based on pairs of False Positive 
Rate (FPR) thresholds, optimized separately for each of the two models (HumDiv and HumVar). 
Currently, the thresholds for this ternary classification are 5%/10% FPR for the HumDiv model and 
10%/20% FPR for the HumVar model. Mutations whose posterior probability scores correspond to 
estimated false positive rates at or below the first (lower) FPR value are predicted to be probably 
damaging (more confident prediction). Mutations whose posterior probabilities correspond to false 
positive rates at or below the second (higher) FPR value are predicted to be possibly damaging (less 
confident prediction). Mutations with estimated false positive rates above the second (higher) FPR 
value are classified as benign. If no prediction can be made due to a lack of data, the outcome is 
reported as unknown. 
The SIFT score ranges from 0 to 1. The amino acid substitution is predicted damaging if 
the score is < 0.05, and tolerated if the score is > 0.05). 
 Finally, we made a revision using the the Combined Annotation Dependent Depletion 
(CADD). CADD instructions suggest to use a cutoff on deleteriousness somewhere between 10 and 
20 of the PHRED score. Since 15 is also the median value for all possible canonical splice site 
changes and non-synonymous variants, we used this value to differentiate pathogenic from neutral 
variants. 
3.3 Splicing variant effects 
Alamut v3.1 was used to determine the impact our variants could produce on the splicing 
of their genes. This software introduces a splicing module which integrates a number of prediction 
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methods. On the one hand it predicts splice signals, using SpliceSiteFinder-like, MaxEntScan, 
GeneSplicer, NNSPLICE and Human Splicing Finder. On the other hand, it also allows us to predict 
if our variants may affect important exonic splicing enhancer (ESE) binding sites, employing the 
ESE Finder (computes putative binding sites for exonic splicing enhancers) and RESCUE-ESE 
(identifies specific candidate hexanucleotide sequences as candidate ESEs). 
3.4 Evaluated MAF scores in different databases 
We further assessed the MAF scores by consulting the Exome Aggregation Consortium 
(Exac), the CIBERER Spanish Variant Server (CSVS), the NHLBI Exome Sequencing Project 
(ESP) and 1000 genomes. We accepted only those variants whose MAF did not exceed 0.05. 
3.5 Gene expression tissues 
Taking into account that the candidate genes were selected depending on their function, it 
was also necessary to know where the selected genes are expressed and the possible role our variants 
could play in the testicular tissue or any other tissue they might affect. We performed this study 
using the GTEx Portal platform. Expression values are shown in RPKM (Reads Per Kilobase of 
transcript per Million mapped reads), calculated from a gene model with isoforms collapsed to a 
single gene. Genes were selected based on expression thresholds of >0.1 RPKM in at least 10 
individuals and ≥6 reads in at least 10 individuals. Expression values were quantile normalized to 
the average empirical distribution observed across samples. For each gene, expression values were 
inverse quantile normalized to a standard normal distribution across samples. 
4. VALIDATION STUDIES 
 
4.1 Primer design 
For validating the candidate variants we designed specific primers using the PRIMER 
DESIGN3 program. We confirmed that the primers were specific for the selected region by doing 
a Blast with the Ensembl tool. Moreover, we ensured that the primer sequence did not cover a region 
with SNPs that could give false-positive results using the SNP Check 3 program, and finally we 
explored in silico if the primers amplified correctly using the “In-silico PCR” tool of the UCSC.  
4.2 Optimization of the PCR 
Although we have optimized standard conditions for PCR (95ºC for 5 mins, 35 cycles of 
94ºC for 30s, annealing temp (specific for each pair of primers) for 45s, extension at 72ºC for 45s 
and a final extension step of 7 mins at 72ºC), certain characteristics must be taken into account for 
each pair of primers. We used the HotMaster Taq DNA Polymerase (5PRIME), dNPTS at a 
concentration of 1.25 mM, and each primer at a concentration of 10Mm (Supplementary Table S2).  
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Even if the program provides the information on how to perform the PCR, we first 
optimized the PCR conditions. We evaluated the effectiveness of the primers 3 degrees below and 
above the melting temperature, to optimize the annealing temperature indicated by the programs. 
Moreover, depending on the %GC that is predicted for the PCR product, we also evaluated different 
DMSO and MgCl2 concentrations. For predicted products with a %GC less than 50%, we added 
5% of the total volume of MgCl2 (25mM), while if the product supposedly contained more than 
60% or 70%GC, we added 5% or 10% of DMSO (78.13g/Mol), respectively. In addition, depending 
on the size of the product, we may have to increase the number of cycles and the time of the 
extension step. Finally, we optimized the DNA concentration required to perform a correct PCR 
without wasting unnecessary sample. 
We evaluated the PCR products in a 2% agarose gel (Low EEO/High electrophoresis 
mobility agarose; Laboratorios CONDA, Madrid). 
4.3 PCR and sequencing of study samples  
The corresponding PCR reactions were performed in a Mastercycler EP gradient S PCR 
System (Eppendorf), followed by Sanger sequencing. This was first done for the probands, and 
afterwards, if the variants were validated, segregation analysis was done including all members of 
the family of whom samples were available.  
5. SPLICING EFFECT VALIDATION 
 
After having validated splicing variants in the carriers at the DNA level, we confirmed at 
the cDNA level if the variant affects the splicing process as predicted by Alamut v3.1.  
5.1 RT-PCR  
In the case of total RNA from peripheral blood, cDNA was obtained from reverse 
transcription of 1200 ng RNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems #4368814) following the manufacturer's instructions. The reaction was carried out at 
25ºC for 10 min and at 37ºC for 120 min in a Mastercycler EP gradient S PCR System (Eppendorf). 
The cDNA samples were stored at -20ºC until further usage.  
5.2 Primer design, PCR optimization and verification of PCR products  
Primers were designed as explained above in the flanking exons to observe if the variants 
produced the predicted exon skipping. Primers were optimized and the products were evaluated on 
a 2% agarose gel (Supplementary Table S3). Exon skipping was verified by Sanger sequencing. 
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6. CASE-CONTROL STUDIES 
 
6.1 Genotyping 
Genotyping was done using the OpenArray® system (Applied Biosystems). This system 
uses fluorescence-based PCR reagents to provide qualitative detection of targets using post-PCR 
(endpoint) analysis. We used this system to perform a genotyping experiment of the variants 
identified in both the monogenic and the polygenic analysis of inheritance in a sporadic cohort and 
a Spanish healthy male population (around 390 samples of each group), in order to discard variants 
present in healthy control samples and confirm the hypothesis that our variants are involved in the 
inheritance of development of this disease. 
First of all, we reduced the MAF to 0.01 and the pathogenicity of all the in silico predictors 
should consider the variant as deleterious. Next, we selected those genes which are common 
between families and those involved in the most important biological pathways described to date; 
we also took the functional effects into consideration and gave priority to the ones that led to the 
truncation of the protein, stop lost/gained, initiator codons, frameshifts, in-frame deletions, and 
splice donor and acceptor sites. Finally, we selected variants that were present in the genes that 
were most frequently mutated in our cohort of individuals. 
A genotyping experiment (also known as an allelic discrimination experiment) is an 
endpoint experiment used to determine the genotype of unknown samples. With this type of 
experiment we can differentiate two alleles of a single nucleotide polymorphism (SNP): 
• Allele 1 homozygotes (samples having only allele 1) 
• Allele 2 homozygotes (samples having only allele 2) 
• Heterozygotes (samples having both allele 1 and allele 2) 
We also performed a TaqMan® genotyping experiment in which the PCR includes 
fluorescent-dye labeled probes specific for each allele of the target SNP, in a platform of 120 
variants in 792 samples. Our experiment included the following samples and controls: 
Sporadic & Spanish male population cohorts: DNA samples of which the genotype of 
the target is unknown. 
Replicates: Identical reactions containing identical components and volumes. 
No template controls (NTCs): Samples that contain water or buffer instead of template; 
also known as negative controls. NTCs should not amplify. 
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Positive controls: Samples from our familial cohort that contain known genotypes 
(homozygotes for allele 1, homozygotes for allele 2, and heterozygotes for alleles 1 and 2). 
Genotype calling and sample clustering was performed using TaqMan Genotyper Software 
v1.0 (Applied Biosciences). Statistical analysis of the data was done using Fisher’s Exact Test or 
Chi-square Test p-values, depending on the number of samples. Fisher's Exact test is more 
restrictive, while the Chi-square test assumes more scenarios, and therefore we used both of them 
for our analysis. Afterwards, the Bonferroni test adjustment and the 95% confidence intervals for 
the Odds Ratio were computed. 
6.2 Discovery study 
Due to the small number of samples that could be studied in the OpenArray® system, we 
decided to increase this number by using information from the Spanish CIBERER variant server 
database to increase the statistical power. Thus, we compared the data from sporadic cases vs data 
of our control cohort plus data from the CIBERER database. We performed Fisher’s and Chi-square 
tests on the frequencies and the results were adjusted by the Bonferroni test.  
Moreover, we studied the susceptibility risk that each variant could confer to the individuals 
for the development of the disease 
6.2.1 Gene enrichment analysis  
Biological process and pathway analyses were performed by an Enrichment analysis in 
order to identify in which of them our significant genes are involved, and to define which pathways 
and biological process are predominantly involved in the Spanish population. 
6.2.2 Analysis of cancer genome atlas data 
Copy number status, mutational profile and data on somatic variants were extracted for 
‘Testicular Germ Cell Tumors’ from the TCGA Broad Firehose pipeline run from cBioportal (Data 
release 6.0). Analysis was done on 156 human TGCTs publicly available through the cancer 
genome atlas project (http://cancergenome.nih.gov/). More than 40% of the cancer susceptibility 
genes are found to be tumorigenic when mutated only in tumor DNA (Rahman, 2014), and 
accordingly we sought to assess whether our significant genes were also frequently lost somatically.  
6.3 Replication study 
To evaluate the possible involvement in the development of this disease of the variants that 
proved significant in the previous analyses, we performed a replication analysis in another 
population. To attain this objective, we collaborated with Dr. Clare Turnbull from the Institute of 
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Cancer Research, London, who shared with us their WES data for our variants in almost 1800 TC 
cases and 3000 English healthy controls. 
7. IN SILICO PROTEIN ANALYSIS OF FINAL CANDIDATE VARIANTS 
 
Heat map representations of independent substitutions for each position of the protein and 
amino acid tolerance test were generated using PredictProtein. Secondary structures (β-strands, α-
helices and loops) of the putative proteins were based on REPROFSec predictions. The predictions 
of the annotation (minimum REPROFSec score of 5) of conserved secondary structures and 
evolutionary profiles for each gene carrying the variant were based on several original prediction 
methods (NORSnet, DISOPRED2, PROFbval and Ucon) implemented in Predict Protein. 
Conservation of the protein and specifically of the amino acid of interest was assessed using 
multiple sequence alignment with several species (Homo sapiens, Mus musculus, Danio rerio, 
Xenopus tropicalis, Gallus gallus, Macaca mulatta, Equus caballus and Pan troglodytes) using 
different platforms (Clustal Omega of the EMBL-EBI and Clustal X of Praline and Phyre software). 
We also assessed the conserved domains more carefully using the CD-Search of the NCBI. 
8. ASSOCIATION BETWEEN GENETIC AND CLINICAL INFORMATION 
 
Finally, we tried to design a risk algorithm to combine the genetic information with the 
clinical data in order to obtain a susceptibility risk value. We performed an association test of the 
data obtained from the foregoing analyses and the clinical information obtained from the 
questionnaire shown in Table 2. Firstly, we tried to stratify the data to find variants associated with 
the two principal types of tumor, seminomas and non-seminomas, using a Chi-square test. We then 
performed a Mann-Whitney U test taking into account the age at diagnosis. Whenever possible we 
also considered the most important risk factors, in order to translate the results obtained into the 
clinical practice for early identification of individuals at risk, and incorporation into a minimally 
invasive follow-up program. 
 
  
 
 
 
Results 
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1. ANALYSIS OF THE AVERAGE AGE OF ONSET BETWEEN FAMILIAL AND 
SPORADIC CASES 
 
 We have identified 19 families with familial testicular cancer that at least include two 
affected members (41 affected and 30 healthy members) to perform WES, and a second group of 
500 sporadic cases for performing case control assay. When the age of onset was compared between 
both groups, we could detected that familial cases develop TGCT at a median age of 28 years old 
(range= 9-34) while sporadic cases develop it significantly later at 33 years old (range= 1-70) The 
results suggest that having a family history of TGCT have significant effects (Pvalue= 0.0001).in 
the earlier development of the disease. 
 
 
Figure 13. Box plot of the distribution of familial and sporadic cases in relation to the age of 
onset. Significant differences were detected related to the median age of onset between familial 
and sporadic cases with a *** P= 0.0001 according to U Mann–Whitney test.  
 
2. WHOLE EXOME SEQUENCING STUDY 
  
 WES was performed by Sistemas Genómicos, Valencia, Spain, on the 71 selected 
individuals from the 19 families collected (see Figure 12). The workflow of this analysis is shown 
in Figure 14. Data was analyzed for both types of model of inheritance, monogenic and polygenic. 
Afterwards, the selected variants from both models were studied in a case control assay and 
validated in a replication analysis in English population.  
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Figure 14. Workflow of the sequencing process carried out by Sistemas Genómicos. 
 
Of the nineteen families studied by WES, 3 had three affected members and 16 had 2 
affected members. Ten families could be sequenced completely because we obtained blood samples 
from all family members, parents and affected individuals, and even cousins as in family 16. 
However, in 5 of the families we were only able to sequence the affected individuals and one of the 
parents. Finally, in the remaining 4 families, we could sequence only the affected individuals, all 
of them pairs of brothers, although afterwards we obtained samples from other family members for 
the segregation studies (Figure 12 & Supplementary Table S1).  
2.1 Monogenic model of inheritance 
As mentioned in the Materials and Methods section, we have studied for each family all the 
different patterns of inheritance this model include, dominant (maternal and paternal inheritance), 
recessive, compound heterozygous and chromosome- linked. The pipeline used for the studies 
described in this thesis was previously described by our own group (Calvete, et al., 2015b) (Figure 
15), although due to our type of pedigrees we were a priori more flexible, because as we were 
searching for high/moderate and low susceptibility variants we had to increase the MAF from 0.01 
up to 0.1. Moreover, we also included as a filter, a possible relationship of our genes with any of 
the described principal pathways involved in the development of the disease. 
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Figure 15. Summary of the pipeline used for the studies described in this thesis. 
2.1.2 WES Candidate variants. 
A group of 160 variants was selected from the filtered pipeline carry out (Figure 15) on the 
WES raw data. Of these variants, 134 were validated by Sanger sequencing, but 3 of them were 
identical to WES data of other pathologies and they were therefore ruled out. Moreover, 22 variants 
were false positive (14%). Some of them were expected to be false positive just because of the WES 
reads, but we wanted to validate them because they presented highly important functions. 
Furthermore, 4 variants were validated, but their locations did not coincide with the ones indicated 
by the WES data, so they were not considered as validated because of discrepancies in the variant 
annotation 
Finally, segregation analysis was performed on a total of 131 variants (Table 2). Of them, 
119 came from a dominant model of inheritance (57 with a paternal and 54 with a maternal origin, 
and 8 with an unknown origin), 8 variants (4 genes) were compound heterozygous, 2 variants were 
linked to the X chromosome and another 2 presented a recessive model of inheritance. The 
functional role and pathway in which each gene is involved are summarized in Supplementary Table 
S4. This filter was based on the gene's individual function as described in the different databases 
mentioned in the pipeline scheme, and the pathway in which it was involved. The selection was 
finally determined by the combination of all information (Figure 15). 
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Table 2. Candidate variants selected by the WES pipeline and validated by Sanger sequencing 
Model of inheritance  Gene Variant effect HGVSp Existing variant 
ALL 
MAF 
Condel SIFT PolyPhen 
Maternal Dominant Model 
  
  
  
SPAG1 inframe_insertion p.Lys353_Ser354insAsp . rs56246127 - 0.58 0.07 0.743 
TEX19 missense_variant p.Gly93Trp rs147220016 0.002 0.54 0.02 0.975 
EPHX2 inframe_insertion p.Ser402_Arg403insArg rs71553864 0.027 - - - 
NOP10 missense_variant p.Asp12His rs146261631 0.003 0.750 0.01 0.884 
UBN1 splice_donor_variant - - - - - - 
PKN1 missense_variant p.Arg45Trp - - 0.707 0 0.805 
MEA1 inframe_deletion p.Glu120del rs375030293 - - - - 
MYCT1 missense_variant p.Arg133Cys rs41292880 0 0.935 0 0.999 
TAF1L_V1 missense_variant p.Pro1266Arg rs140558556 - 0.762 0.05 0.975 
PDE11A frameshift p.Thr58ProfsTer41 TMP_ESP_2_178936993 - - - - 
SH2D4A missense_variant p.Arg324Trp rs150534166 0.001 0.665 0 0.633 
KCNU1 missense_variant p.Tyr263His rs374327006 - 0.855 0 0.968 
INCENP missense_variant p.Arg252Trp rs149820986 0.0005 - 0 1 
GREB1 missense_variant p.Ala115Val rs142882892 0.0046 0.46 0.05 0.846 
SEMA4D missense_variant p.Ala72Thr rs13284404 0.0193 0.433 0.01 0.487 
USP47 missense_variant p.Asp328His COSM1604203 NA 0.47 0.06 - 
SSH1 missense_variant p.Gly949Arg COSM1358541 NA 0.413 0.09 0.999 
GRP frameshift p.Arg141ThrfsTer4 rs149962068 NA - - - 
ODF1_V1 inframe_deletion p.Asn219_Cys227del COSM330203 NA 0.736 0 1 
SSTR5 missense_variant p.Cys220Gly - NA 0.4 0.07 0.988 
PSRC1 missense_variant p.Pro256Ser rs76057315 0.0046 0.397 0.02 0.001 
GAR1 missense_variant p.Arg8Pro rs150273267 0.0028 0.45 0.18 0.001 
TAF1L_V3 missense_variant p.Asp848Asn rs141368669 NA - 0 1 
CYP2C8_V1 missense_variant p.Gly384Ser rs143386810  0.7 0.01 0.976 
SHQ1 missense_variant p.Phe72Cys rs78491606 0.0069 0.46 0 1 
CYP2C8_V3 initiator_codon_variant p.Met1? rs142470035 0.0009 0 0 1 
DDX4 missense_variant p.Ile440Met rs201103498 NA 0.54 0.01 0.529 
  
 
 
8
1
 
  
 Maternal Dominant Model 
 
CCDC62 missense_variant p.Pro526Ala rs141689290 0.0005 0.48 0.06 0.999 
GFRA1 missense_variant p.Gly3809Arg rs8192662 0.0197 0.635 0.03 0.74 
CYP2C8_V2 missense_variant p.Ile264Met rs1058930 0.0257 0.843 0 1 
HERC2 missense_variant p.Arg3644Pro - 0.0 0.805 0.02 0.979 
NGF missense_variant p.Arg80Gln rs11466111 0.0051 0.906 0 0.996 
RHBG frameshift p.Asp424ArgfsTer18 rs71591938 0.0 - - - 
JAG2 missense_variant p.Lys1220Ile - 0.0 0.911 0 0.997 
TET1 missense_variant p.Val128Phe rs142008363 0.0078 0.667 0.01 0.721 
YY1 inframe_deletion p.His71del COSM949287 0.0 - - - 
LIG3 stop_gained p.Arg811Ter - 0.0 - - - 
GOLGA3 missense_variant p.Ser81Cys rs76213047 0.0197 0.693 0.03 0.853 
SMYD2 missense_variant p.Phe166Cys rs61755311 0.0064 0.710 0.01 0.809 
FANCD2 missense_variant p.Val958Met rs372574627 0.0 0.553 0.02 0.508 
NLRP14 missense_variant p.Thr397Ile rs76670455 0.0037 0.935 0 0.999 
LRP4 missense_variant p.Arg373Trp rs118009068 0.0078 0.766 0.02 0.937 
PIF1 missense_variant p.Cys284Arg rs118062397 0.0138 0.945 0 1 
SERPINB11 missense_variant p.Ala367Glu - 0.0 0.935 0 0.999 
TDRD6 missense_variant p.Asp172Ala - 0.0 0.695 0.03 0.855 
BRD4 missense_variant p.Arg1097His rs35676845 0.0069 - - 0.522 
TDRD6_V2 inframe_deletion p.Glu705del rs144670071 0.0092 - - - 
PRKDC_V1 missense_variant p.Arg3473Trp - - 0.648 0.03 0.764 
AKAP3 missense_variant p.Ser700Phe rs2041291 - 0.750 0.01 0.882 
RECQL4 missense_variant p.Asn616Ser rs199654783 - 0.871 0 0.982 
POLE2 missense_variant p.Leu275Ile rs141483427 - 0.896 0.01 0.999 
KIF18A missense_variant p.Pro334Ser rs34913484 0.0051 0.945 0 1 
ADAM20 missense_variant p.Tyr554Cys rs45554935 0.008 - 0 0.854 
DNAH9 frameshift_variant p.Arg24GlyfsTer36 - - - - - 
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Paternal Dominant Model 
  
SYCP2 missense_variant p.Thr751Ile rs6071006 0.01 0.665 0.01 0.715 
DDX54 missense_variant p.Arg669Trp rs201635496 0.0005 0.756 0 0.824 
VNN1 missense_variant p.Ala253Val rs189034822 0.002 0.696 0.02 0.825 
CYP3A43 missense_variant p.Arg419Ser rs143991326 0.004 0.945 0 1 
ABCA1 missense_variant p.Ser824Leu COSM273811 - 0.696 0.02 0.825 
SOX30 missense_variant p.Cys55Arg rs184421438 0.005 0.598 0 0.467 
MLH3 missense_variant p.Val741Phe rs28756990 0.02 0.560 0.03 0.571 
CCDC33 splice_donor_variant - rs369047254 - - - - 
SBF1 missense_variant p.Arg1733Cys rs199972466 - 0.818 0 0.925 
CYR61 missense_variant p.Ser316Cys rs148330006 0.003 0.663 0.05 0.834 
PLEC missense_variant p.Arg433Gln rs138924815 0.006 - 0- - 
GYS2 missense_variant p.Leu592Val rs202136674 0.0005 0.896 0.01 0.999 
DNAAF1 missense_variant p.Asn182Lys rs144018942 0.0018 0.731 0 0.771 
MAP4_V1 missense_variant p.Arg23Gln rs2230169 0.03 0.670 0.02 0.772 
MAP4_V2 missense_variant p.Glu441Gln rs11711953 0.03 0.935 0 0.999 
SPZ1 frameshift_variant. p.Glu340AsnfsTer17 rs111595904 0.01 - - - 
SPATA12 missense_variant p.Gly355Asp rs76587478 0.02 0.45 - 0.458 
CYP1A1 missense_variant p.Arg464Ser rs41279188 0.001 0.69 0 0.814 
APLF_V2 frameshift_variant p.Arg510GlufsTer5 rs149897324 - - - - 
FSIP2_v2 missense_variant p.Asp2397Val rs76311269 0.03 0.716 0 0.74 
FSIP2_v1 missense_variant p.Gly3809Arg rs11892184 0.0275 0.595 0.05 0.694 
TNK2 missense_variant p.Arg1086His rs13433937 0.022 0.853 0 0.966 
TRIM16 missense_variant p.Arg493Trp rs3174720 NA 0.74 0.02 0.901 
BCHE missense_variant p.Asp98Gly rs1799807 0.0083 0.892 0 0.992 
PINX1 missense_variant p.Arg215Ile rs17855458 0.0092 0.725 0.02 0.878 
NWD1 stop_gained p.Arg710Ter rs777897918 0.0 - - - 
GPRC6A stop_gained p.Tyr775delinsTer - 0.0 - - - 
KDM1B missense_variant p.Gly383Asp rs72840622 0.0055 - 0.02 - 
HIST1H1D missense_variant p.Ala216Pro rs202225825 0.0 - 0.04 - 
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 Paternal Dominant Model 
  
 
FOXR1 missense_variant p.Pro64Ala rs45602538 9.0E-4 0.651 0.02 0.735 
GGN stop_gained p.Gln647Ter rs62123481 0.0069 - - - 
PDCL2 missense_variant p.Arg76Trp COSM1430232 0.0 0.875 0 0.984 
FGD2 missense_variant p.Pro102Ser - 0.0 0.841 0.02 0.995 
PLEC_4 missense_variant p.Thr4044Met rs78461695 0.01 - 0.05 0.975 
TINF2 missense_variant p.Pro241Ser rs17102311 0.0041 0.747 0 0.803 
HSPA4 missense_variant p.Cys13Ser rs61745470 0.0142 0.845 0.05 1 
USP49 frameshift p.Asp636TrpfsTer25 rs201338884 0.0078 - - - 
KDM6B missense_variant p.Lys973Gln rs61764072 0.0055 0.616 0.01 0.607 
HORMAD1 missense_variant p.Gln25Arg - 0.0 0.619 0 0.517 
DCLRE1C missense_variant p.Gly153Arg rs41297018 0.0096 0.716 0.03 0.893 
PLEC_5 missense_variant p.Arg2694Trp rs201569045 0 - 0 0.96 
ERCC5 missense_variant p.Met254Val rs1047769 0.017 0.651 0.01 0.688 
STARD6 missense_variant p.Glu121Lys rs374944431 0.0 0.623 0.01 0.624 
NOTCH3 missense_variant p.Val1952Met rs115582213 0.0078 0.797 0 0.895 
SPAG4 missense_variant p.Arg419Cys - - 0.945 0 1 
DNAH8 missense_variant p.Glu355Asp rs367805228 - 0.833 0.02 0.993 
TAF1L_V4 missense_variant p.Arg1509His - - 0.789 0.01 0.938 
TAF1L_V5 missense_variant p.Arg1016Cys rs35905429 0.011 0.895 0 0.993 
ZP2 stop_gained p.Tyr737Ter - - - - - 
TBP missense_variant Not characterized - - - - - 
ZPBP2 inframe_deletion p.Leu12Pro - - 0.847 0.01 0.99 
PINX1_v2 missense_variant p.Gln50His rs189959562 0.0023 0.649 0.05 0.807 
STARD6 stop_gained p.Arg19Ter rs17292725 0.0165 - - - 
KDM4B missense_variant p.Arg155Trp - - 0.563 0.01 0.477 
EXO5 frameshift_variant p.Arg344AlafsTer10 rs150018949 0.011 - - - 
CAPZA3 missense_variant p.Arg39Cys rs61912355 0.0012 - 0.09 0.796 
ATP8B3 missense_variant p.Thr3Ser - - 0.667 0 0.636 
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Dominant Model 
HRASLS splice_donor_variant - rs116653160 0.0023 - - - 
NEK11 stop_gained p.Glu603Ter rs140471991 - - - - 
H1FNT missense_variant p.Ala23Val rs117292373 0.0142 0.719 0.02 0.866 
PRKDC_V2 missense_variant p.Leu3899Val rs201214138 - 0.867 0.01 0.996 
CEP152 splice_acceptor_variant - rs199773611 - - - - 
SP100 splice_donor_variant - rs150147150 0.0005 - - - 
LAMA1 missense_variant p.Cys2457Ser - - 0.945 0 1 
CDC25B missense_variant p.Arg320Cys rs141314132 - 0.905 0.01 1 
Compound heterozygous 
MAST4_v1 inframe_insertion p.Gln62_Pro63insPro - - - - - 
MAST4_v2 missense_variant p.Pro2571Arg - - 0.639 0 0.568 
KAT6B_V1 inframe_deletion p.Glu1097del rs71929101 - - - - 
KAT6B_V2 missense_variant p.Val1545Ile rs145158232 - 0.881 0 0.987 
ERCC4_V1 missense_variant p.Glu875Gly rs1800067 0.0087 0.580 0.02 0.573 
ERCC4_V2 missense_variant p.Arg415Gln rs1800124 0.0312 0.831 0.01 0.981 
ZAN_v1 inframe_deletion p.Asn1099del rs201422303 0.0285 - - - 
ZAN_v2 missense_variant p.Arg1922Cys rs314299 - - 0.05 - 
Recessive 
YLPM1 missense_variant p.Pro636Ala rs45617140 0.0505 0.59 0.04 - 
KIF17 missense_variant p.Arg111Gly rs35835983 0.0129 0.697 0.01 0.78 
X-linked chromosome 
CTAG2 missense_variant p.Gly181Arg rs113459988 0.0218 - 0 0.997 
MAGEE1 missense_variant p.Thr246Asn rs41298484 0.0121 0.388 0.06 0.092 
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2.1.3 Data curation of the candidate WES variants 
Due to some disparities, such as discrepancies in variant annotation owing to the version of 
Ensembl used for the alignment, or discrepancies between the pathogenicity predictors of WES 
data, we decided to make a more comprehensive search of each variant by enrichment analysis for 
the functional role, by confirming predicted pathogenicity with other pathogenicity predictors, and 
by taking into account the MAF in other public databases. Additionally, we also examined the tissue 
expression of each gene in order to obtain more information about the extent to which they might 
be associated with the tumorigenesis process of the disease in terms of the development of the 
organ. 
2.1.3.1 Functional role and involvement in pathways 
Most genes can be simultaneously involved in different processes and pathways. As an 
example, the clustergram below (Figure 16) shows how many genes participate in several biological 
processes. In this case, we can determine that almost 100% of the genes selected may have a 
relevant function or involvement in the development of this disease 
 
Figure 16. Clustergram of Biological Process enrichment  
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Table 3. Enrichment analysis of the WES variants 
Annotation Cluster 1 Enrichment Score: 9.34 p-value Benjamini Genes annotated 
GOTERM_BP sexual reproduction 1.3E-16 1.1E-13 
DNAH9, H1FNT, ZP2, TDRD6, CAPZA3, ZAN, MEA1, 
SOX30, LIG3, SPAG1, JAG2, PRKDC, TBP, HERC2, 
SYCP2, GGN, CDC25B, SBF1, ZPBP2, FANCD2, SPAG4, 
ADAM20, NLRP14, AKAP3, ATP8B3, ODF1, TEX19, 
CYP1A1  
GOTERM_BP gamete generation 7.7E-10 3.7E-7 
GOTERM_BP 
reproductive process in a multicellular 
organism 
2.6E-9 8.2E-7 
GOTERM_BP multicellular organism reproduction 2.6E-9 8.2E-7 
GOTERM_BP male gamete generation  1.2E-7 2.8E-5 
GOTERM_BP spermatogenesis 1.2E-7 2.8E-5 
Annotation Cluster 2 Enrichment Score: 4.39 p-value Benjamini Genes annotated 
GOTERM_BP fertilization 8.9E-7 1.7E-4 
H1FNT, ZP2, TDRD6, CAPZA3, ZPBP2, ZAN, PRKDC, 
AKAP3, ATP8B3, CDC25B; KCNU1      
GOTERM_BP reproductive cellular process 1.2E-6 2.0E-4 
GOTERM_BP single fertilization 2.7E-6 3.7E-4 
GOTERM_BP binding of sperm to zona pellucida 1.8E-4 1.3E-2 
GOTERM_BP sperm-egg recognition 1.8E-4 1.3E-2 
GOTERM_BP cell-cell recognition 3.0E-4 2.0E-2 
GOTERM_BP cell recognition 5.8E-3 1.6E-1 
Annotation Cluster 3 Enrichment Score: 3.86 p-value Benjamini Genes annotated 
GOTERM_CC non-membrane-bounded organelle 1.3E-5 2.5E-3 FGD2, DNAH9, H1FNT, SSH1, TDRD6, GAR1, CAPZA3, 
RHBG, MLH3, SYCP2, DNAH8, CTAG2, INCENP, GYS2, 
BRD4, TINF2, ERCC4, PLEC, PINX1, HIST1H1D, SP100, 
KIF17, PIF1, SOX30, PSRC1, KIF18A, CEP152, NOP10, 
NEK11, GGN, CDC25B, FANCD2, SPAG4, DDX54,TAF1L, 
MAP4      
GOTERM_CC 
intracellular-non-membrane-bounded 
organelle 
1.3E-5 2.5E-3 
GOTERM_CC cytoskeleton 1.5E-2 1.2E-2 
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Annotation Cluster 4 Enrichment Score: 3.41 p-value Benjamini Genes annotated 
GOTERM_CC nuclear lumen 1.0E-4 6.1E-3 
SP100, GAR1, YY1, SOX30, YLPM1, LIG3, PRKDC, TBP, 
TRIM16, NOP10, UBN1, NEK11, GGN, CDC25B, ERCC5, 
POLE2, BCHE, FANCD2, HRASLS, BRD4, DDX54, TINF2, 
ERCC4, NGF, PINX1     
GOTERM_CC nucleoplasm 1.5E-4 5.4E-3 
GOTERM_CC membrane-enclosed lumen 2.0E-4 6.2E-3 
GOTERM_CC intracellular organelle lumen  2.8E-4 7.3E-3 
GOTERM_CC organelle lumen 3.9E-4 9.0E-3 
GOTERM_CC nucleoplasm part 9.7E-3 9.0E-2 
Annotation Cluster 5 Enrichment Score: 3.39 p-value Benjamini Genes annotated 
GOTERM_BP reproductive cellular process 1.2E-6 2.0E-4 
  H1FNT, ZP2, TDRD6, CAPZA3, ZPBP2, ZAN, PRKDC, 
AKAP3, ATP8B3, CCDC62, CYP1A1  
GOTERM_BP reproductive developmental process 1.8E-3 7.2E-2 
GOTERM_BP germ cell development  3.0E-2 5.2E-3 
Annotation Cluster 6 Enrichment Score: 2.71 p-value Benjamini Genes annotated 
GOTERM_BP chromosome organization 3.6E-6 4.2E-4 
H1FNT, HIST1H1D, KIF18A, PRKDC, TRIM16, MLH3, 
SYCP2, UBN1, DCLRE1C, FANCD2, KDM4B, ERCC4, 
TINF2, KDM6B, PINX1  
GOTERM_CC nuclear chromosome 8.5E-5 7.8E-3 
GOTERM_CC nuclear chromosome part 1.4E-4 6.3E-3 
GOTERM_CC chromosome  7.6E-4 1.5E-2 
GOTERM_CC chromosome, telomeric region  8.5E-4 1.6E-2 
SP_PIR_KEYWORDS chromosomal protein  1.4E-3 4.1E-2 
GOTERM_BP regulation of telomere maintenance 2.8E-3 1.0E-2 
GOTERM_BP regulation of organelle organization 3.2E-3 1.1E-2 
GOTERM_CC chromosomal part  3.5E-3 4.8E-2 
Annotation Cluster 7 Enrichment Score: 2.69 p-value Benjamini Genes annotated 
GOTERM_CC nuclear chromosome 8.5E-5 7.8E-3 H1FNT, PIF1, INCENP, MLH3, SYCP2, TINF2, ERCC4, 
PINX1  GOTERM_CC nuclear chromosome part 1.4E-4 6.3E-3 
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Annotation Cluster 8 Enrichment Score: 2.6 p-value Benjamini Genes annotated 
SP_PIR_KEYWORDS ATP-binding 1.5E-4 1.1E-2 RECQL4, NWD1, H1FNT, DNAH9, KIF17, PIF1, KIF18A, 
SPAG1, LIG3, PRKDC, PKN1, ABCA1,  DNAH8, NEK11, 
NLRP14, HSPA4, TNK2, DDX54, ATP8B3 
SP_PIR_KEYWORDS nucleotide-binding 4.6E-4 1.9E-2 
Annotation Cluster 9 Enrichment Score: 2.57 p-value Benjamini Genes annotated 
GOTERM_BP telomere maintenance 3.3E-5 3.5E-3 
 RECQL4, DCLRE1C, ERCC5, SP100, POLE2, FANCD2, 
LIG3, PRKDC, PKN1, MLH3, ERCC4, NEK11,PIF1, APLF, 
GPRC6A, USP49, EXO5   
GOTERM_BP response to DNA damage stimulus  3.6E-5 3.4E-3 
GOTERM_BP telomere organization 3.8E-5 3.3E-3 
SP_PIR_KEYWORDS DNA repair 1.1E-4 1.1E-2 
GOTERM_BP DNA repair 1.1E-4 8.8E-3 
SP_PIR_KEYWORDS DNA damage 1.7E-4 8.7E-3 
GOTERM_BP cellular response to stress 3.6E-4 2.1E-2 
GOTERM_BP DNA metabolic process 5.2E-4 2.7E-2 
GOTERM_BP DNA recombination 6.7E-4 3.1E-2 
GOTERM_BP double-strand break repair 7.6E-4 3.4E-2 
Annotation Cluster 10 Enrichment Score: 2.32 p-value Benjamini Genes annotated 
SP_PIR_KEYWORDS spermatogenesis 5.2E-4 1.8E-2  H1FNT, TDRD6, MEA1, NLRP14, GGN, SPAG4 
Annotation Cluster 11 Enrichment Score: 1.98 p-value Benjamini Genes annotated 
GOTERM_BP M phase 3.3E-4 2.1E-2 
FANCD2, INCENP, LIG3, KIF18A, HORMAD1, MLH3, 
SYCP2, CDC25B, PINX1    
GOTERM_BP meiosis  4.9E-4 2.7E-2 
GOTERM_BP M phase of meiotic cell cycle 4.9E-4 2.7E-2 
GOTERM_BP meiotic cell cycle  5.3E-4 2.6E-2 
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Annotation Cluster 12 Enrichment Score: 1.69 p-value Benjamini Genes annotated 
GOTERM_CC microtubule cytoskeleton 2.9E-3 4.3E-2 
DNAH9, CTAG2, KIF17, INCENP, SPAG4, PSRC1, 
KIF18A, DNAH8, CEP152, CDC25B, DNAAF1         
Annotation Cluster 13 Enrichment Score: 1.67 p-value Benjamini Genes annotated 
GOTERM_CC developmental programmed cell death  2.4E-3 3.8E-2 JAG2;PRKDC;CYR61 
Annotation Cluster 14 Enrichment Score: 1.31 p-value Benjamini Genes annotated 
GOTERM_CC histone H3 acetylation  2.9E-3 4.3E-2 KAT6B;TRIM16;BRD4 
GOTERM_CC regulation of DNA methylation 3.6E-4 3.1E-2 KDM1B;TET1 
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Our selected genes can be divided into 14 significant clusters (Table 3) based on the overall 
enrichment score calculated for each group from the EASE scores of each term member (>1.3), and 
taking as references the Benjamin and Bonferroni tests and the EASE Score Threshold (Maximum 
Probability), a modified Fisher's exact p-value for gene-enrichment analysis. Fisher's exact p-value 
ranges from 0 to 1. An exact p-value = 0 represents perfect enrichment. Usually a p-value equal to 
or smaller than 0.05 is considered strongly enriched in the annotation categories (GOTERM_MF 
(Molecular Function); GOTERM_BP (Biological Process); GOTERM_CC (Cellular component); 
SP_PIR_KEYWORDS (Protein information). 
Although the enrichment score indicates that our genes are involved in many different 
processes, it is important to point out that most of the genes have several functions so that they can 
be included in more than one cluster. Moreover, functional analyses indicate that several genes can 
be involved in any function that could be related to the development of the disease. However, the 
pathway analysis did not give the same results (Table 4 and Figure 17).  
Table 4. Reactome 2016 pathway analysis of WES variants 
Pathway name 
Entities Entities 
pValue FDR 
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) 5.49E-6 2.45E-3 
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) 6.85E-5 9.78E-3 
DNA Double-Strand Break Repair 8.16E-5 9.78E-3 
DNA Repair 8.81E-5 9.78E-3 
Nucleotide Excision Repair 1.13E-4 1.01E-2 
 
 
Figure 17. Distribution of the pathway enrichments of the selected variants according to 
the Reactome 2016 database. 
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Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) and synthesis of (16-
20)-hydroxyeicosatetraenoic acids (HETE) involved in metabolic pathways were the most 
significant (α<0.05), followed by the DNA repair and Nucleotide Excision Repair pathways (Table 
4). Pathways that were expected to be more significant, such as fertilization or reproduction, did 
not reach significant values. However, by doing an in-depth search of the literature (Supplementary 
Table S4) regarding each gene, we found that most of them were involved in several biological and 
molecular processes as the previous analyses showed, so we decided to take both aspects into 
consideration to choose the best candidate genes. So, even if they were selected because of their 
own function, or due to the pathway or biological process they are associated with, the distribution 
that they finally represent for us exclusively in the pathways that have been already described in 
the literature (Pyle et al., 2016) to be involved in the development of the disease (male germ cell 
development, reproduction, microtubule and kinetochore assembly, cytoskeleton, chromosome 
organization and structure, telomere maintenance and organization, and DNA repair and damage) 
is shown in Figure 18.:  
 
 
 
Figure 18. Distribution of the genes along the pathways described in the literature as being 
involved in the development of TGCT. 
2.1.3.2 Pathogenicity and Frequency evaluation 
Taking into account the variability between the pathways, biological processes and 
functional analyses, we decided to improve the fidelity of our results by being stricter with the MAF 
frequency and pathogenicity predictors. Even though filters used in the WES data analysis were 
available, we did our own search to rule out possible mistakes in the updated data (Table 5). 
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Table 5. In silico patogenicity predictors and MAF values from different public databases of WES 
variants 
Gene Existing variant 
Public databases Pathogenicity predictors 
Exac ESP 
1000 
Genomes 
CSVS Condel SIFT PolyPhen Phred 
SPAG1 rs56246127 0.194 0.199 0.15 0.1 - - - 0.004 
TEX19 rs147220016 0.003 0.004 0.002 - - - 0.997 23.4 
EPHX2 rs71553864 0.045 0.059 0.023 0.016 - - - 0.1 
NOP10 rs146261631 0.01 0.012 0.002 - 0.43 0.02 0.629 30 
UBN1 - - - - 0.001 - - - 23.8 
PKN1 - - - - - 0.34 0 0.807 28.2 
MEA1 rs375030293 0.002 0.001 0.003 0.003 - - - 18.6 
MYCT1 rs41292880 0.002 0.003 <0 0.001 0 0.01 0.988 35 
TAF1L_V1 rs140558556 0.001 0.003 0.001 - 0.05 0.02 0.975 23.8 
PDE11A TMP_ESP_2_178936993 - <0 - - - - - 19.3 
SH2D4A rs150534166 0.001 0.002 0.001 - 0.429 0.04 0.999 34 
KCNU1 rs374327006 <0 <0 - - 0.6 0 0.997 23.4 
INCENP rs149820986 0.001 <0 0.002 - 0.37 0 1 22.6 
GREB1 rs142882892 0.012 0.018 0.005 0.022 0.46 0.05 0.846 25.5 
SEMA4D rs13284404 0.03407 0.083 0.015 0.023 0.433 0.01 0.718 28.5 
USP47 rs765821727 <0 - - 0.001 0.47 0.06 - 28 
SSH1 rs570218503 <0 - <0 - 0.413 0.09 0.999 29.6 
GRP rs149962068 0.03 0.043 0.016 - - - - 33 
ODF1_V1 rs568456031 <0 - 0.313 0.037 - - - 10.99 
SSTR5 - <0 - - - 0.736 0 1 23.6 
PSRC1 rs76057315 0.00862 0.013 0.004 - 0.397 0.02 0.001 28 
GAR1 rs150273267 0.003 0.002 0.002 - 0.45 0.18 0.001 23.4 
TAF1L_V3 rs141368669 0.001 <0 - 0.001 - 0 1 23.4 
CYP2C8_V1 rs143386810 0.001 0.001 <0 0.001 0.700 0.01 0.976 26.1 
SHQ1 rs78491606 0.015 0.018 0.004 0.011 0.857 0 0.971 27 
CYP2C8_V3 rs142470035 <0 - 0.001 0.001 0.825 0 0.935 19.5 
DDX4 rs201103498 <0 <0 - 0.001 0.54 0.01 0.529 24.4 
CCDC62 rs141689290 0.001 0.002 0.001 - 0.48 0.06 0.999 24.6 
GFRA1 rs8192662 0.027 0.032 0.017 - 0.635 0.03 0.74 26.7 
CYP2C8_V2 rs1058930 0.039 0.055 0.017 0.048 0.74 0.02 0.901 21.1 
HERC2 rs777897918 <0 - - - 0.445 0.02 0.985 35 
NGF rs11466111 0.011 0.027 0.005 - 0.61 0 0.9 32 
RHBG rs71591938 <0 - - - - - - 29.8 
JAG2 - <0 - - - 0.53 0 0.99 26 
TET1 rs142008363 0.01408 0.017 0.005 - - 0.01 0.721 24.4 
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YY1 rs568477380 - - 0.012 0.003 - - - 15.51 
LIG3 - <0 - - - - - - 50 
GOLGA3 rs76213047 0.008 - 0.003 0.006 0.43 0.01 0.853 23.2 
SMYD2 rs61755311 0.002 - 0.01 - 0.39 0.19 0.725 28.4 
FANCD2 rs372574627 0.00014 <0 <0 - 0.55 0.01 0.922 24.7 
NLRP14 rs76670455 0.003 0.004 0.006 - 0.69 0 0.996 27.3 
LRP4 rs138924815 0.012 0.017 0.004 - 0.536 0.04 0.88 33 
PIF1 rs118009068 0.019 0.027 0.11 - 0.597 0.14 0.997 26.4 
SERPINB11 rs118062397 0.017 0.015 0.016 - 0.77 0 0.939 27.3 
TDRD6 - - - - - 0.38 0.14 0.578 23.8 
BRD4 rs35676845 0.011 0.018 0.006 - 0.44 0.01 0.964 25.3 
TDRD6_V2 rs144670071 0.01515 0.027 0.007 - - - - 10.71 
PRKDC_V1 - <0 - - - 0.57 0.04 0.916 33 
AKAP3 rs2041291 0.1398 0.158 0.158 0.025 0.36 0.01 0.882 22 
RECQL4 rs199654783 0.001 <0 - - - 0 0.982 25.3 
POLE2 rs141483427 0.0002 0.0004 - - 0.57 0.01 0.982 28 
KIF18A rs34913484 0.012 0.019 0.003 - 0.72 0 0.999 25.5 
ADAM20 rs45554935 0.002 0.003 0.001 0.004 0.58 0 0.854 23.6 
DNAH9 - - - - - - - - 19.99 
SYCP2 rs6071006 0.021 0.032 0.011 - 0.371 0 0.944 23.5 
DDX54 rs201635496 - - - 0.001 0.33 0 0.997 34 
VNN1 rs189034822 0.001 <0 0.001 - 0.6 0.03 0.88 33 
CYP3A43 rs143991326 0.001 - 0.007 - 0.79 0 - 24.5 
ABCA1 rs551884479 <0 - <0 - 0.53 0.37 0.949 24.3 
SOX30 rs184421438 0.007 0.007 0.009 0.003 0.55 0 0 21.2 
MLH3 rs28756990 0.015 0.007 0.026 - 0.43 0.11 0.89 21.4 
CCDC33 rs369047254 <0 <0 <0 - - - - 25.2 
SBF1 rs199972466 0.001 <0 0.002 - 0.49 0.01 0.925 35 
CYR61 rs148330006 0.005 0.007 0.003 - 0.5 0.03 0.992 24.9 
PLEC rs138924815 0.01 0.01 0.004 0.006 0.472 0.04 1 23.6 
GYS2 rs202136674 <0 - <0 - 0.6 0.08 0.99 27.5 
DNAAF1 rs144018942 0.001 0.003 0.001 - 0.4 0.07 0.988 27.1 
MAP4_V1 rs2230169 0.051 0.073 0.027 - 0.41 0.02 0.991 24.3 
MAP4_V2 rs11711953 0.055 0.078 0.029 0.066 0.48 0.17 1 34 
SPZ1 rs111595904 0.003 <0 0.011 - - - - 20.9 
SPATA12 rs76587478 0.029 0.039 0.02 - 0.45 - 0.458 13.09 
CYP1A1 rs41279188 0.004 0.007 0.001 - 0.69 0 0.814 33 
APLF rs149897324 0.01 0.015 0.005 - - - - 35 
FSIP2_v2 rs76311269 0.005 - 0.029 - 0.716 0 0.74 21.5 
FSIP2_v1 rs11892184 0.005 - 0.029 - 0.595 0.05 0.694 19.13 
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TNK2 rs13433937 0.031 0.049 0.016 0.043 0.853 0 0.966 29.8 
TRIM16 rs3174720 0.039 0.049 0.02 0.031 0.74 0.02 0.901 26.5 
BCHE rs1799807 0.012 0.02 0.006 - 0.54 0.01 0.576 23.7 
PINX1 rs17855458 0.016 0.012 0.016 - 0.412 0 0.31 25.4 
NWD1 rs138924815 0.012 0.017 0.004 - - - - 42 
GPRC6A - - - - 0.13 - - - 39 
KDM1B rs72840622 0.012 0.023 0.004 - 0.43 0.01 0.977 23.8 
HIST1H1D rs202225825 <0 <0 - - 0.34 0.01 0.004 18.63 
FOXR1 rs45602538 0.004 0.008 0.001 - 0.69 0 0.564 22.4 
GGN rs62123481 0.008 0.012 0.005 - - - - 40 
PDCL2 rs756587149 <0 - - - 0.574 0 0.999 33 
FGD2 - <0 - - - 0.43 0.01 0.994 25.8 
PLEC_4 rs78461695 0.007 0.011 0.006 0.008  0.03 0.975 25.9 
TINF2 rs17102311 0.002 0.0001 0.007 - 0.57 0.28 0.978 23.4 
HSPA4 rs61745470 0.013 0.018 0.01 0.041 0.27 0.44 0.991 27.6 
USP49 rs201338884 0.012 0.017 0.006 - - - - 35 
KDM6B rs61764072 0.008 0.013 0.004 0.007 0.424 0.24 0.994 24.7 
HORMAD1 - - - - - 0.48 0 0.517 24.4 
DCLRE1C rs41297018 0.011 0.015 0.006 - 0.644 0.03 0.288 33 
PLEC_5 rs201569045 <0 - <0 - 0.513 0.01 0.96 27.1 
ERCC5 rs1047769 0.029 0.036 0.019 - 0.4 0.11 0.365 24 
STARD6 rs374944431 <0 <0 - - 0.478 0.01 0.624 26.8 
NOTCH3 rs115582213 0.008 0.01 0.005 - 0.5 0 0.988 34 
SPAG4 - <0 - - - 0.53 0 0.986 35 
DNAH8 rs367805228 <0 <0 <0 0.002 0.536 0 0.999 26.2 
TAF1L_V4 - <0 - - - 0.43 0 0.938 31 
TAF1L_V5 rs35905429 0.019 0.027 0.008 - 0.47 0 0.998 28.8 
ZP2 - - - - - - - - 35 
TBP No characterize - - - - - - - - 
ZPBP2 - - - - - 0.5 0 0.942 24.8 
PINX1_v2 rs189959562 0.004 0.006 0.002 - 0.479 0.15 0.995 24.2 
STARD6 rs17292725 0.028 0.04 0.015 - - - - 35 
KDM4B - <0 - - - 0.49 0.02 0.747 27.2 
EXO5 rs150018949 0.013 0.023 0.008 0.01 - - - 28.3 
CAPZA3 rs61912355 0.005 0.002 0.001 - - 0.01 0.72 29.9 
ATP8B3 - <0 - - - 0.45 0 0.636 14.8 
HRASLS rs116653160 0.002 0.003 0.001 - - - - 26.7 
NEK11 rs140471991 <0 <0 - - 0.4 0.08 0.267 41 
H1FNT rs117292373 0.024 0.03 0.016 - 0.422 0 0.61 25.5 
PRKDC_V2 rs201214138 0.001 0.001 0.001 - 0.32 0.01 0.996 24.6 
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CEP152 rs199773611 <0 <0 - - - - - 23.1 
SP100 rs150147150 0.002 0.003 <0 - - - - 13.42 
LAMA1 - - - - - 0.649 0 1 27.1 
CDC25B rs141314132 <0 <0 - - 0.424 0.01 1 35 
MAST4_v1 - - - - - - - - 21 
MAST4_v2 - - - - - 0.48 0.01 0.695 23.4 
KAT6B_V1 rs71929101 - - 0.002 0.035 - - - 0.069 
KAT6B_V2 rs145158232 <0 0.0001 - - 0.53 0 0.99 26.7 
ERCC4_V1 rs1800067 0.056 0.077 0.029 - 0.46 0 0.585 27.7 
ERCC4_V2 rs1800124 0.013 0.017 0.006 - 0.57 0.01 0.98 35 
ZAN_v1 rs201422303 <0 - - - - - - 22.7 
ZAN_v2 rs314299 0.5146 - 0.237 0.499 0.6 0.04 0.947 23.7 
YLPM1 rs45617140 0.078 0.096 0.043 0.089 0.59 0.04 - 21.1 
KIF17 rs35835983 0.014 0.016 0.007 - 0.68 0 0.77 23.5 
CTAG2 rs113459988 0.007 0.072 - - 0.4 0.02 0.884 12.77 
MAGEE1 rs41298484 0.015 0.017 0.006 - 0.388 0.06 0.939 12.84 
 
Variants with a MAF that exceeds 0.05 in two of the tree databases (highlighted in red), or 
were considered as tolerated in 2 of the four principal pathogenicity predictors (highlighted in 
green) were excluded from further analysis with predictSNP (Supplementary Table S5). The 
variants that were discarded correspond to the genes SPAG1, GAR1, AKAP3, SPATA12, YLPM1 
and MAGEE1. The genes that are indicated in orange boxes, MAP4_V1, MAP4_V2, ERCC4_V1, 
and ZAN_V2 are variants that exceed the MAF threshold, but they were not excluded from the 
analysis because they were considered in a compound heterozygous model; we therefore did not 
consider the individual MAF score of each variant and included these genes in further analysis, 
because MAFs are not described for this type or pattern of inheritance. In the end, we obtained 125 
possible candidate variants from the monogenic pattern of inheritance.  
2.1.4 Analysis of tissue expresion 
Afterwards, we consulted the GTEx database to determine in which tissue our genes were 
expressed to gauge the possible importance of the gene for testicular development, or to what extent 
the gene could be involved indirectly in the process. In addition, we needed this information for the 
validation of the splicing variants, because we only have peripheral blood samples (Supplementary 
Table S6) and if the gene is not expressed in whole blood we would not be able to validate it. 
Apart from the genes that are exclusively expressed in testis (FOXR1, SPZ, DDX4, 
CCDC62, ODF1, KCNU, and TEX19), based on the average RPKM value, 40% of the genes are 
expressed most abundantly in testis, for 5% the testes are the second, for 6% they are the third, and 
for 7% they are the fourth-most abundant tissue; for 3% of the genes the testes are the last tissue of 
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the top five. On the other hand, 42 genes are expressed in the testis but at low levels, 8 of them 
present values <1 RPKM, and the remaining 80% present values between 4.6 and 1.13 RPKM.  
2.5 Validation of splicing variants 
After having obtained as much information as possible for each gene, we began analyzing 
the splicing variants. First, in silico analysis was done with Alamut v3.1; as mentioned above, this 
program includes five different algorithms that calculate the effect on splicing of each nucleotide 
change and finally gives an overview of possible splicing-related events in almost a consensus 
result. Five splicing variants were found in the monogenic model of inheritance, four were splice 
donor site variants and only one was a splice acceptor site variant. To evaluate the effect these 
variants might have on transcript splicing, we studied the effect at the cDNA level. Unfortunately, 
we could only study the variant in three genes because we did not have RNA samples from all 
individuals (Table 6).  
Table 6. WES Splicing variants: in silico analysis and material availiable for each validation 
Gene cDNA Effect  Prediction Consequence Prediction 
Material available 
RNA 
Expresion 
in blood 
UBN1 c.249+1 splice_donor_variant skip exon 2b yes yes 
CCDC33 c.638+1 splice_donor_variant skip exon 6 yes no 
CEP152 c.1578-1 splice_acceptor_variant skip exon 13 yes no 
SP100 c.1546+1 splice_donor_variant skip exon 16 no - 
HRASLS c.454+1 splice_donor_variant skip exon 2 no - 
 The only splice acceptor variant is located in the CEP152 gene, at c.1578-1. It is predicted 
to interrupt the canonical splice acceptor site, and consequently to cause skipping of exon 13 (Figure 
19). 
.  
Figure 19. Alamut v3.1 in silico prediction for the CEP152 variant foresees a new splice site. 
New splice site 
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 Even though, any of the five algorithms predicted a new splice acceptor site along the 
sequence, Sanger sequencing revealed that the second potential splice site was not activated, but 
that a new one was activated and that produces the loss of 14 bp at the start of the exon (Figure 20). 
 
   
Figure 20. Sanger Sequencing for CEP152 variant validation. 
The variant located in the UBN1 gene is located at the c.249+1 position, and leads to a G>A 
change, producing the loss of the splice donor site. All predictors agree on this in silico prediction 
with high parameter values about the skip of exon 2b (Figure 21). 
Figure 21. Alamut v3.1 in silico prediction for UBN1 variant foresees the loss of a splice donor 
splice site. 
However, Sanger sequencing revealed different results. Although the in silico prediction 
showed that the putative splice donor site is located upstream of the canonical one, it does not seem 
to be activated: the chromatogram shows that, in absence of the canonical site, the activated splice 
donor site is rather producing the loss of the last 27 bp of the exon and disrupts the protein (Figure 
22). 
New donnor site 
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Figure 22. Sanger Sequencing for UBN1 variant validation 
The last splicing variant studied is located in the CCDC33 gene (c.638+1). It is predicted 
to affect a splice donor site, producing its loss and consequently skipping of exon 6 according to all 
five in silico predictors (Figure 23). 
Figure 23. Alamut v3.1 in silico prediction for CCDC33 variant foresees the loss of a splice donor 
splice site. 
However, Sanger sequencing revealed that the donor variant was not modified and no exon 
skipping took place.  
2.2 Polygenic model of inheritance 
To carry out this study, we used the raw data from the WES, only filtered by canonical 
isoform and pathogenic predictors, and performed the Family based assotiation test (FBAT). This 
test allows us to study those genes that are supposedly more associated with the disease and also 
have a familial scenario. The basis of this test is to bring up the genes that are most mutated (they 
should present more than 3 variants) and are associated with a phenotype, in our case TGCT. 
Moreover, it also lets us introduce different covariates; in our case we could study the nuclear 
Loss of donnor site 
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familial, in which we compared data form the pair of brothers and their parents, because our 
principal covariate was the relationship between the individuals.  
Since to date only low susceptibility variants have been identified that are involved in the 
development of the disease, and since we are studying families, we are searching for rare variants, 
and two different analyses based on the FBAT test were performed. On the one hand, we performed 
the FB-SKAT, which considers common and rare variants in the two possible scenarios for each 
gene, protective or risk behavior, while the FB-Burden analysis considers only rare variants, and 
all of them should have the same behavior. These tests let us search for genes that could be 
associated with the development of the disease with a defined pattern of inheritance, while, on the 
other hand, we also performed a SKAT analysis that is similar to FB-SKAT but for independent 
samples, and searched for variant genes that were linked to the disease, i.e., they appear only in 
affected patients and are absent in the healthy members of the families. To carry out these analyses, 
we used the data from the WES approach, but we filtered them with the pathogenicity predictors 
and we only considered variants located in the canonical isoform.  
2.2.1 FBAT results 
Although we were looking for high/moderate susceptibility genes, we had to take into 
account that for complex diseases the combination of low susceptibility variants is the best genetic 
approach that fits in with the disease, which is the reason that we performed the two types of FBAT. 
For the analysis of the FBAT with a MAF of 0.05 (Burden test), we obtained 929 genes that present 
more than 3 variants in any of the affected members of the family and in at least one of the parents 
so that it could have been inherited; however, only 153 genes had sufficiently significant p-values 
to be considered in the next step. For the FB-SKAT with a MAF of 1, 1104 genes were supposedly 
associated with the disease and presented a pattern of inheritance, but only 202 genes had significant 
p-values when taking the Kernel association test into consideration. Afterwards, we selected genes 
with a function that could be related to the development of the disease, or that were involved in any 
of the described pathways. To achieve this, we used different databases to curate our selection: the 
Ernrichr database, the David annotation tool, and the Gene ontology. Next, as we were looking for 
high or moderate susceptibility variants, and the results obtained from the WES offers all type of 
variants, we used Venny to create Venn diagrams to analyze how many genes were in common 
between the 2 analyses that were performed with a MAF of 0.05 (which corresponds to a Burden 
test) and a MAF of 1 (FB-SKAT). 
We created a Venn diagram (Figure 24) with the two groups of genes (63 and 70 genes), 
and we created two different data sets to start the study. The first one consisted of the 22 genes that 
appeared only to be significant in the analysis of the FB-Burden test with a MAF≤ 0.05, and the 
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other data set (131genes) consisted of those genes that appeared to be significant in both analyses 
and that appeared in the Venn diagram as common to both lists. 
We have to realize that, although the genes with a MAF≤ 0.05 should also be included in 
the MAF≤ 1 analysis, the program requires that the gene must have at least 3 variants. So, if the 
analysis performed with a MAF≤ 1 returns many genes, what could be taking place is that the 22 
genes were less significant in this analysis than other genes, so that they were not included in list 2 
(Figure 24). 
 
Figure 24. Venn diagram showing variants common to both groups. 
 
2.2.1.1 Analysis of List 1: FB-Burden tests (MAF ≤ 0.05): 
Overall, only 22 genes that presented a significant p-value for this test (0.005675293-
0.050335676) had been selected and clustered as an independent group.  
First of all, we selected the genes depending on their function and on their involvement in 
any of the main pathways described as responsible for causing the diseases (Pyle & Nathanson, 
2016). Of the 22 genes, only 8 genes looked in first instance as candidate genes. We then evaluated 
the presence of the variants from these genes in the WES data, depending on how common they are 
in affected vs healthy members. Of the 8 genes, 73 variants were contemplated as risk variants. 
Afterwards, as we looked for a genetic model of inheritance, we studied the pattern of inheritance 
of each one, and 47 variants accomplished a dominant or a recessive model; of these, only 29 had 
an interesting impact effect, considering frameshift, missense, synonymous, stop, in frame deletion 
or insertion, and splice site variants. However, 17 of them exceeded the parameters of the WES 
data quality analysis and were discarded. Finally, we looked at their possible pathogenicity with the 
in silico predictors (Supplementary Table S7) used in the other model of inheritance and obtained 
a final group of 11 variants selected as potential candidates (Table 7). Function and pathways in 
which these genes are involved are shown in Supplementary Table S8 
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Table 7. Characteristics of the candidate variants obtained by FB-Burden analysis 
Gene 
Variant 
effect 
Existing 
variant 
Public databases Pathogenicity predictors 
Exac ESP 
1000 
genomes 
CSVS Condel SIFT Polyphen Phred 
DNAH7 
missense rs146463525 0.00 0.00 0.00 - 0.69 0 1.00 33 
missense - - 0.00 - - 0.73 - - 0.48 
missense rs62623377 0.02 0.03 0.01 - 0.69 0 1.00 27 
missense rs144390858 0.01 0.01 0.01 0.01 0.39 0 0.31 23.7 
LRP2 
missense rs34291900 0.03 0.04 0.02 0.03 0.62 0 1.00 33 
splice region rs766473797 - - - - - - - 13.08 
PKDREJ 
Inframe 
insertion 
rs538611590 0.00 - - - - - - 23.7 
frameshift 
TMP_ESP_22_
46653399_466
53402 
0.00 0.02 - 0.00 - - - 34 
BZRAP1 
frameshift rs376971639 0.03 - - - - - - 31 
synonymous rs3744098 0.02 0.03 - - - - - 9 
SIRT1 missense - - - - - 0.39 0.02 0.00 19.84 
 
2.2.1.2 Analysis of List 2: FB-SKAT tests (MAF ≤ 1): 
This dataset was composed of 131 genes. First of all, as we did for the analysis above, we 
filtered genes out considering a combination between their involvement in biological processes and 
pathways; 34 genes remained that had significant p-values and important functions. 
Then, we looked through the WES data and discarded those genes that appear only in 
healthy individuals. This left 207 possible risk variants, and bring up those variants that have a 
paternal origin, which make up a group of 145 variants. Afterwards, we filtered taking into 
consideration the type of variants and their impact effect (we selected frameshift, missense, 
synonymous, stop, in frame deletion or insertion variants, and variants that affected splice sites), 
leaving a group of 58 variants. After filtering for impact effect, we looked at the behavior of each 
variant in the raw WES data; the ones that presented low reads, a var/depth in disagreement with 
the results or either uncover should be ruled out, but, in this case all of them had correct parameters 
and therefore no additional variants were discarded. Finally, we confirmed the pathogenicity with 
the in silico predictors (Supplementary Table S9) used in the other model of inheritance, and 
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discarded 5 variants. Splicing effect was evaluated with Alamut v3.1 and ruled out 7 variants. In 
the end, even though we are considering rare and common variants, we decided to filter for a 
MAF<0.05, which is the standard allele frequency for low susceptibility variants, and finally we 
obtained a group of 24 potential candidate variants (Table 8). Function and pathways in which these 
genes are involved are given in Supplementary Table S10 
Table 8. Characteristics of the candidate variants obtained by FB-SKAT analysis 
Gene 
Variant 
effect 
Existing 
variant 
Public databases Pathogenicity predictors 
Exac ESP 
1000 
genomes 
CSVS Condel SIFT Polyphen Phred 
ADAM8 missense rs36054052 0.003 - 0.01 - 0.72 0.01 0.987 24.5 
APLF missense rs36021078 0.03 0.03 0.03 0.03 0.42 - - 25.20 
CCR5 
missense rs145061115 0.00 0.00 0.00 0.00 0.79 0.00 0.99 24.50 
missense rs1799863 0.01 0.02 0.01 0.04 0.71 0.00 1.00 24.30 
missense rs34418657 0.00 - - - 0.64 0.00 1.00 29.80 
DHX34 
missense rs143911542 0.00 0.00 - - 0.54 0.02 0.70 24.90 
missense rs12984558 0.05 0.05 0.02 0.08 0.33 0.02 0.70 24.90 
missense rs151213663 0.00 0.00 0.00 0.01 0.33 0.03 0.58 26.70 
GREB1 missense rs145454387 0.02 0.01 0.01 0.04 0.40 0.18 0.50 19.12 
HERC2 
missense - - - - - 0.53 0.01 0.79 23.10 
missense - - - - - 0.61 0.00 0.98 26.20 
missense - - - - - 0.45 0.02 0.98 35.00 
missense - - - - - 0.46 0.00 0.96 27.30 
KAT6B 
inframe 
deletion 
rs71929101 - - - - 
- 
- - 
0.07 
missense rs145158232 0.00 - - - 0.54 0.00 0.99 26.70 
MAP3K1 
inframe 
deletion 
- - - - - 
- 
- - 
16.99 
MYH14 missense - - - - - 0.59 0.00 0.98 26.00 
 missense - - - - - 0.45 0.16 0.79 27.20 
NF1 missense - - - - - 0.50 0.00 0.94 32.00 
 missense - - - - - 0.46 0.02 0.94 34.00 
SALL3 synonymous rs7233194 0.03 0.03 0.02 0.05 - 0.01 - 9.00 
 missense 
COSM19618
5 
0.02 - - - 
0.52 
0.00 0.98 
23.70 
SLC22A16 missense rs75035916 0.00 0.01 0.01 0.00 0.35 1.00 0.00 23.60 
 missense rs41288594 0.01 0.02 0.01 0.02 0.76 0.00 1.00 24.70 
TNXB     missense - - - - - 0.76 0.01 0.95 23.70 
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2.2.2 Case control study using WES data: SKAT results 
As we mentioned above, we have also performed a case control analysis using the WES 
data in order to study variants implicated in TGCT but withouth the covariante of pattern of 
inheritance, we used the data of healthy individuals (30 familial members) as controls vs the data 
of the probands (19 affected individuals) from each family as if they were independent cases. Of 
1209 initial genes, only 96 had significant p-values. After having studied if their function could be 
related to the development of the disease or be involved in any of the described pathways, we 
considered 78 genes as interesting. Then we looked through their distribution in the WES data and 
classified the variants as pathogenic or not depending on the percentage in which they appeared in 
the healthy individuals vs affected members. After applying this filter, we left a group of 125 
variants, 62 of which did not have a paternal origin. We filtered for the impact effects of these 
variants and ruled out variants that presented low reads, a var/depth in disagreement with the results, 
or variants that are yet undescribed; this left us with 23 variants. Finally, we confirmed the 
pathogenicity with the in silico predictors (Supplementary Table S11) used in the other model of 
inheritance and splicing effects, and reduced the MAF filter to 0.05 which gave us a group of 10 
potential candidate variants (Table 9). Function and pathways in which these genes are involved 
are shown in Supplementary Table S12 
Table 9. Characteristics of the candidate variants obtained by SKAT analysis 
Gene Variant effect 
Existing 
variant 
Public databases Pathogenicity predictors 
Exac ESP 
1000 
genomes 
CSVS Condel SIFT Polyphen Phred 
ABCA1 
synonymous 
rs9282537 0.04 0.09 0.08 0.03 - - 0.97 21 
splice acceptor - 
0.00 
 
- - - - - 27.1 
DACT1 missense rs34015825 0.04 0.05 0.03 0.06 0.42 0.01 0.36 23.6 
IRX1 missense rs3596328 - - - - 0.47 0.03 0.79 23.9 
LBP missense rs2232607 0.01 0.09 0.07 0.08 0.33 0.01 0.75 23.7 
MAGI2 
missense - 0.01 - - - 0.36 0.02 - 22.9 
missense - - - - - 0.38 0.00 - 22.9 
PGRMC2 missense - - - - - - 0.02 - 23.4 
RYR2 synonymous rs72549414 0.03 0.02 0.03 0.03 - - 0.99 2.9 
SYT8 missense rs138428155 0.01 0.01 0.01 0.01 0.36 0.01 - 23.4 
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2.2.3 Analysis of tissue expression 
To assess the importance of each gene in the development of the testes, we consulted the 
GTEx database for information on the tissues in which our candidate genes were expressed, with 
special focus on the testes. 
The expression of these genes in the testes was in general low: of the 22 genes, only 3 are 
most abundantly expressed in the testes, for 1 gene the testes were the second-most abundant tissue, 
and for one gene it was the fifth-most abundant tissue. Overall, 82% of the genes are expressed in 
the testes at a low level, and of two genes testicular expression is virtually absent (Supplementary 
Table S13).  
2.2.4 Splicing variants 
Of the six candidate variants that came from the polygenic model of inheritance, only two 
were studied. The variants located in the genes RYR2, LRP2 and ABCA1 were discarded in the first 
approach of the case control study because Alamut's in silico predictors showed that they were 
clearly less strong candidates than the others. The BZRAP1 variant (c.1500 C<T; p.Gly500Gly) is 
a synonymous variant predicted to change the putative binding sites in the exonic splicing enhancer; 
this variant could only be validated at the genomic level by the Openarray assay. The SALL3 variant, 
which is also a synonymous variant (c.3240 C<T; pPro1080Pro), is suggested to produce a new 
splice donor site (Figure 25) resulting in the loss of 1172 bp, an effect that can be validated at the 
cDNA level. 
 
Figure 25. Alamut v3.1 in silico prediction for SALL3 variant foreseen the generation of a new 
splice donor splice site. 
As the image shows, the nucleotide change is predicted by all 5 in silico predictors, and 
with high parameters values, to produce a new splice donor site in the middle of exon 2, although 
New donnor site 
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the Alamut v3.1 software predicts that this variant will not alter the protein sequence. Due to the 
discrepancy between the data we decided to analyze the cDNA to study the possible splice effect 
this synonymous variant could be producing. In this case, Sanger sequencing of the cDNA revealed 
that the splicing process was not affected. 
 
3. CASE CONTROL ASSOCIATION STUDY 
The OpenArray assay allow us to evaluate the frequency of our variants in different 
populations. In this thesis, we have studied the candidate variants that came from the both models 
of inheritance in two types of populations: a cohort of unaffected individuals composed of 382 
samples from healthy Spanish males obtained from the Bar association in Madrid, and a cohort of 
391 sporadic cases collected by ourselves through collaborations with a number of Spanish 
hospitals. 
3.1 Selection of candidate variants for the OpenArray system 
Although we had 125 candidate variants from the monogenic model and 46 candidate 
variants from the polygenic model, we could only study 120 variants in the TaqMan® genotyping 
platform due to restrictions imposed by the capacity of the platform. We therefore applied again 
some of the previous filters, but in this case more stringently 
3.1.1 Variants shared ammong families 
Considering the raw data, it is important to point out that some of the variants are common 
among families; fourteen and seven variants are shared between 2 and 3 different families, 
respectively (Table 10). Moreover, there are 2 different variants located in the GRP and ERCC4 
genes that are present in 4 and 6 families, respectively. We first chose those variants that were 
common among different families. 
Table 10. Variants share ammong families 
Nºof Families with mutation carriers Gene 
Existing 
variant 
Mutation 
carriers 
2 
SHQ1 rs78491606 8 
FSIP2_v2 rs76311269 8 
FSIP2_v1 rs11892184 8 
NWD1  rs138924815 3 
GPRC6A  - 6 
YY1  COSM949287 3 
STARD6_V2 rs17292725 6 
RECQL4 rs199654783 3 
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2 
ERCC4_V2 rs1800124 6 
DHX34 rs151213663 4 
IRX1 rs3596328 3 
MAGI2 - 3 
MAGI2 - 4 
SLC22A16 rs41288594 5 
PGRMC2 - 4 
3 
CYR61 rs148330006 7 
GGN  rs62123481 8 
HSPA4 rs61745470 8 
KIF17 rs35835983 7 
LBP rs2232607 6 
SYT8 rs138428155 5 
KAT6B rs71929101 7 
4 GRP rs149962068 10 
6 ERCC4_V1 rs1800067 15 
 
3.1.2 Impact effect 
We next took the functional effect into account, considering the most interesting ones the 
variants affecting stop codons, initiation codons, frameshifts, in-frame deletions or insertions and 
variants affecting splice sites; finally, we also selected the missense variants (Figure 26). 
  
Figure 26. Distribution of the variants selected according to their impact effect 
 
3.1.3 Most frequent variants per gene 
Furthermore, as we are looking for potential genes, we decided to include those genes in 
which more than one variant appears, even though they were not in the same family (Figure 27),.  
4%
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Initiator_codon
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Figure 27. Representation of the number of variants the most mutated genes have. 
3.2 OpenArray results 
Taking all the information together about the characteristics of each variant, the presence 
in the family, their distribution in the pedigree, functional impact, and possible involvement because 
of their function in the development of TGCT, we finally obtained a group of 120 variants to be 
genotyped. A total of 95 variants were analyzed, but no significants results were obtained from the 
analysis. Most of the variants were considered as rare variants because only a few number of cases 
or controls carried the variant. Although we had a considerable group of samples, taking into accoun 
that the variants we are evaluating were almost all rare variants, we needed a larger number of 
samples to increase the statistical power to evaluate their possible involvement in testicular cancer. 
due to its low frequency in the population. 
3.3 Discovery study results 
To achieve our objective and increase the number of samples, we used the data from the 
CIBERER Spanish variant server (CSVS), which contains WES data of around 788 unaffected 
TGCT individuals. With this analysis that corresponds to the discovery analysis we studied the 
behavior of the 95 variants previously studied in the Open array assay that gave null results in the 
Spanish population 
The discovery analysis of the Spanish population revealed 27 significant variants with p-
values <0.05 and widely varying Odds Ratios (ORs) (Table 11). First, we evaluated if the variants 
conferred a protective effect or a risk effect for the development of the disease. This evaluation 
depends on the OR values and on the condition that p-values are significant: if the OR is less than 
2
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2
2
2
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22
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HERC2
TAF1L
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1, the presence of the alternative allele will be considered to confer a protective effect, while if the 
OR>1, the presence of the alternative allele will be associated with risk of developing the disease. 
In our case, as Table 12 shows, all variants must be considered as risk variants.  
Afterwards, we evaluated the effect that the alternative allele of our variants could have on 
the probability of developing the disease. To achieve this objective, we used the standard values 
described, which range from low susceptibility if the OR <2, to moderate if 2<OR<4, and to high 
if the OR is more than 4. Only the allele of one variant, located in the GPRC6A gene, conferred 
low-risk susceptibility (OR 1.9; p<0.005), and 12 alleles conferred a moderate-risk susceptibility 
for the development of the disease. Furthermore, fourteen of the variants presented OR values of 
more than 4, which indicates that the alternative allele of these variants could be considered as an 
allele that confers high-risk susceptibility for the disease. However, some of the OR values were 
extremely high, such as the ones for PLEC (OR=71.2; p-value<0.05) or ERCC4_V2 (OR=34.9; p-
value<0.05) (Table 11). These high OR are due to the fact that the variants are present only in some 
cases and absent in controls, such for that statistic analysis give these numbers, however they can 
easily change by adding one more positive case or control. So we can not be sure about the meaning 
of these OR. The distribution of these variants (Table 12) among the 19 families (Figure 12) is quite 
variable: 63% of them are present only in one of the families, 22% in two families, and variants in 
the LBP and LRP4 genes are present in three families (pedigrees 9, 11, 16 and 2, 12, 16, 
respectively). Finally, the variant located in the GRP gene is shared among 4 families (pedigrees 
2,4,11,17), and the one in the ERCC4_V1 gene is shared among 6 families (pedigrees 2,4,5,8,16,17) 
(Figure 28). However, in not every case there is complete penetrance of the variant along the 
pedigree. 
 
 
Figure 28. Distribution of the 27 siginificant variants per family. 
63%
22%
7% 4% 4%
1 2 3 4 6
Variants per family
Number of families 
ERCC4_V1 GRP 
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Moreover, it is important to point out that 12 of the families (Figure 12) share some of these 
variants (Table 11), which may suggest the existence and additive or cumulative effects of the 
variants in these families that could explain the possible origin of the development of the disease.  
 
Pedigrees Gene affected 
      
3 CCR5  VNN1 
      
4 ERCC4_V1  GRP 
      
8 ERCC4_V1  BCHE 
      
9 ERCC4_V2  LBP 
      
15 TAF1L_V5  BRD4 
      
19 DHX34  SLC22A16_V2 
      
1 TNXB  BCHE SBF1 
     
17 ERCC4_V1  ERCC4_V2 GRP 
     
14 BZRAP1  SLC22A16_V1 NOTCH3 DCLRE1C 
    
2 ERCC4_V1  GRP LRP4 GPRC6A PLEC 
   
11 DNAH7  GRP LBP GPRC6A RECQL4 
   
16 ERCC4_V1  LRP4 LBP EXO5 DHX34 H1FNT SLC22A16_V2 RECQL4 
 
Figure 29. Representation of the variants shared among different families. 
 
Furthermore, some combinations of the variants are shared by different families, such as 
the presence of the variants located in the genes GPRC6A and GRP, or the ones in DHX34 and 
SLC22A16_V2 that appear together in 2 families (Figure 29). But more interesting is the 
combination between ERCC4_V1 and GRP, which not only is shared among 3 families, but also 
appears in combination with LRP4 in one family while ERCC4_V1 appears together with LRP4 in 
another family. 
Finally, when looking at the pattern of inheritance and excluding 2 variants could not be 
analyzed, we observed that the rest of the variants presented a dominant model; what is more, except 
for variant rs1800067 which present both origins, 55% are of a paternal origin and 30% are of a 
maternal origin. 
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Table 11. Results of the Discovery and Replication Analyses 
Gene 
Existing 
variant 
Dominant 
Inheritance Model 
Discovery analysis Replication study 
OR p-value 
MAF MAF 
OR p-value Family 
cases 
Sporadic 
cases 
Controls Cases Controls 
ERCC4_V1 rs1800067 Paternal or Maternal 4.30 2.74E-17 0.19 0.11 0.12 0.08 0.08 - - 
ERCC4_V2 rs1800124 Paternal 34.93 2.43E-13 0.07 0.03 0.04 0.02 0.02 - - 
PLEC rs138924815 Paternal 71.28 3.35E-12 0.06 0.03 0.02 0.00 0.00 - - 
GRP rs149962068 Maternal 3.57 1.46E-08 0.09 0.05 0.06 0.07 0.089 - - 
LRP4 rs118009068 Maternal 4.67 4.27E-08 0.09 0.04 0.03 0.03 0.02 - - 
TNXB - Unknown origin 3.81 9.21E-07 0.04 0.04 0.03 0.00 0.00 - - 
TAF1L_V5 rs35905429 Paternal 5.26 6.09E-06 0.01 0.03 0.02 0.03 0.03 - - 
KIF18A rs34913484 Maternal 5.08 7.51E-06 0.04 0.03 0.02 0.02 0.02 - - 
BRD4 rs35676845 Maternal 7.51 4.41E-05 0.03 0.02 0.01 0.04 0.05 - - 
LBP rs2232607 
Paternal & unknown 
origin 
3.85 1.37E-04 0.08 0.03 0.02 0.02 0.02 - - 
EXO5 rs150018949 Paternal 3.66 3.38E-04 0.03 0.02 0.02 0.02 0.02 - - 
DHX34 rs151213663 Paternal 7.99 1.95E-03 0.06 0.01 0.00 0.01 0.01 - - 
PSRC1 rs76057315 Maternal 10.48 2.30E-03 0.06 0.01 0.00 0.01 0.01 - - 
H1FNT rs117292373 Unknown origin 2.98 2.33E-03 0.09 0.03 0.03 0.03 0.03 - - 
CCR5 rs1799863 Paternal 2.54 3.77E-03 0.04 0.02 0.02 0.02 0.03 - - 
BZRAP1 rs3744098 Maternal 4.37 4.03E-03 0.06 0.01 0.01 0.00 0.00 - - 
GPRC6A - Paternal 1.91 5.54E-03 0.09 0.05 0.06 0.00 0.00 - - 
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BCHE rs1799807 Paternal 3.25 6.95E-03 0.04 0.03 0.04 0.00 0.00 - - 
SLC22A16 rs75035916 Paternal 8.06 1.03E-02 0.03 0.01 0.00 0.00 0.00 - - 
SBF1 rs199972466 Paternal 5.33 1.06E-02 0.06 0.01 0.01 0.00 0.00 - - 
DNAH7 rs144390858 Maternal 2.94 2.43E-02 0.04 0.02 0.02 0.02 0.01 - - 
SLC22A16 rs41288594 Paternal 2.22 3.30E-02 0.07 0.02 0.02 0.06 0.04 1.66 0.02 
NOTCH3 rs115582213 Paternal 3.02 3.58E-02 0.04 0.01 0.01 0.01 0.01 - - 
ADAM8 rs36054052 Paternal 4.83 4.41E-02 0.03 0.01 0.00 0.00 0.00 - - 
RECQL4 rs199654783 Maternal 9.59 4.47E-02 0.04 0.00 0.00 0.00 0.00 - - 
VNN1 rs189034822 Paternal 3.38 4.66E-02 0.09 0.00 0.00 0.00 0.00 NA 0.03 
DCLRE1C rs41297018 Paternal 2.58 4.88E-02 0.04 0.01 0.02 0.02 0.01 - - 
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3.3.1 Gene set enrichment analysis of the candidate variants 
To complement the WES approach, we conducted a Gene Set Enrichment Analysis based 
on the GO Biological Process Ontology (Figure 30) and the KEGG pathway database Release 80.2, 
2016 (Figure 31) in order to identify the most significant pathways and biological processes in 
which our genes are involved, and consequently the ones that were most likely to be associated with 
TGCT. 
 
Figure 30. Distribution among biological processes of the significant variants resulting from the 
discovery analysis  
 
 
Figure 31. Pathway analysis of the significant variants resulting from the discovery analysis 
As expected, due to the first selection we did in the pipeline filtering analysis 
(Supplementary Tables S3, S5, S6 and S7) based on the previously described pathways and 
biological processes (Pyle et al., 2016), the most enriched process in which our genes appear to be 
involved are the ones involved in the male development pathway, which includes spermatogenesis 
and male gamete generation. This is subsequently followed by gamete generation, a reproductive 
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process in which there are genes whose functions are related to both sexes, genes involved in the 
DNA repair system, and finally some processes that were not directly related to TGCTs. By 
contrast, according to the pathway analysis, genes involved in the DNA repair system are the most 
common, but it should be pointed out that the biological processes involve a wide range of 
pathways, and it is therefore important to take into consideration information obtained from both 
the bioinformatics analyses and the literature to select a potential candidate gene. 
3.3.2 Analysis of the Cancer Genome Atlas (TCGA) data of the candidate variants 
Around 60% of our cancer susceptibility genes are also found to be mutated in tumor DNA 
according to the data extracted from the TCGA database in 156 TGCT samples. Nevertheless, all 
variants found in somatic TGCT tissue correspond to the ones we identified in germline DNA by 
the WES approach (Supplementary Table S14), although all these genes present somatic mutations 
in other tissues, but in different proportions. A total of 159 cancer studies were carried out in almost 
11300 samples by the TCGA platform; our genes appear mutated from 1.9% of all cases 
(SLC22A16) to 24% (PLEC) (Supplementary Figure S1). Moreover, interpreting the distribution of 
the alterations in the TGCT cases, we found that most of them (59%) are mutations, of which 61% 
are present in non-seminoma tissue, followed by deletions (26%), of which 70% were also present 
in non-seminomas, and amplifications (15%) that are exclusively present in seminoma tumors 
(Table 12). Evaluating the alteration rates of each subtype, the most altered ones were the non-
seminomas (81%), followed by seminomas (45%) and 28% of mixed tumors, even though the cases 
analyzed in TCGA were not very unevenly distributed (71 non-seminomas, 67 seminomas, and 18 
mixed tumors; Supplementary Table S15). 
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Table 12. Genomic characterization of TGCA results for the 25 genes obtained in the discovery analysis 
Genes 
Mixed Germ Cell Tumor Seminoma Non-seminoma 
Mutation Amplification Deletion Mutation Amplification Deletion Mutation Amplification Deletion 
ERCC4 - - - - - - - - - 
PLEC 22.2% - - 4.5% 1.5% - 9.0% - - 
GRP 5.6% - 5.6% - - 1.5% 2.1% - 4.2% 
LRP4 - - - 2.1% - - 1.5% - - 
TNXB - - - 1.5% - - 14.3% - - 
TAF1L - - - - 1.5% - 2.1% - - 
KIF18A - - - - - - - - - 
BRD4 5.6% - - - - - 2.1.% - - 
LBP - - - - - - - - - 
EXO5 - - - - - - - - - 
DHX34 - - - - - - - - - 
PSRC1 - - - - - - - - - 
H1FNT - - - - 1.5% - 4.8% - - 
CCR5 - - - - - - - - - 
BZRAP1 - - - - - - 4.8% - - 
GPRC6A - - - - - - - - 2.1% 
BCHE - - - - 3.0% - - - - 
SLC22A16 - - - 1.5% - - - - 2.1% 
SBF1 - - - - - - 2.1% - 2.1% 
DNAH7 - - - - - - 2.1% - - 
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NOTCH3 - - - 3.0% - - 4.2% - - 
ADAM8 - - - - 1.5% 1.5% - - 13.1% 
RECQL4 5.6% - - 1.5% 1.5% - - - - 
VNN1 - - - - - - 2.1% - 2.1% 
DCLRE1C - - - - - - 4.2% - 2.1% 
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3.4 Replication study results 
Since our variants are almost all rare variants, we decided to replicate the study in a larger 
population, and determine the involvement of our variants in the development of the disease. In this 
case, WES data from around 1000 TGCT cases (familial and sporadic cases) and 1575 healthy 
English male controls was shared by a group at the Institute of Cancer Research in London. 
Twenty-seven significant variants from the discovery analysis were evaluated in this 
replication study in the English population. This analysis revealed that only two variants, 
corresponding to the genes SLC22A16 and VNN1, have significant p-values <0.05, and both 
alternative alleles confer high-risk susceptibility 
The rs189034822 variant located in the VNN1 gene (c.758C>T; p.Ala253Val) has a MAF 
<0.01 in almost all populations. It is present with an allele frequency of 0.004 in Europeans and of 
0.006 in Americans in heterozygosis, and of 0.003 and 0.002, respectively, in homozygosis. It is 
absent from the Spanish variant server public database. This variant was not significant in the 
OpenArray essay, possibly due to the low number of samples we had; when we increased the cohort 
in the discovery analysis, it became significant with an absolute p-value of 0.04, and an OR of 3.36. 
Afterwards, in the replication analysis it had a p-value of 0.026 and the OR was not computable. 
However, looking through the raw data, the variant was completely absent in the control samples 
of both analyses (approximately 2500 individuals), while it appeared in 0.5% and 0.23% of Spanish 
(391 individuals) and English sporadic cases (550 individuals), respectively, and it was present with 
a MAF of 0.09 in familial cases. 
The other significant variant rs41288594 (c.695A>G; p.Glu232Gly) is located in the 
SLC22A16 gene; this gene contains another variant, rs75035916, that was only significant in the 
discovery analysis. Both variants were found in the analysis of the polygenic model of inheritance, 
in particular from the FB-SKAT. Variant rs41288594 was found in two families, both with a 
dominant paternal model of inheritance, whereas rs75035916 was observed in only one family. The 
frequency of both variants in the population is a MAF <0.015 in all public databases. Moreover, 
they were validated in the OpenArray essay, but neither of them reached significance; variant 
rs75035916 has a frequency of 0.007 in sporadic cases and of 0.002 in controls, while rs41288594 
has a frequency of 0.015 in sporadic cases and of 0.024 in healthy controls. However, when we 
performed the discovery analysis both reached significance: 75035916 with a p-value of 0.01 and 
an OR of 8.06, and rs41288594 with a p-value of 0.033 and an OR of 2.2. Finally, replication 
analysis in approximately 550 affected cases and 2500 healthy individuals revealed that only 
rs41288594 was significant, (OR=1.65; p-value= 0.021). These results suggest that the alternative 
allele of this variant confers a low-risk susceptibility for the development of the disease. 
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3.5 In silico analysis of the candidate variants 
3.5.1 PredictProtein in silico pathogenicity prediction of the variants 
Functional effect was predicted by SNP2 (Figure 35). Results of the prediction are 
identified as dark red (indicates a high score > 50, strong signal for effect), white indicates weak 
signals (-50 < score < 50), and green indicates a low score (score < -50, strong signal for neutral/no 
effect). Black marks the corresponding wildtype.  
.  
  
Figure 35. A) rs189034822 of the VNN1 gene is identified as deleterious. B) SLC22A16 variant 
rs41288594 ispredicted as extremely deleterious. 
3.5.2 Aminoacid conservation analysis 
PRALINE multiple sequence alignment software was used to assess the conservation 
among species of the amino acids affected by the two variants (Figure 36). The scoring scheme 
works from 0 for the least conserved alignment position up to 10 for the most conserved alignment 
position. The color assignments are as follows: 
 
 
A) 
A) 
B) 
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Figure 36. A) Amino acid A253 (blue boxed), affected by VNN1 gene variant rs189034822, is 
extremely conserved among species except in Danio rerio, in which the protein does not exist. B) 
The SLC22A16 gene is not expressed in Equus caballus. Amino acid E232 (blue boxed), affected 
by variant rs41288596, is 100% conserved in every species.  
3.5.3 Secondary structure analysis 
P Secondary structure of the part of the protein affected by the variants was predicted using 
DSSP (Kabsch & Sander, 1983) and PSIPRED (Jones, 1999). The 3-state (helix, strand and coil) 
secondary structure of each sequence is represented by colors (helix in red and strand in blue). If a 
sequence in the alignment has no colors assigned, this means that no prediction is possible for that 
sequence. Taking into account that in silico predictions are only approximations, we also used the 
PHYRE software in which 3-state prediction could be identified as α-helix, β-strand or coil. Green 
helices represent α-helices, blue arrows indicate β-strands and faint lines indicate coils. The 'SS 
confidence' line indicates the confidence of the prediction, with red being high confidence and blue 
low confidence (Figure 37). 
 
 
Figure 37. A-B) VNN1 amino acid secondary protein structure correspond with a helix region and 
consequently in a buried region.. C-D) Prediction for rs41288594 aminoacid residue of the 
SLC22A16 gene product is located in a helix structure..  
B) 
B) 
C) D) 
A) 
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 3.5.4 Conserved domain study 
 
 
 
Figure 38. A) The amino acid affected of VNN1 forms part of the putative dimer interface and the 
catalytic triad of the protein, and mainly in the biotinidase-like domain. B) SLC22A16 forms part 
of the Major Facilitator Superfamily (MFS), and has several putative substrate translocation pores. 
 The principal domain of the VNN1 protein (Figure 38) belongs to the nitrilase superfamily 
and is identified as a biotinidase (EC 3.5.1.12), characterized by both hydrolase and transferase 
activities. It hydrolyzes free biocytin or small biotinyl peptides produced during the proteolytic 
degradation of biotin-dependent carboxylases, to release free biotin (vitamin H), and it can transfer 
biotin to acceptor molecules such as histones. The nitrilase superfamily to which this subgroup 
belongs is comprised of nitrile- or amide-hydrolyzing enzymes and amide-condensing enzymes, 
which depend on a Glu-Lys-Cys catalytic triad. This protein is predicted to contain two 
transmembrane helices but our amino acid is not located in either of them (Figure 39).  
 
 
Figure 39. Topology predicted for VNN1 sequence of transmembrane helices 
A) 
B) 
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 The SLC22A16 transporter is also known as a human testis-specific carnitine transporter 
and it contains various putative substrate translocation pores along the length of the protein which 
permit access from both sides of the membrane. This type of pores is common to members of the 
Major Facilitator Superfamily (MFS). The MFS is a large and diverse group of secondary 
transporters that includes uniporters, symporters, and antiporters. These proteins facilitate transport 
across cytoplasmic or internal membranes of a variety of substrates including ions, sugar 
phosphates, drugs, neurotransmitters, nucleosides, amino acids, and peptides. They do so using the 
electrochemical potential of the transported substrates. MFS proteins are typically 400 to 600 amino 
acids in length, and the majority contain 12 transmembrane alpha helices (TMs) connected by 
hydrophilic loops. In our case, the affected amino acid is located just at the start of the loop of the 
S4 compartment (Figure 40). 
  
Figure 40. Topology predicted for SLC22A16 sequence of transmembrane helices 
 3.5.5 Tissue Gene expression profile 
 The tissue expression distribution of each gene was evaluated in 53 normal tissues 
reported by Gtex. 
 
A) 
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Figure 41.A) The VNN1 gene is hardly expressed in testis. B) Analysis of the expression of the 
SLC22A16 gene in various tissues shows that this gene in mainly expressed in testis. 
3.5.6 Cancer Genome Atlas data analysis 
 
 
 
Figure 42. Representation of the mutations found in the TCGA database vs our candidate variants 
(indicated with a red arrow). A) Mutations in the VNN1 gene. B) Mutations in the SLC22A16 gene. 
 The mutation extracted from the TCGA located in the VNN1 gene not only is far from the 
one we identified, but it is also predicted to have a medium pathogenicity value by the Mutation 
Assessor. In the case of the SLC22A16 gene the variant present in the TCGA is located close to our 
variant, but our variant was not identified in this somatic tissue platform. The variant reported by 
B) 
B) 
A) 
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the TCGA is a missense variant considered to have a low pathogenicity by the Mutation Assessor. 
Focusing on the somatic mutations present in the TCGA database we consulted the Ensembl 
genome database to determine their possible presence in germline DNA, but none were described. 
4. ANALYSIS OF ALREADY IDENTIFIED TGCT PREDISPOSITION LOCI 
Taking into account that the risk allele frequencies of the variants located in the 
predisposition loci for TGCTs described in Table 1 are quite high (MAF > 0.2), we examined them 
in our WES data, in order to know their representation in our Spanish familial testicular cancer 
cases. Surprisingly, no results were obtained. We did find other variants located in the same gene, 
which suggested the existence of other as yet unidentified variants in those regions that could be 
acting in combination with other genes in the development of the disease. What is more, some of 
those variants are shared by several of our families. Specifically, two of them are shared between 4 
families which correspond with an allele frequency of 0.20, 2 other variants were shared by 3 
families, and 7 variants were shared by two families (Supplementary Table S16). 
 
5. ASSOCIATION BETWEEN GENETIC AND CLINICAL INFORMATION 
We also attempted to determine whether specific clinical features might permit us to 
identify a subset of genetic variants that confer a particular risk of developing TGCT. On the one 
hand, 51% of familial cases suffer from seminoma tumor, 24% non seminoma, and 21% mixed 
tumors. Within non seminoma tumors we had 4 mix tumors, 1 embryonal carcinoma, 1 teratoma, 
and 3 unclassified. While in the mixed tumors most of them were composed by seminoma and 
embryonal carcinoma and only two had also part of yolk sac tumor. On the other hand, more than 
a half of the sporadic cases suffered from seminoma, and 31% from non seminoma. Among the non 
seminomas, the most common subtype one was the embryonal carcinoma (Figure 43). 
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Figure 43. Classification of sporadic cases according to their TGCT subtype. 
 
Although we have a small set of samples, it was sufficiently large to find out that one of 
our variants, rs41288594 located in the SLC22A16 gene, is associated with a risk of developing 
seminoma tumors (OR=8.9; CI[1.037:77.93]; p-value=0.026).  
 
In addition, we also collected other clinical information such as some of the most important 
risk factors included in the questionnaire (Table 13 and Supplementary Table S1), and performed 
an analysis to study the association between the age at diagnosis with some of the most important 
risk factors. But our analysis did not yield significant results due to the constraints imposed by the 
small number of samples.  
Table 13. Classification of risk factors classification 
Risk Factors 
Familial cases Sporadic cases  
Seminoma Non-seminoma Mixed  Seminoma Non-seminoma Mixed  
None 11 7 4 158 98 37 
Bilaterality 2 - 1 2 3 3 
Cryptorchidism 2 - 2 8 3 3 
Microlithiasis 4 2 - 11 4 1 
Hydrocele 1 - 1 1 2 - 
Infertility - - - 3 - - 
Inguinal hernia 1 1 1 2 - - 
Varicocele - - - 3 - - 
Mixted  1 - 2 7 1 1 
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 In the present study we have analised the genetic bases of familial testicular cancer in order 
to identify some genes that could help to explain the cancer susceptibility in that families and to 
stablish preventive methods in those members carrying a mutation in the candidate gene/s. After 
several approaches we discard the existence of high susceptibility genes in our series. Only two 
genes VNN1 and SLC22A16, could contribute to this type of tumor although they must be 
considered as low/moderate susceptibility genes. Both genes are currently under functional studies 
in order to get to know the consequences of mutations in any of  them. 
1. GENETIC BACKGROUND OF TGCT 
Our results are in agreement with previous studies. TGCT is a genetically highly 
heterogeneous disease with an estimated hereditability of 48.9%. However, despite the sizeable 
familial relative risk, large family clusters arise infrequently. Early studies suggested the recessive 
model as the main model to explain these families. Moreover, although these studies were limited 
by relatively small numbers of enrolled families, the autosomal recessive model was also suggested 
by statistical analyses based on published data related to TGCT age at diagnosis and to the 
prevalence of bilateral disease in familial and sporadic cases (Nicholson et al., 1995)(Heimdal et 
al., 1997). However, the results were not conclusive.  
In addition, several candidate gene approaches failed to identify high penetrance 
susceptibility genes (Rapley et al., 2000) (Nathanson et al., 2005) (Linger et al., 2008) (Horvath et 
al., 2010), while the identification of low susceptibility alleles seems to be more frequent. The used 
of GWAS in unrelated testicular cancer patients identified SNPs that were strongly associated with 
TGCT risk (Table 1). Recently, it has been published other two metanalysis based on GWAS data 
and replication series, in which they identified 27 new susceptibility risk loci associated with 
TGCTs (Kanetsky et al., 2009b)(Rapley et al., 2010)(Turnbull et al., 2010) (Kanetsky et al., 
2011)(Kratz et al., 2012)(Chung et al., 2013)(Litchfield, et al., 2015a)(Litchfield et al., 2015d) 
(Goldmann et al., 2016) (Litchfield et al., 2017) (Wang et al., 2017). Due to their strong association 
effects, we first searched for those SNPs in our WES data, but none of them were represented in 
our familial cases. Overall, these data suggest that a single major locus does not account for the 
majority of the familial aggregation of TGCT Instead, multiple low-penetrance susceptibility loci 
acting in concert may be responsible for the genetic component of the TGCT etiology (Mueller et 
al., 2014). But even though no high penetrance susceptibility genes have been found, there is no 
doubt that FTGCT has a genetic component since it has the third highest estimated hereditability 
among all cancers (Czene et al., 2002). The observation that the TGCT standardized incidence ratio 
(SIR) is substantially higher in monozygotic (SIR = 76.5) than in dizygotic (SIR = 35.7) twins also 
suggest that the genetic component of TGCT risk is far larger than those for most other cancers (A. 
J. Swerdlow et al., 1997).  
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Taking into account the genetic landscape described above, our approach to decipher the 
genetic basis of FTGCTs was to study 71 related individuals from 19 families with at least 2 affected 
cases of TGCT (Figure 12) and to analyze every family from the point of view of every type of 
model of inheritance. In the case of a monogenic model, we considered every possible pattern of 
inheritance (dominant -with equal maternal or paternal origin-, recessive, sex chromosome-linked, 
and compound heterozygous) in order to find causal mutations in most of the cases with a low MAF 
that were exclusively present in our cohort of patients and members of their families. In the 
polygenic model we focused on finding low/moderate susceptibility variants, whether they were 
common or rare alterations, in the same cohort of family samples.  
2. MONOGENIC MODEL OF INHERITANCE 
Analysis of the WES data was done following the pipeline described previously by our 
group (Calvete et al., 2015b), but performing a sex differentiation filtering in the dominant and 
chromosome-linked models. Taking this into consideration, the absence of variants for the Y 
chromosome-linked pattern did not mean that mutations in this chromosome could not be associated 
with the pathology of the disease. In fact, the Y chromosome is of particular interest as it carries a 
number of testis and germ cell-specific genes (Machiela et al., 2016). The 1.6-Mb deletion 
(designated gr⁄gr) on this chromosome is present in 3.0% of TGCT cases with a family history, in 
2% of TGCT cases without a family history, and in 1.3% of unaffected male controls (Nathanson 
et al., 2005). This indicates that the deletion confers an approximately two-fold risk of TGCT over 
the general population. 
Focusing on the 125 final candidate variants that we found, the most important filter to 
prioritize for experimental characterization was the functional analysis (Supplementary Table S3) 
of each gene, more than the analysis of the single variants, although there are some genes that were 
not related to any pathway or biological process (Table 3), even though they have an important 
function based on the literature, such as for example the FSIP2, PDE11A and the GPRC6A genes. 
Interestingly, the FSIP2 gene was previously described in a similar WES study performed in the 
English population: it was concluded that there is a recurrent amplification of this gene in 15% of 
42 TGCTs cases (Litchfield et al., 2015e). FSIP2 codes for a protein associated with the sperm 
fibrous sheath, a unique cytoskeletal structure located in the principal piece of the sperm flagellum, 
alterations in which were linked to male infertility (Brown et al., 2003). Furthermore, the PDE11A 
gene was not related to any of the pathways or biological processes analyzed, but it has been 
demonstrated that mutations in this gene modify the risk of familial and bilateral testicular tumors 
(Horvath et al., 2009)(Pyle et al., 2016). This gene is an essential regulator of cyclic AMP signaling 
in the adrenal gland. Genetic aberrations in this pathway were associated with non-germ testicular 
cell tumors (Wayman et al., 2005). Finally, polymorphisms in the GPRC6A gene were recently 
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reported as novel risk factors for testicular failure and deranged spermatogenesis because the 
complete or partial inactivation of this gene contributes to reducing the exposure to androgens, 
leading to cryptorchidism during fetal life and/or low sperm production in adulthood (Toni et al., 
2016).  
Regarding the splicing variants, it has been suggested that one third of all disease-causing 
mutations impact on splicing (Singh et al., 1995). Interestingly, to date no splicing variant has been 
identified to be associated with TGCT risk, although we found three potential splicing errors that 
were validated at the cDNA level. During the last years, thanks to this in silico predictor, several 
splicing variants have been found to be the cause of the development of different diseases (Balicza 
et al., 2016; Ciara et al., 2016; Latger-Cannard et al., 2016). However, in our case, the in silico 
predictors not always get across with the correct splicing effect as Sanger sequencing revealed. The 
variant located in the CEP152 gene was predicted to affect the canonical splice acceptor site of 
exon 13, which consequently was supposed to produce the retaining of an intron or the skipping of 
part of the exon. However, we found that the nucleotide change generated a new splice acceptor 
site, not identified by the in silico predictor, located at the beginning of the exon and causing the 
loss of the first 14 bp and consequently a disruption of the reading frame, instead of what was 
predicted. The displacement of the splice site led to more RNA being spliced out than expected, 
which resulted in shorter exons and ultimately producing an inactive protein. Allelic differences in 
mRNA splicing are likely to be a common and important source of phenotypic diversity at the 
molecular level (Lim et al., 2011). Moreover, the splice donor site located in the UBN1 gene in 
exon 20 was predicted to disappear, so we thought that it would provoke the inclusion of the intron 
which should be repaired by the nonsense-mediated mRNA decay mechanism. However what we 
found is that the loss of the splice donor site activated another potential splice donor site 27 bp 
upstream, generating the loss of these base pairs and consequently producing a disruption of the 
reading frame. Due to the complexity of the new results, it is important to point out that sequence 
variation not only may affect the primary structure of a protein, but it may also affect the binding 
of regulatory factors whose proper function is many times position-dependent. Alternative splicing 
of pre-mRNA transcripts is regulated by a system of trans-acting proteins (activators and repressors) 
that bind to cis-acting sites or "elements" (enhancers and silencers) on the pre-mRNA transcript 
itself. These proteins and their respective binding elements promote or reduce the usage of a 
particular splice site. The binding specificity is in part determined by the sequence and structure of 
the cis-elements. Moreover, in addition to the position-dependent effects of enhancer and silencer 
elements, the location of the branch point (i.e., distance upstream of the nearest 3’ acceptor site) 
also affects splicing (Lim et al., 2011) (Tang et al., 2016).  
As previously mentioned, to date no high susceptibility genes have been identified that were 
associated with FTGCTs, and only common variants with low susceptibility risk were described 
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(Table 1). Our study supports the idea there is not a single gene responsible for the development of 
the disease that could explain its origin, but we did find some rare variants with low MAFs that 
were shared among different affected families (Table 10); this may indicate that we have found 
some new susceptibility genes associated with the development of the disease. This should be 
studied further in larger familial and sporadic cohorts, with the appropriate controls.  
3. POLYGENIC MODEL OF INHERITANCE 
 During the last years, a polygenic risk score has been developed and used by several groups 
for different complex diseases (Domingue et al., 2017) (Paquette et al., 2017), including breast 
cancer (Lecarpentier et al., 2017). This parameter is determined by the co-inheritance of multiple 
risk variants, many of which are common. The score was calculated by the combined effect of all 
risk SNPs under study and modeling them under a log-normal relative risk distribution (Litchfield 
et al., 2015c)(Litchfield et al., 2015d). However, when using this method it is crucial that the set of 
SNPs contains only independent variants to avoid overrepresentation of the same signal (Bohossian 
et al., 2014). Preliminary assessment of genetic profiling in TGCT was done by two groups 
(Litchfieldet al., 2015b) (Greene et al., 2015), who used polygenic risk-score (PRS) models to 
assess the combined effects of the 19 SNPs described to confer TGCT risk (Table 1). The latest, 
(Greene et al., 2015), demonstrates with this approach that men in the top 10% of genetic risk have 
a 4.1-fold elevated relative risk of developing TGCT, whilst men in the top 1% have a 9.2-fold 
elevated risk of developing TGCT compared with the population median (0.5-fold) (Litchfield et 
al., 2016b) (Sung et al., 2016). Although our study population did not fulfill the principal 
requirement, because our data came from related individuals and we are studying rare variants 
(MAF usually <0.01), we tried to calculate the PRS and, as expected, we did not obtain any results. 
Currently, the study of complex diseases is based on studying common variants in usually unrelated 
individuals, just the opposite of our scenario, and we therefore considered the use of other 
approaches, in which we could study familial data, pattern of inheritance and rare variants. We 
decided to try a type of family-based study that has been shown to be helpful in describing familial 
aggregation of cancer (Coté et al., 2012), and to be more robust in the search of rare variants with 
WES data (Kiezun et al., 2013)(Lee et al., 2014). Recently, an adaptation was described of the two 
most common approaches used to analyze the association of the cumulative effects of multiple 
variants in a genomic region, previously identified by GWAS or described in the literature. This 
adaptation, the Burden and variance-component tests (SKAT), has subsequently been adapted to 
Family-Based association tests (FBATs). These tests not only allow us to test the parental origin 
effects and different co-variables, but they also allow us to consider small values of the sibling risk 
ratio, which for a genetically heterogeneous disease with complex traits is the most common 
situation (Ionita-Laza et al., 2013). These tests have already been used independently in other 
complex diseases such as Schizophrenia (Purcell et al., 2014), and recently a report on TGCTs was 
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published that used the Burden test in order to detect only rare variants (Litchfield et al., 2016a). 
By contrast, our approach was based on searching for both types of variants and considering both 
scenarios. Since both tests test the null hypothesis that no genetic variants in the region are 
associated with the disease, and differ in the assumptions on distribution, effect size and behavior 
of the variants, we performed both tests. The FB-Burden test tends to be more powerful in the search 
of rare variants because it assumes that all variants go in the same direction (risk or protective), 
while the FB-SKAT test considers both scenarios. Additionally, we performed the SKAT test in 
order to look also for variants (common and rare) without family aggregation to cover every 
scenario, and also as a control of the other tests. Due to the amount of data that result from all  
analyses we decided to apply our own pipeline, based on the one used for the monogenic model and 
described previously (Litchfield et al., 2016a). The disadvantage of this type of analysis is that it 
assumes that the most associated genes are the ones that are mutated most, and this creates a very 
high threshold because the genes should contain at least three variants; in our case this would be an 
error, since our purpose is to find additive single variants. Therefore, we combined the results from 
both models to perform the case control study, because the monogenic model will cover those 
variants that we would be losing in the polygenic model. 
4. CASE CONTROL ASSOCIATION STUDY 
More than twenty case-control studies have been performed up to now in TC cases (Pathak 
et al., 2015) (Litchfield et al., 2016b) Litchfield et al., 2017) (Wang et al., 2017), but none in our 
country. To the best of our knowledge, ours is the only existing WES and case-control study 
targeting multiple-case TGCT Spanish families and sporadic cases for the identification of new 
susceptibility genes that could help define the genetic basis of FTGCTs. In all GWAS and meta-
analyses described to date, only low susceptibility genes and variants with a high MAF have been 
identified (Table1), (Kratz et al., 2012) (Litchfield et al., 2015d), whereas the variants we evaluated 
in familial cases were almost 90% rare variants with a MAF<0.01, owing to our objective of 
searching causal mutations in genes with high/moderate susceptibility risk. Due to the capacity of 
the OpenArray platform we could only genotype 120 variants, but the ones that were not selected 
for this first approach have not been discarded and are kept for future analysis. The selection of the 
120 candidate variants to be evaluated in the genotyping analysis was based on their biological 
implications and functions (Turnbull et al., 2011) (Litchfield et al., 2015c), which is why we not 
only looked for their function but also for their presence in the different families, their functional 
effect, and the range of variants per gene.  
Although the OpenArray analysis did not yield significant results, it is interesting to note 
that 25.4% of the variants were absent in both cohorts (sporadic cases and healthy controls), 12.6% 
were present only in sporadic cases at a low frequency (maximum of 0.0031), and the remaining 
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62% were present in both cohorts, with a maximum frequency of 0.11. So even though we did not 
obtain significant results, it remains a possibility that we obtained a group of candidate disease-
associated variants with an exclusively Spanish origin. To confirm this hypothesis and to increase 
the statistical power, we used WES data from 788 unaffected individuals shared by CIBERER and 
performed the same analysis considering it as the discovery study. We found 27 variants with 
significant p-values at the genome level of α=0.05, and all of them confer risk susceptibility due to 
their OR values (Table 11). But we have to take into account that at least 90% of these variants are 
rare and have a MAF of less than 1%, so it is understandable that the ORs were extremely high 
compared to the ones published recently (Table1) (Litchfield et al., 2016b). We will need a larger 
Spanish cohort to evaluate the effect of these variants that will permit us to evaluate correctly the 
OR to apply it in the replication analysis. Interestingly, some of the significant variants correspond 
to the ones that are common among the different families (Table 10), and some of them even appear 
in combination in the different families, such as for example family 16, which has 8 variants, 
families 11 and 2, which have 5 variants, and family 14, which has 4 variants (Figures 12 and 29). 
In addition, in some of the cases a combination of variants was shared among families, such as 
variants in GRP and GRPC6A that were shared by families 11 and 2 (Figures 12 and 29). Finally, 
as we are considering family cases, we looked at the pattern of inheritance of each variant and found 
that they all presented a dominant model (55% with a paternal origin and 30% with a maternal 
origin). Thus, our results differ from the results obtained in earlier segregation studies, in which an 
autosomal recessive model appeared to be the most appropriate model (Heimdal et al., 1997), and 
is more in agreement with the idea of a polygenic model in which the sequential combination of the 
variants, regardless their origin, could have and additive and cumulative effect that causes the 
development of the disease. Besides, the GO biological process Ontology places the 27 significant 
variants mostly in spermatogenesis, male gamete generation and DNA repair (Figure 30), whereas 
according to the Kegg pathway analysis they are predominantly involved in nucleotide excision 
repair and non-homologous end-joining (Figure 31); all these processes and pathways have been 
previously described to be associated with TGCTs risk (Litchfield et al., 2015c). Moreover, none 
of our variants appear in the somatic mutational spectrum of the TGCA platform, which comprises 
data from 159 cancer studies, confirming they are specific germline mutations (Supplementary 
Table S9). However, looking at the mutational profile of each gene independently, we found that 
all of them present other somatic mutations in different tissues including testes, with SLC22A16 
being the least (1.9%) and PLEC being the most mutated gene (24%) (Supplementary Figure S1). 
The distribution of the alterations (mutations, deletions and amplifications) among the different 
subtypes of TGCT studied in 156 samples (Table 12) reveals that mutations are the most frequent 
alterations in the three subtypes of TGCT evaluated, and considering all alterations together, non-
seminomas present twice as many alterations as seminoma, and three times more than mixed 
tumors. Our results are in agreement with other genetic germline studies of TGCT, in the sense that 
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no differential genotype risks were observed between histological subgroups (Supplementary Table 
S10), although we need to increase our cohort size in order to obtain consistent results (Rapley et 
al., 2009)(Turnbull et al., 2010)(Ruark et al., 2013). Finally, our results also support the hypothesis 
that the same oncogenic pathways are activated in all TGCTs, with differentiation occurring later 
in the tumor formation (Gori et al., 2005). This hypothesis is further supported by the observation 
of TGCT cases with mixed pathology as well as bilateral and familial cases displaying tumors with 
inconsistent histological types (Forman et al., 1992)(Mai et al., 2010). 
In addition, to evaluate how the 27 significant variants (Table 11) from the discovery study 
might be involved in the development of this disease, we tried to replicate our results in an English 
population composed of approximately 770 TGCT cases and 1300 healthy controls, as was done 
by other groups (Rapley et al., 2010)(Kanetsky et al., 2011) (Litchfield et al., 2016a). The 
replication study revealed that only 2 variants displayed promising associations: rs189034822 
(OR=NA) and rs41288594 (OR=1.66; p-value 0.02) located in the VNN1 and SLC22A16 genes, 
respectively (Table 11).  
5. CANDIDATE GENES 
 VNN1 is characterized as a direct SF-1 target gene in the developing mouse testis (Wilson 
et al., 2005). This gene is expressed immediately following Sry expression, just before the formation 
of the testis cords. As we mentioned in the introduction, SRY is responsible for male sex 
differentiation in the bipotential gonads (Figure 33) (Martin et al., 2001). The VNN1 proximal 
promoter contains putative binding sites for the transcription-activating factors SF-1 and SOX9 
(Figure 32) (Eggers et al., 2014); it has also been reported that this gene might be involved in the 
migration stage from the mesonephros or the coelomic epithelium before activation of the male-
specific differentiation pathway, due to its expression in the Sertoli cell lineage just prior to testis 
cord formation, and it regulates cell homing in other contexts (Grimmond et al., 2000).  
 
Figure 44.Genes involved in testis development and differentiation (Eggers et al., 2014). 
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 Besides, the VNN1 product is a glycosylphosphatidylinositol-linked membrane-associated 
pantetheinase, a family of enzymes that catalyze the hydrolysis of pantetheine (Pitari et al., 2000) 
into pantothenate which is converted to CoA, required for the initial steps of cholesterol synthesis 
(Nadal et al., 2000). Cholesterol is required for the synthesis of the steroid hormones produced by 
both the adrenal gland and the Leydig cells of the testis (Wilson et al., 2005).  
 
Figure 45. Proposed role of  VNN1 in Sertoli and steroidogenic cells based on its enzymatic 
activity. SF-1 has been found to up-regulate expression of enzymes required for both cholesterol 
and steroid hormone synthesis. VNN1 recycles pantetheine, produced by the degradation of CoA, 
to pantothenate to be reused in CoA synthesis. CoA is required for the early steps of cholesterol 
synthesis; cholesterol is a key component in the generation of steroid hormones. Production of 
cysteamine by VNN1 is likely to play an important role in regulating the oxidative stress response 
of these tissues in particular in the protection of the nearby germ cells from reactive oxygen 
species(Wilson et al., 2005) 
In addition to a likely role in steroid metabolism, increasing evidence supports a role for 
VNN1 in the cellular/tissue stress response. Alterations in the levels of reactive oxygen species 
present in tissues, affect cellular proliferation, differentiation, and apoptosis. Cysteamine, a product 
of VNN1 activity, is a potential antioxidant (Berruyer et al., 2004) which has been shown to reduce 
the toxicity of various agents in Sertoli-germ cells (Pitari et al., 2000). The major role of Sertoli 
cells is to support the germ cells within the testis, and they are known to express high levels of 
enzymes that catalyze the synthesis of antioxidants or scavenge reactive oxygen species such as 
glutathione S-transferase and superoxide dismutase (Bauché et al., 1994). The presence of VNN1 
on the surface of Sertoli cells is likely to produce high levels of cysteamine surrounding germ cells 
within the testis cords, which likely act as a protectant against reactive oxygen species. Disruption 
of VNN11 expression could generate alterations in sperm maturation due to the lack of the 
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cysteamine product and also because of the production of reactive oxygen species. Besides being a 
direct target of SF-1, Vanin-1 has also been described to be a downstream target of SOX9 in mice 
(Wilson et al., 2005) (Eggers et al., 2014), essential in male gonad differentiation and development. 
Thus, it is likely that VNN1 plays a crucial role in testis development in humans as well. However, 
functional studies will be required to address the role of VNN1 in gonadogenesis.  
The SLC22A16 gene encodes a member of the organic zwitterion transporter protein family, 
specifically located in human testis. They transport carnitine, a compound biologically important 
for mitochondrial β-oxidation of long-chain fatty acids and for the generation of ATP (Enomoto et 
al., 2002). Carnitine has been linked to the regulation of spermatozoa motility in several mammalian 
species (Figure 34) (Jeulin et al., 1996). L-Carnitine is secreted from mammalian epithelium into 
epididymal plasma and ultimately into spermatozoa, where it accumulates as free and acetylated L-
carnitine (C Jeulin et al., 1994). Several studies have shown that the role of L-carnitine in the 
epididymis is to foster fertilizing and maturation of spermatozoa (Hinton et al., 1979). Moreover, 
within the epididymal lumen, it has been shown that the initiation of sperm motility occurs in 
parallel with the increase in L-carnitine (Bressler et al., 1995) (Jeulin et al., 1996). And that 
regulated by androgens, previous studies demonstrate that the epididymal epithelium secretes L-
carnitine into the epididymis lumen by a saturable process (Srinivas et al., 2007). Thus, the increase 
of the L-carnitine is related to the stage of the spermatogenesis process (Enomoto et al., 2002). 
 
Figure 46. Metabolism of free L-carnitine, free coenzyme A (CoA), acetyl-CoA and the location of 
carnitine acyltransferases in the mammalian spermatozoa (Jeulin et al., 1996). 
Due to its function in the metabolism of fatty acids, this carnitine transporter has been 
related to several types of cancer, such as acute myeloid leukemia (Wu et al., 2015) or colorectal 
cancer (Han et al., 2016), in which cancer cells have increased dependence on carnitine and its 
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absence induces death of malignant cells. For that reason, this transporter plays an important role 
in cancer chemotherapy-induced multiple organ toxicity. In humans, 75% of the total body carnitine 
originates from dietary sources and the remaining 25% from endogenous synthesis (Sayed-Ahmed 
et al., 2010). However, in cancer patients serum carnitine concentrations are low, largely due to a 
decreased dietary intake and impaired endogenous synthesis of this substance, which contributes to 
the reduction of the viability of cancer cells and impairs cell cycle progression. Thus, disruption of 
this transporter may reduce the growth and viability of tumors. 
Focusing on TGCT, as mentioned above, this carnitine carrier is involved in the maturation 
of the spermatozoa. Sperm mitochondria, like those of heart, have active acetylcarnitine-carnitine 
translocases. Acetylcarnitine serves as a readily accessible energy pool for use in both activation of 
respiration and motility in mammalian spermatozoa, but its level is tightly regulated because high 
concentrations of it have been shown to inhibit oxygen uptake by spermatozoa (Hinton et al., 1979) 
(Jeulin et al., 1994). In the epididymal lumen, the concentrated L-carnitine passes through the sperm 
plasma membrane by passive diffusion and serves as accessible energy storage when needed. When 
spermatozoa enter the epididymis, they are immotile and L-carnitine content is low, and during 
their transit through the epididymis spermatozoa initiate flagellar motion in parallel with the 
accumulation of high concentrations (mM) of free L-carnitine from the luminal fluid (Enomoto et 
al., 2002). Therefore, the roles of carnitine are associated with improving sperm quality and fertility 
and its absence could produce an interruption in the spermatogenesis process. 
Additionally, even though we did not have a sufficiently large set of samples to determine 
a consistent association between the clinical data and our variants, and taking into account that there 
was not any significant association between the histological subtype and a previously described  
genetic alteration (Ruark et al., 2013) (Litchfield et al., 2015e), it is interesting that our analysis 
produced variant rs41288594 as significantly associated with the clinical diagnosis of seminoma 
tumors.  
To our knowledge, this study represents the first comprehensive sequencing study of TGCT 
conducted in Spain. While we implemented strategies to accurately identify the mutational genetic 
landscape of familial cases with this tumor, we were only sufficiently powered to identify genes 
with a high mutational frequency. Hence, further insights into the biology of TGCT should be 
forthcoming through additional sequencing initiatives involving larger numbers of samples and 
meta-analyses of such data. This is likely to become especially important, because we have 
identified 27 significant variants in Spanish population, and two of them were replicated in a larger 
independent analysis in English population. This results may help us for further genetic counseling 
in Spanish TGCTs cases.
  
 
 
Conclusions / Conclusiones 
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CONLUSIONS  
1. We have studied 19 families with familial testicular cancer that at least include two affected 
members and a second group of 500 sporadic cases. Significant differences (p-value 0.0001) were 
observed in the average age of onset between between both groups, we could detect that familial 
cases developed TGCT at a median age of 28 yeras old, while sporadic cases developed it 
significantly later at a median age of 33 yeras old. The results suggest that having a family history 
of TGCT have significant effects in the earlier development of the disease 
2. By WES of 71 affected and healthy members from the 19 families with testicular cancer, a total 
of 95 variants were identified according to a monogenic or a polygenic model of inheritance. After 
a case-control association study, 27 of them were considered as candidate variants that could confer 
susceptibility to testicular cancer development, however, because most of them were rare variants 
we cannot conclude they are high/moderate or low susceptibility alleles. 
3. This group of variants was replicated in a second independent series of cases and controls from 
the ICR (UK) and two of them were validated: VNN1 (OR= NA because no positives were found in 
controls) a transporter related with the steroid hormonal synthesis and SLC22A16 (OR=1.6), a 
solute carrier implicated in the spermatogenesis process  
4. The variant rs41288594 located in the SLC22A16 gene not only confers a low susceptibility risk 
(OR=1.6) in the general population and a moderate risk (OR=2.2) in the Spanish population for the 
development of TGCTs, but it is also the only variant identified thus far in the Spanish population 
to be specifically associated with the development of seminoma tumors. This result should be 
confirmed in a larger set of samples, in order to increase the statistical power, so that it may be used 
in the future as a risk factor in genetic counselling, diagnosis and possible treatment. However, 
functional studies are necessary to confirm its role in the tumorigenesis process. 
5. Our results (two low-moderate susceptibility genes) support a polygenic model of inheritance for 
familial testicular cancer instead of a monogenic model that would increase the number of known 
genes up to 21.  
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CONCLUSIONES 
1. Hemos estudiado 19 familias con cáncer testicular familiar con, al menos, dos miembros afectos, 
y un segundo grupo compuesto 500 casos esporádicos. hemos podido detectar diferencias 
significativas (p-valor 0.0001) en la edad media de diagnóstico entre ambos grupos los casos 
familiares desarrollan el cáncer testicular a una edad media de 28 años, mientras que los casos 
esporadicos lo desarrollan significativamente mas tarde, a una edad media de 33 años. Los 
resultados sugieren que el tener antecedentes familiares de cáncer testicular tiene efectos 
significativos en desarrollar más tempranamente la enfermedad. 
2. Mediante la técnica de secuenciación masiva de exoma, realizada en 71 miembros afectos y 
sanos, hemos podido identificar un total de 95 variantes segun los modelos de herencia monogénico 
y poligénico. Después de un estudio de asociación caso-control, 27 han sido consideradas como 
variantes candidatas que podrían incrementar el riesgo de susceptibilidad a desarrollar cáncer 
testicular; sin embargo, como la mayoría son variantes raras, no podemos concluir si los alelos son 
de alta/moderada o baja susceptibilidad. 
3. Este grupo de variantes se ha replicado en una segunda serie independiente de casos y controles 
cedida por el ICR (Inglaterra), y dos de ellas se han validado: VNN1, (OR= no disponible por 
ausencia de casos positivos en controles) que codifica para un transportador relacionado con la 
síntesis hormonal de esteroides, y SLC22A16 (OR= 1.6), un transportador soluble implicado en el 
proceso de espermatogénesis. 
4. La variante rs41288594, localizada en el gen SLC22A16, no solo confiere un riesgo bajo de 
susceptibilidad OR=1.6 en la población general, sino que también es la única variante identificada 
hasta el momento en población española relacionada específicamente con el desarrollo de tumores 
de tipo Seminoma. Este resultado debería ser evaluado en un número mayor de muestras para 
potenciar su valor y utilizarlo en un futuro como un factor de riesgo en consultas de consejo 
genético, en el diagnóstico, y en el posible tratamiento.  
5. Nuestros resultados (2 genes de baja-moderada susceptibilidad) apoyan un modelo de herencia 
poligénico, en lugar de un modelo monogénico para el desarrollo del cáncer familiar testicular, por 
lo que incrementarían el número de genes conocidos a 21.  
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Finalidad y descripción del proceso  
Este documento tiene por objeto informarle y solicitar su consentimiento escrito para someterse a un estudio 
diagnóstico de susceptibilidad genética al cáncer familiar de testículos (CNIO-GH-001-2015). Este estudio 
se llevará a cabo por el personal facultativo de la Consulta de Cáncer Familiar del Hospital Universitario de 
Fuenlabrada (HUF) y del Centro Nacional de Investigaciones Oncológicas (CNIO) valorando su riesgo 
genético, y por el Programa de Genética del Cáncer Humano (PGCH) del CNIO que realizará los estudios 
diagnósticos correspondientes en la muestra que se le extraiga.  
Los síndromes de cáncer hereditario tienen importantes implicaciones a nivel individual, familiar y social, 
ya que las personas portadoras de mutaciones hereditarias tienen un riesgo para desarrollar tumores mayor 
que el de la población general. Es en estos síndromes donde las posibilidades de prevención, o al menos 
de detección temprana, son más altas, al poder identificar a los portadores de estas mutaciones antes de 
que hayan desarrollado la enfermedad.  
Para el desarrollo de este estudio,  procederemos a examinar su exoma, el cual nos aportará información 
sobre la susceptibilidad genética suya, y de sus familiares, para padecer una enfermedad oncológica. 
El exoma es la parte del genoma formado por los exones, es decir, las partes codificantes de los  genes 
que formaran parte del ARN mensajero maduro y que daran lugar a las proteínas. Es la parte funcional más 
importante del genoma y la que contribuye en mayor medida al  genotipo final de un organismo. En el caso 
del exoma humano, este consta de  aproximadamente 180.000 exones que dan lugar a 22.000 genes. Su 
tamaño corresponde aproximadamente al 1% del tamaño total del genoma. 
La secuenciación de exoma ha demostrado ser una estrategia de extraordinaria eficiencia en el diagnóstico 
de enfermedades genéticas hereditarias 
Los motivos por los que se aconseja que se someta al presente estudio diagnóstico de susceptibilidad es 
la ocurrencia de alguno/s de los siguientes supuestos:  
• Agregación de cáncer en la familia  
• Aparición del cáncer a una edad temprana  
• Bilateralidad/multifocalidad de los tumores.  
• Aparición de un cáncer asociado a malformaciones o defectos congénitos.  
• Varios tumores primarios en un mismo individuo. 
En la actualidad las personas con riesgo elevado por ser portadoras de un gen alterado pueden ser 
controladas y seguidas por su médico de una forma más minuciosa y continuada. Junto a las medidas de 
detección precoz, en algunos casos concretos podrán aplicarse otras medidas de reducción del riesgo 
mediante quimioprevención y cirugía profiláctica.   
¿En qué consiste el estudio de diagnóstico genético a realizar? 
Por ello, el objetivo del presente estudio diagnóstico de susceptibilidad genética al cáncer, es analizar parte 
de su información genética, por medio del análisis del exoma de su información genética que esté implicado 
en la enfermedad______Cáncer de Testículos_______________________________________, 
Para ello, se utilizarán en la muestra de sangre que se le extraerá, las técnicas de citogenética y de biología 
molecular necesarias para el diagnóstico genético pretendido. En principio, dicha extracción de sangre se 
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llevará a cabo mediante venopunción. Dicha técnica implica una serie de riesgos, normalmente menores y 
poco frecuentes, entre los que se destacan los siguientes: 
- Sangrado excesivo 
- Desmayo o sensación de mareo 
- Hematoma (acumulación de sangre debajo de la piel) 
- Infección (un riesgo leve en cualquier momento que se presente ruptura de la piel) 
- Punciones múltiples para localizar las venas 
 
Igualmente, junto con la extracción de la muestra de sangre mencionada, para el estudio diagnóstico 
pretendido, es necesario (en ocasiones) el análisis de la/s muestra/s de su tumor o del de su/s familiar/es 
diagnosticados de cáncer; por ello, solicitamos  su consentimiento para disponer de las mismas si fuera 
necesario. En el caso de que usted haya sido diagnosticado de cáncer previamente, y para la consecución 
del presente estudio diagnóstico de susceptibilidad genética al cáncer sobre su persona y familia, con la 
firma del presente documento consiente expresamente, la utilización de  su tejido de tumor extraído sobre 
el que se llevó a cabo su diagnóstico de cáncer. 
Consejo Genético 
Conforme exige la Ley de Investigación Biomédica (Ley 14/2207), nos comprometemos  a suministrarle 
consejo genético tras los análisis realizados. Dicho consejo genético consiste en informarle de las posibles 
consecuencias para usted,  sus descendientes y otros familiares de los resultados obtenidos, así como de 
los riesgos y, en su caso, las distintas alternativas preventivas existentes. 
Sin embargo, es posible que de dicho estudio diagnóstico de susceptibilidad genética al cáncer no se derive 
ningún resultado concluyente acerca de la patología consultada, debido al conocimiento incompleto de las 
bases genéticas de la enfermedad o al elevado número de genes implicados. 
En todo caso, dado que el presente consentimiento informado va referido a una prueba diagnóstica, usted 
será informado del resultado de la misma, salvo que con anterioridad nos exprese su voluntad en contrario. 
Igualmente pueden encontrarse dentro del estudio del exoma hallazgos en los genes bajo estudio o en 
otros próximos que puedan estar relacionados con patologías diferentes a la consultada (siempre en 
relación a enfermedad oncológica). Ud debe decidir si quiere ser informado de estos otros hallazgos  
El presente estudio diagnóstico de susceptibilidad genética al cáncer puede comportar igualmente, 
información genética relevante respecto de sus familiares, correspondiéndole a Usted, conforme establece 
la Ley de Investigación Biomédica, decidir si desea que dicha información les sea o no transmitida. 
En todo caso, antes de decidir sobre esta cuestión, es conveniente que sepa que, cualquiera que sea su 
opción, de acuerdo con lo dispuesto por la misma Ley, puede acordarse, según criterio del médico 
responsable del estudio, y con el fin de evitar un grave perjuicio para la salud de sus familiares biológicos, 
informarles. En todo caso, la comunicación se limitará exclusivamente a los datos necesarios para estas 
finalidades y, además, ello se decidirá previa consulta con el comité asistencial si lo hubiera. 
Adicionalmente el estudio puede reportar resultados que a la fecha actual no pueden asociarse con la 
predisposición a padecer una enfermedad oncológica, pero que en el futuro y con los avances científicos 
pudieran llegar a asociarse. En dicho caso Ud puede volver a ser contactado para informarle de estos 
hallazgos y la posible enfermedad relacionada, siempre que Ud así lo consienta 
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Confidencialidad 
Los datos personales que se recojan sobre Usted, incluidos aquellos que se soliciten adicionalmente 
conforme a la necesidad del estudio genético que nos ocupa, únicamente serán tratados y accedidos por 
el personal médico y sanitario que realizará el estudio.  Dicha información será confidencial y procesada de 
acuerdo con la Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal y 
la legislación vigente, con la finalidad diagnóstica y de seguimiento médico descrita a lo largo del presente 
documento, pudiendo ejercer en cualquier momento, los derechos de acceso, rectificación, cancelación u 
oposición, reconocidos por la citada normativa en materia de protección de datos de carácter personal, 
poniéndose para ello en contacto con la presente Consulta de Cáncer Familiar. 
Por último, se informa que los resultados obtenidos podrán ser utilizados para una posible publicación 
científica, si bien, en dicha publicación se guardará absoluta confidencialidad de su identidad. 
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CONSENTIMIENTO PARA ESTUDIO GENÉTICO DEL EXOMA 
 He sido informado adecuadamente de los puntos anteriores y de los temas que de ellos se han 
derivado, así como he podido resolver cuantas dudas me han surgido, por parte del 
Dr._______________________ y doy mi consentimiento al estudio genético correspondiente 
Llevando a cabo los ensayos que sean necesarios sobre muestra de sangre o sobre muestras de tumor 
procedente de mí persona (en el caso que yo sea paciente diagnosticado de cáncer)  
En_____________________________, a ________ de __________________________ de 20_____. 
 
 
 
Firma del paciente 
 
 
 
Firma Rte. Legal 
 
 
 
Firma Testigo 
 Consiento a ser informado sobre los hallazgos en relación con mi posible enfermedad que sean 
encontrados en otros genes  
 
SI             NO 
 Consiento a ser informado sobre los hallazgos encontrados  en estos genes bajo estudio o en 
otros que estén asociados con la probabilidad de enfermedad oncológica de cualquier tipo  
SI             NO 
 
 Consiento a ser re-contactado en caso que en el futuro se encuentre asociación entre los cambios 
genéticos encontrados en mi exoma y alguna enfermedad oncológica no establecidos a la fecha 
del presente estudio 
 
SI             NO 
 
En_____________________________, a ________ de __________________________ de 20_____. 
 
 
 
Firma del paciente 
 
 
 
Firma Rte. Legal 
 
 
 
Firma Testigo 
 
 
_______________________________ 
El facultativo  de la Consulta de Cáncer Familiar 
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CONSENTIMIENTO PARA COMUNICACIÓN con mi FAMILIA 
 En el caso de obtenerse información genética relevante para sus familiares, ¿autoriza Usted a que 
se le comunique dicha información?:    
 
        SI                   NO 
 
 
 
Firma del paciente 
 
 
 
Firma Rte. Legal 
 
 
 
Firma Testigo 
 
CONSENTIMIENTO En caso de familiar fallecido 
 
Consiento AL ESTUDIO DE muestra de tumor de mi familiar (filiación): 
_______________________________________________________________, para completar estudio 
diagnóstico genético, EXCEPTO QUE DICHO FAMILIAR HAYA EXPRESADO EN CONTRA  
 
 
 
 
Firma del paciente 
 
 
 
Firma Rte. Legal 
 
 
 
Firma Testigo 
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ALMACENAMIENTO  Y USO POSTERIOR CON FINES DE INVESTIGACIÓN BIOMÉDICA 
Finalidad  
El presente documento tiene como objeto, conforme regula la Ley 14/2007, de 13 de diciembre, de 
Investigación Biomédica,  solicitar su autorización escrita para la donación gratuita de parte de la muestra 
sobrante de tejido (incluyendo sangre) extraído, para su  uso con fines de investigación biomédica del cáncer, 
y su almacenamiento en una colección de muestras o en un Biobanco a cargo del Centro Nacional de 
Investigaciones Oncológicas (CNIO). 
Puede que haya algunos términos que no sean de su comprensión. Por favor, no dude en preguntarme  (su 
médico responsable) mientras lee la información y yo se lo explicaré de la manera más satisfactoria para 
usted. 
Descripción del proceso 
En uno u otro caso, ya sea la inclusión de su excedente de muestra biológica en el Biobanco del CNIO como 
en la Colección de Muestras (C.0001433) registrada en el Instituto de Salud Carlos III, de la que es 
titular el Dr. Javier Benítez Ortiz, Jefe del Programa de Genética del Cáncer Humano del CNIO, 
tendrán a su disposición toda la información sobre los proyectos de investigación en los que se utilice 
(responsables de la investigación, lugar de su realización, etc). En todos los casos, un Comité de Ética 
evaluará el Proyecto de Investigación al que se destine su muestra biológica de forma que se respeten todos 
los aspectos éticos y legales que la normativa exige al efecto. 
Los estudios llevados a cabo pueden no tener beneficio clínico para su persona o la de sus familiares, sin 
embargo, los conocimientos obtenidos gracias a los estudios llevados a cabo a partir de su muestra y de 
muchas otras pueden ayudar al avance médico y, por ello, a otras personas. 
La donación de su excedente de muestra biológica no supondrá ningún riesgo o molestia adicional para usted, 
ya que  no se realizará ninguna prueba o intervención distinta de aquella en la que se obtuvo dicha muestra, 
salvo que sea necesario ponerse en contacto con usted para obtener alguna información adicional sobre su 
persona o muestras adicionales que el proyecto de investigación pueda requerir. Asimismo, su colaboración 
en esta donación es completamente voluntaria y no supone ningún  gasto  adicional para usted. Por otra parte 
la donación tiene por disposición legal carácter altruista, por lo que usted no obtendrá ni ahora ni en el futuro 
ningún beneficio económico por la misma. No está previsto compensarle por los productos desarrollados a 
partir de esta investigación. En todo caso, usted renuncia a cualquier beneficio económico que pudiera 
corresponderle en el futuro y que sea, lógicamente, renunciable. 
En cualquier caso, usted podrá revocar en cualquier momento su consentimiento, pudiendo solicitar, si así lo 
desea, la destrucción o  la anonimización de las muestras (destrucción del código que vincula la muestra con 
su identidad).No obstante,  la información obtenida hasta el momento de su revocación podrá ser utilizada  
por el investigador. En caso de producirse esta revocación ello no supondrá ningún cambio en la relación con 
su médico ni perjuicio alguno en su diagnóstico /tratamiento y/o seguimiento de su enfermedad. 
 
Confidencialidad y seguridad 
Los datos asociados y su muestra serán identificados por un código de modo que los investigadores nunca 
conocerán su identidad; sin embargo, sí podrán tener acceso a otros datos como su sexo o edad, 
manteniendo la confidencialidad conforme a la legislación vigente en materia de protección de datos de 
carácter personal. Sólo el personal autorizado del Centro tendrá acceso a su información personal. Los 
resultados de los estudios llevados a cabo pueden ser publicados en revistas científicas, sin que ello suponga 
la revelación de ningún dato personal que pueda llegar a identificarle. 
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De igual modo, se le informa que sus datos personales serán incorporados a un fichero automatizado de 
carácter confidencial, debidamente inscrito en la Agencia Española de Protección de Datos, conforme a los 
términos establecidos en la Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter 
Personal, pudiendo ejercer en cualquier momento los derechos de acceso, rectificación, cancelación u 
oposición al tratamiento de información descrito en líneas anteriores, poniéndose para ello en contacto con 
el Centro en la siguiente dirección: Melchor Fdez. Almagro, 3 (28029 –Madrid): Att. Secretaria de Dirección o 
a la Atención del Biobanco del Centro según haya consentido Ud uno u otro tipo de almacenamiento 
Para la consecución de las investigaciones biomédicas en las que participe su muestra biológica, pudiera ser 
necesario transferir una parte de ésta (la mínima imprescindible), y sus datos asociados, a otros centros y/o 
investigadores colaboradores dentro de la misma línea de investigación, ubicados en nuestro país, en países 
de la Unión Económica Europea, o incluso fuera de ésta, donde la normativa legal en materia de protección 
de datos no es igual que la normativa española o europea. Sin embargo, con carácter previo al envío de datos 
o muestra que se lleve a cabo, por parte de los responsables de la investigación se adoptarán todas las 
garantías exigidas por la normativa española para proceder a su transferencia. En cualquier caso, usted debe 
ser consciente de que sus datos identificativos nunca se incluirá en este tipo de transferencia, por lo que su 
anonimato quedará garantizado, y que la responsabilidad sobre las muestras / datos sique siendo del titular 
de la colección o del biobanco al que Ud otorga este consentimiento. 
Descubrimientos relevantes 
En caso de que de las futuras investigaciones que se lleven a cabo se desprendiesen datos que pudieran ser 
tanto clínica como genéticamente  relevantes para su salud, o la de su familia, Ud. debe decidir si quiere 
recibir o no dicha información, para lo que deberá cumplimentar el correspondiente apartado que se recoge 
más abajo. Si Ud. no desease recibir dicha información y, siempre que fuera necesario según criterio del 
médico o investigador responsable, para evitar un perjuicio para su salud o la de sus familiares, se informará 
a un representante, previa consulta a los correspondientes Comités de Ética, limitándose la comunicación a 
los datos estrictamente necesarios para evitar dichos perjuicios. 
 
Finalmente, en caso de producirse un eventual cierre del Biobanco del CNIO o la revocación de la autorización 
para su constitución y funcionamiento,  la información sobre el destino de sus muestras estará a su disposición 
en el Registro Nacional de Biobancos para Investigación Biomédica, con el fin de que Ud. pueda manifestar 
su conformidad o disconformidad con el destino previsto para las muestras, todo ello sin perjuicio de la 
información que recibiría por escrito antes de otorgar su consentimiento para la obtención y utilización de la 
muestra. 
 
En el caso que el investigador titular de la colección se traslade de centro de trabajo, para disponer de las 
muestras y podérselas llevar deberá volver a contactar con Ud y pedirle su consentimiento para ello, u obtener 
la autorización del Comité de ética correspondientes y siempre bajo acuerdo estricto entre las direcciones de 
los dos centros, el de origen (CNIO) y el de destino del investigador 
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CONSENTIMIENTO ALMACENAMIENTO Y USO POSTERIOR DE LA MUESTRA 
He sido informado adecuadamente de los puntos anteriores y de los temas que de ellos se han derivado, así 
como he podido resolver cuantas dudas me han surgido, por parte del Dr._______________________ y doy 
mi consentimiento al almacenamiento del excedente de mi muestra para uso en investigación biomédica 
 
En_____________________________, a ________ de __________________________ de 20_____. 
 
 
 
 
Firma del paciente 
 
 
 
Firma Rte. Legal 
 
 
 
Firma Testigo 
 
Consiento que el excedente de muestra biológica utilizada en el estudio genético se integre en EL 
BIOBANCO titularidad del Centro Nacional de Investigaciones Oncológicas (CNIO), con la finalidad de ser 
utilizado en investigaciones biomédicas relacionadas con el Cáncer. (Calle Melchor Fdez. Almagro, 3, 28029 
–Madrid) 
y/o 
 
Consiento que mi excedente de muestra biológica utilizada en el estudio genético se integre en la 
COLECCIÓN DE MUESTRAS BIOLÓGICAS TITULARIDAD DEL Dr. __________________________, con 
la finalidad de ser utilizada en investigación biomédica relacionada con el cáncer., concretamente en la 
colección nº --------------------------------------cuyo nombre es -------------------------------------------------------------------
------------------------------------------------------------------------------------------ 
Si Ud  marca ambas opciones parte de su muestra se integrará en el Biobanco CNIO y otra parte será incluida en la colección indicada 
AUTORIZACION DE INFORMACIÓN  
Autorizo a informar sobre  datos adicionales de mi historia clínica siempre 
que sean necesarios para el desarrollo de cualquier proyecto de investigación 
 
Autorizo que se transfieran mis muestras a terceros, incluidos terceros países 
en las condiciones anteriormente descritas. 
 
Autorizo que se me comunique la información importante para mi persona o 
la de mis familiares derivada de la investigación 
 
Autorizo a ser contactado en el caso que se necesite más información para 
cualquier proyecto en el que se utilicen mis muestras. 
En caso de revocación por mi parte decido que mi muestra se anonimice  
 
SÍ                 NO 
 
 
 
 
SÍ                  NO  
 
 
 
SÍ                  NO  
SÍ                  NO 
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En caso de revocación por mi parte decido que mi muestra se destruya  
 
SÍ                  NO 
 
SÍ                  NO 
 
 
Declaración de la persona que recoge el CI (facultativo responsable del estudio genético) 
Constato que he explicado las características de las condiciones de conservación y seguridad que se 
aplicarán a la muestra y a los datos clínicos conservados, así como las consecuencias derivadas de la 
donación de la muestra para el sujeto fuente. 
 
Nombre:…………………               Fecha……………………  Firma ………………….. 
Indique también, por favor, aquellas investigaciones en las que no desea que su muestra sea utilizada 
(ej. cáncer de colon, cáncer de páncreas…) 
 Centro Nacional de Investigaciones Oncológicas, c/ Melchor Fdez. Almagro 3, 28029 MADRID Teléfonos: + (34) 917 328 000 + (34) 912 246 
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Hoja de información y consentimiento informado. 
 
Introducción 
Le solicitamos su participación en un estudio destinado al estudio de variantes candidatas 
identificadas por secuenciación masiva de exoma de casos con agregación familiar de 
cáncer testicular. Para ello es necesario recoger muestras de sangre de individuos que 
presenten tumores germinales esporádicos con el fin de cotejar los hallazgos obtenidos 
hasta el momento. 
El estudio se está llevando a cabo en el Centro Nacional de Investigaciones Oncológicas en Madrid. Su 
participación en el estudio es voluntaria, puede rechazar participar en él y puede retirarse del estudio 
en cualquier momento sin que esto afecte su atención médica posterior. 
Cuando ya no se prevea la utilización de la muestra en los correspondientes estudios esta será 
eliminada, anonimizada o cedida con sus datos a un biobanco según lo que Ud. nos indique  en la hoja 
de consentimiento informado. 
A continuación describiremos los datos y las pruebas que son necesarias y para las cuales solicitamos 
su colaboración: 
1. Se le pedirá actualizar la información sobre sus antecedentes personales y familiares de 
cáncer de testículo y otros tumores mediante la cumplimentación de un formulario. 
2. Se le pedirá una muestra de sangre. 
 
Extracción de muestras 
La recogida de muestras para el estudio aprovechará las intervenciones médicas que se le realicen en 
relación al diagnóstico y tratamiento de su enfermedad para evitarle molestias y riesgos. En caso de 
que esto no sea posible, la extracción de sangre se llevará a cabo mediante la venopunción (extracción 
de sangre por aguja), cuyos riesgos son mínimos y se incluyen en el Anexo 1. 
En caso de que se produzca un efecto adverso derivado de su participación en el estudio, usted debe 
de ponerlo en conocimiento del Investigador Principal a través de los datos de contacto que se facilitan 
en la parte final del documento, debiendo acudir, además, a su médico lo antes posible. 
Uso de muestras y datos 
Todas estas muestras serán utilizadas exclusivamente con fines científicos relacionados con los 
objetivos del estudio.  
El material biológico que nos cede formará parte del bio-depósito de este centro y será registrado hasta 
su uso en el proyecto de investigación. Una vez finalizado el estudio, la muestra será almacenada en 
una colección (C.0001433) registrada en el Instituto de Salud Carlos III, de la que es titular el Dr. Javier 
Benítez Ortiz, Jefe del Programa de Genética del Cáncer Humano del CNIO; su cesión a investigadores 
de otros centros participantes estará condicionada a la aprobación del Comité Científico del estudio. 
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El material se conservará durante un máximo de 50 años para realizar, posiblemente, posteriores 
determinaciones como parte de este proyecto o de futuros estudios relacionados. En este último caso 
su muestra solo será utilizada si el proyecto es autorizado por un Comité de Ética de la Investigación 
(CEI).  
Confidencialidad 
Los datos personales que se recojan sobre usted, serán confidenciales y procesados de acuerdo con la 
Ley Orgánica 15/1999 de Protección de Datos de Carácter Personal, así como de acuerdo a la legislación 
sanitaria y a la relativa a la investigación biomédica vigente 14/2007, tratándose los mismos únicamente 
de acuerdo con los objetivos descritos en el presente proyecto de investigación u otros relacionados 
sobre el cáncer de testículo familiar. Asimismo, se informa de que los resultados obtenidos de los 
diferentes estudios llevados a cabo con las muestras, pueden ser publicados en revistas científicas, sin 
embargo, nunca será facilitada su identidad o datos que puedan llegar a identificarle. 
En el momento que usted consienta el uso de la muestra para los fines de investigación aplicada 
descritos, dicha muestra será sometida a un proceso de disociación. Es decir, sólo será identificado por 
un código, constando todos sus datos debidamente codificados, sin embargo, y dado que se trata de 
un análisis cuyo resultado podría redundar en beneficio del paciente y/o de sus familiares, únicamente 
el investigador principal tendrá acceso a la información necesaria para asociar el código con sus datos 
personales.  
De igual modo, sus datos personales serán incorporados a un fichero automatizado de carácter 
confidencial, cuya titularidad corresponde al CNIO, debidamente inscrito en la Agencia Española de 
Protección de Datos con número 2042540353, conforme a los términos establecidos en la Ley Orgánica 
15/1999, pudiendo ejercer en cualquier momento, los derechos de acceso, rectificación, cancelación u 
oposición, reconocidos por la citada normativa en materia de protección de datos de carácter personal, 
poniéndose para ello en contacto con el Responsable del Estudio en su Hospital.  En caso de revocación, 
su muestra dejará de formar parte de la investigación y se destruirá aunque los datos obtenidos hasta 
ese momento sí formarán parte de la misma.  
La información obtenida en el estudio será confidencial, de acuerdo con lo que establece 
la Ley tratándose únicamente de acuerdo con los objetivos descritos en el presente 
documento. Nadie, excepto los miembros del estudio, LAS AUTORIDADES SANITARIAS, 
ASÍ COMO COMITÉS DE ÉTICA DE INVESTIGACIÓN CLÍNICA, tendrá acceso a su 
información. 
Consejo Genético 
Los datos que se obtengan de los análisis de las muestras serán archivados, y formarán parte del 
proyecto de investigación, manteniéndose durante un máximo de 50 años para realizar, posiblemente, 
posteriores análisis. Los métodos utilizados en investigación biomédica suelen ser diferentes a los 
aprobados para la práctica clínica, por lo que puede no tener valor clínico para usted.  
No obstante, le corresponde a usted decidir si quiere recibir o no dicha información, tanto en relación 
con su persona como con su familia, para lo que deberá cumplimentar el apartado correspondiente de 
la hoja de consentimiento. 
Si se adquiere un compromiso de facilitarle esta información, y de conformidad con la normativa 
vigente, una vez obtenidos y evaluados los resultados de los análisis realizados y en caso de que éstos 
tengan un valor clínico comprobado, nos comprometemos a suministrarle consejo genético, es decir, 
informarle sobre las posibles consecuencias tanto para usted como para sus descendientes de los 
resultados de los referidos resultados, así como de sus ventajas y riesgos.  
Seguro 
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De acuerdo con lo dispuesto en el Art. 18 de la Ley 14/2007 de Investigación Biomédica, se ha suscrito 
una póliza de seguro para cubrir los daños que pudiera ocasionársele por la extracción de la muestra 
de sangre descrita anteriormente para poder llevar a cabo este proyecto de investigación  
Beneficios potenciales, riesgos y compensación 
La donación tiene, por disposición legal, carácter altruista, por lo que usted no obtendrá ni ahora ni en 
el futuro ningún beneficio económico por la misma. No está previsto compensarle por los productos 
desarrollados a partir de esta investigación. Sin embargo, su participación, junto con la de otras muchas 
personas, es muy importante para ayudar a entender mejor cómo se desarrolla y evoluciona el cáncer 
de testículo y para que, con ello, se beneficien otros pacientes futuros. Los resultados de la investigación 
corresponderán a los investigadores participantes en el proyecto.  
Asimismo, y para poder completar el presente proyecto de investigación, cabe la posibilidad de que sea 
necesario requerir nuevamente su participación para realizarle una nueva extracción de sangre u 
obtener otra muestra biológica,  siempre que la viabilidad de la presente investigación científica pueda 
requerirlo.  
 
A continuación se adjunta: 
- Hoja de consentimiento 
- Anexo 1: Riesgos de la venopunción 
- Anexo 2: Resumen del proyecto 
- Formulario a cumplimentar. 
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Consentimiento Informado  
 Sí No 
1. Confirmo que he leído y entendido la hoja de información, y que he tenido la 
oportunidad de hacer todas las preguntas que creía necesarias. 
 
 
 
 
2. Estoy de acuerdo en participar en las siguientes partes del estudio:   
            Entrevista personal   
 
 
 
            Recogida de sangre  
 
 
 
            Recogida de tejido parafinado  
 
 
 
            Acceso al historial clínico  
 
 
 
            Contacto personal en el futuro  
 
 
 
            Contacto familiar en el futuro 
 
 
 
 
 
3. En el caso de producirse resultados que pudieran ser clínicamente relevantes, 
relacionados con la susceptibilidad a padecer cáncer de testículos para 
mi familia deseo que se me comuniquen estos datos. 
4. En el caso de producirse resultados que pudieran ser clínicamente relevantes, no  
relacionados con la susceptiblidad a padecer cáncer de testículos, para 
mí o mi familia deseo que se me comuniquen estos datos. 
 
 
  
5. Una vez finalizado el proyecto, doy permiso a que el sobrante de mis muestras 
biológicas se almacenen para su uso en otros estudios no relacionados*:  
 
- Tras su anonimización (proceso por el cual no es posible establecer relación entre un 
dato o muestra y el sujeto al que se refiere) 
- De forma no anónima (aunque con procedimientos de disociación para preservar la 
confidencialidad de los datos de carácter personal). 
* La no aceptación de este punto implica que la muestra será destruida una vez finalizado el 
proyecto. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Otorgo mi consentimiento de manera voluntaria y entiendo que soy libre de retirarme en cualquier 
momento, sin dar explicaciones, sin consecuencias legales y sin que tenga ningún efecto sobre mi 
tratamiento médico futuro. 
 
 
 
Nombre y Apellidos del participante                    Fecha                          Firma                        
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Nombre del representante legal                         Fecha   Firma 
 
 
 
Nombre del médico/investigador                             Fecha   Firma  
 
 
Le agradecemos su cooperación en este proyecto de investigación. Si tiene alguna pregunta sobre el 
estudio, puede llamar al investigador principal del estudio, Beatriz Paumard Hernández, estudiante pre-
doctoral del Grupo de Genética Humana del CNIO, Madrid, Tfno: 912246900, ext 3311. Este protocolo 
ha sido revisado y aprobado por el Comité Ético.  
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ANEXO I 
Riesgos de la venopunción 
 
Riesgos generales de la venopunción: 
· Sangrado excesivo (ej: casos de uso de medicamentos anticoagulantes como Simtron) 
· Desmayo o sensación de mareo 
· Hematoma (acumulación de sangre debajo de la piel) 
· Infección (un riesgo leve en cualquier momento que se presente ruptura de la piel) 
· Punciones múltiples para localizar las venas 
De estos son habituales o frecuentes el hematoma y las punciones múltiples. El tamaño de las venas 
y las arterias varía de un paciente a otro y de una parte del cuerpo a otra, por tal razón obtener 
muestras de sangre en algunas personas puede ser más difícil que en otras. 
Consideraciones especiales 
· Puede existir una mayor dificultar de acceso venoso en caso de afectación cutánea en la región del 
antebrazo. 
· Existe un mayor riesgo de sangrado excesivo por déficit de plaquetas y factores de la coagulación. 
· Existe un mayor riesgo de trombosis e inflamación venosa en algunas personas. 
En el caso de que se materialice algún efecto adverso de los citados anteriormente, durante su 
participación en este Proyecto, debe ponerlo en nuestro conocimiento, debiendo acudir, además, a su 
médico lo antes posible. 
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ANEXO II 
Resumen del proyecto 
 
El cáncer de testículo es una enfermedad rara, representa entre un 1-1.5% de las neoplasias 
masculinas y un 5% del total de los tumores urogenitales. Se desarrolla entre los 15 y 40 años 
aunque puede afectar a varones de cualquier edad. Presenta una de las tasas de curación más altas 
de todos los tipos de cáncer, por encima del 90%, y prácticamente del 100% si no se ha extendido.  
La agregación familiar de cáncer de testículos constituye en torno al 1% de los casos. 
Aproximadamente el 1-3% de los hombres con cáncer testicular reportan la presencia de otro varón 
afectado en su familia. Hijos de hombres con tumores de células germinales de testículo tienen un 
riesgo de cuatro a seis veces mayor de padecer tumor testicular, y hermanos de ocho a diez veces 
superior, en comparación con la población general. 
Las bases genéticas del cáncer familiar de testículos son actualmente desconocidas, no se ha 
identificado ningún gen de alta penetrancia que explique alguna de estas familias. Diversos estudios 
de asociación del genoma (GWAS) han descrito alteraciones en genes de baja susceptibilidad 
genética a desarrollar este tipo de cáncer, pero tan solo mutaciones en el gen TGCT1 (Testicular 
Germ Cell Tumor Susceptibility 1) se han descrito como alteraciones genéticas de moderada 
susceptibilidad a desarrollar este tipo de cáncer. 
El objetivo de este estudio es la identificación de las bases genéticas de susceptibilidad al cáncer 
testicular familiar.  Para ello realizamos una secuenciación de exoma completo en individuos 
pertenecientes a familias con cáncer testicular familiar previamente seleccionadas por presentar al 
menos dos miembros afectos. El resultado de nuestro estudio se basa en la aplicación y traslado a la 
práctica clínica de los resultados obtenidos con el objetivo de identificar precozmente individuos a 
riesgo y establecer las medidas de seguimiento adecuadas.  
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Supplementary Figure S1. Alterations our candidate genes from the discovery analysis present in the TGCA platform (159 different tumors studies)
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Supplementary Table S1. Clinical information of the 19 families (71 individuals) identified 
 
Origin Pedigree Family status WES 
Tumor 
Sample 
Family History 
TGCT Histopathology diagnosis 
Risk Factors Age dx 
Seminoma Non Seminomatous  
Centro 
Nacional de 
Investigaciones 
Oncológicas 
1 
Father - T Renal cancer    - 
Index case WES T  Seminoma   dx34 
Brother WES T  Seminoma Embryonal carcinoma  dx26 
Brother WES T  Seminoma 
Embryonal carcinoma 
& Teratoma 
 dx30 
2 
Sister -      - 
Brother -  
Fanconi Anemia & 
Colorectal 
Adenocarcinoma 
   dx47 
Index case WES T  Seminoma Embryonal carcinoma 
Inguinal Hernia, 
Cryptorchidism 
dx22 
Brother WES T  Seminoma   dx37 
Father WES  Prostate cancer    dx81 
Mother WES      - 
Hospital 
Universitario 
Gregorio 
Marañón 
3 
Father WES  
Otorhinolaryngolog
y tumour 
   - 
Mother WES      - 
Index case WES T   
Embryonal carcinoma 
& Teratoma 
 dx31 
Brother WES T   
80% Embryonal 
cancinoma & 20% 
Yolk sac tumour 
Microlithiasis dx37 
Uncle -  Prostate cancer    - 
Cousin WES   Seminoma 40% 
Embryonal carcinoma 
60% 
 dx29 
Sister -      - 
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Centro Integral 
Oncológico 
Clara Campal 
4 
Mother -           - 
Father WES      - 
Brother WES     Hydrocele - 
Index case WES T   Seminoma  
Inguinal Hernia, 
Cryptorchidism 
dx34 
Brother WES      Seminoma     dx30 
 
 
 
 
 
 
 
 
 
 
Hospital Sant 
Pau 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
Index case WES      Seminoma   Microlithiasis dx33 
Brother WES   
Bilateral 
Seminoma 
 Male infertility dx36 
Mother WES      - 
Father WES           - 
6 
Index case WES     
Bilateral 
Seminoma  
  Hydrocele dx27 
Brother WES    Seminoma Focal teratoma  Cryptorchidism dx27 
Mother WES      - 
Sister -      - 
Father WES           - 
7 
Index case WES     
Bilateral 
seminoma   
  
Bilaterality 
Microlithiasis 
dx28;dx34 
Brother WES   Seminoma  Microlithiasis dx31 
Brother -  
Bilateral 
Microlitiasis 
   - 
Father  WES      - 
Mother WES           - 
8 
Father WES           - 
Mother WES      - 
Index case WES    Seminoma   Hydrocele dx32 
Brother WES      Seminoma     dx18 
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Hospital Sant 
Pau 9 
Index case WES     Seminoma   
Microlithiasis, 
Impaired 
Spermatogenesis 
dx37 
Brother WES   Seminoma 
Embryonal carcinoma 
& Yolk sac tumour 
 dx30 
Mother -      - 
Sister -      - 
Father -           - 
Hospital 
Universitario 
Morales de 
Messeguer 
10 
Brother -           - 
Sister -      - 
Index case WES    Seminoma Non Seminomatous  Hydrocele dx36 
Brother WES    
Embryonal carcinoma 
95% & Teratoma 5% 
Inguinal Hernia dx29 
Father WES      - 
Mother WES           - 
11 
Index case WES T    Seminoma     dx59 
Father WES T   Seminoma    dx31 
Brother WES      - 
Uncle -           - 
Clinic 
Barcelona 
12 
Index case WES       Non Seminomatous    dx35 
Brother WES   
Testicular 
Sarcoma 
  dx37 
Cousin WES       Non Seminomatous    dx37 
13 
Brother WES     Seminoma     - 
Index case WES   
Seminoma Left 
testicle 
(Microlithiasis) 
Non Seminomatous 
right testicle 
Contralateral 
tumour 
dx17 (right); 
dx19 (left) 
Mother WES             
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Clínica Rotger, 
Baleares  
14 
Mother WES           - 
Father WES    Teratoma  dx32 
Index case WES    Embryonal carcinoma  dx15 
Sister -           - 
Hospital 
Universitario 
Sant Joan de 
Reus    
15 
Index case WES     Seminoma       
1970 
dx2003 
Mother WES      - 
Cousin  WES   Seminoma   Cryptorchidism 
1972 
dx2003 
Aunt WES      - 
Cousin  -      - 
Cousin  -           - 
Hospital 
Universitario 
de Fuenlabrada 
16 
Cousin WES       
Embryonal 
Teratocarcinoma 
Microlithiasis dx35 
Index case WES T   Seminoma   dx34 
Father WES      - 
Mother WES      - 
Brother WES      - 
Aunt WES      - 
Uncle WES      - 
17 
Index case WES T   Seminoma      dx30 
Brother WES   Seminoma   dx31 
Brother -           - 
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Hospital 
General 
Universitario 
de Albacete 
18 
Index case WES   40% Seminoma 
60% Embryonal 
carcinoma 
 dx23 
Brother WES   40% Seminoma 
50 % Embryonal 
carcinoma& 10 % 
Yolk sac tumour 
 dx18 
Sister -      - 
Mother WES      - 
Father WES           - 
Instituto 
Catalán de 
Oncología 
19 
Index case WES     Seminoma     dx31 
Brother WES    
Embryonal carcinoma 
& Yolk sac tumour 
 dx28 
Mother WES      - 
Father WES           - 
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Supplementary Table S2. Primers of variants for being validated at DNA level. (F correspond to Forward and R to Reverse primer) 
      
Gene Primer Sequence Product (pb) Annealing temperature Position GRCh37 
PDE11A 
F AAGATTACTTGATGCGGAAGG 
279 66º 
178937097 178937077 
R CTCTCCGCTGCAGGTTCC 178936836 178936819 
SH2D4A 
F TTTTGAGGGCATTATTTTCAA 
399 59º 
19230979 19230999 
R TTTGGGCAGCACCAATAAAT 19231258 19231267 
SBF1 
F CTGACCCAAGTCCCAACCT 
104 58º 
50886903 50886885 
R CCCTCCTGCAGGTACACAC 50886818 50886800 
INCENP 
F TAAGAAGTCGAAGGCCAGGA 
380 68º 
61897659 61897678 
R GCTCTTCGGCAGTCTTCTTG 61898057 61898038 
CYP3A43 
F CCACCACACCCTGCATAAC 
173 67º 
99461080 99461098 
R AGAGCAAACCTCATGCCAAT 99461233 99461252 
DDX54 
F AAGTCCCCGAGAAGCCACT 
277 67º/10%DMSO/0s ext 
113601194 113601176 
R ACCCAGCCAGCCACTCAC 113600936 113600919 
MEA1 
F GGTTCCTGAACAGGTGAAGC 
257 66º 
42980834 42980815 
R GGGTCTTCCTCTGAAACTTCC 42980536 42980556 
MYCT1 
F TCTCACAGTGGAGTTCAAGCA 
209 67º 
153042988 153043008 
R TTGCAGAAAGGGATGGAAAG 153043176 153043195 
PKN1 
F GTGAGCCTCGCAGCTGGT 
154 69º/ 5%DMS/15s ext 
14551956 14551973 
R AGGTTCTCAGCACCCTCCTT 14552090 1455310 
TAF1L 
F AAAACATCGGGAAGAGATGC 
340 60º 
32631879 32631860 
R TTTCCCGAAGACAATTTTGG 32631528 32631540 
VNN1 
F CCTTTGGAAGTTTTGGCATT 
195 60º 
133014374 133014364 
R TGTTGGATGCAAGGAAATTG 133014209 133014190 
YLPM1 
F CCCCACCATCTCTCTCTTCA 
225 65º/5%DMSO 
75248563 75248582 
R GGGCAGAACCAAAAGACACA 75248768 75248787 
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SPAG1 
F TCAAACCAAAGGGAAAAGGA 
170 57º/5%DMSO 
101206396 101206415 
R AAAAATTGAGCCAGCTCATCA 101206546 101206565 
KCNU1 
F TTCCTGAGTCTTCTCTCTTTGGA 
167 63º/5%DMSO 
36671698 36671721 
R GGTCCGTCCTAAGGATGTCTT 36671845 36671865 
ABCA1 
F CAGTGGGACAACCTGTTTGA 
151 63º/5%DMSO 
107588093 107588074 
R CAGATGCCCAAAGCAGTGTA 107587962 107587943 
SOX30 
F GTCGAGGGCACCTCCTTT 
187 68º/10%DMSO 
157079017 157079000 
R CCTGAGGCTGTGGTAGCAG 157078849 157078831 
TEX19 
F GAAGACAACTGGGACCCTGA 
180 67º/30cycles/5%DMSO/0 ext 
80320192 80320211 
R CAGACCTGCATCTTCCAACC 80320352 80320371 
SYCP2 
F TGAAAATGCCAAGCAGAGTG 
222 63º/5%DMSO 
58467285 58467266 
R TCCCAGGAATTAAGCTCAGAA 58467084 58467064 
EPHX2 
F GTTTTAGGGAGTGGCTGAGG 
190 63º/5%DMSO 
27394294 27394313 
R TGAAAGAAAAGGAGGCCAGA 27394464 27394483 
MLH3 
F AAATCACAAACAGATTGCATA 
162 61º 
75514252 75514232 
R CTTCTCTAAAGATCCTAGCTGTG 75514113 75514091 
NOP10 
F GCAGGAAGGAAATTGACGAA 
220 68º/35%DMSO 
34635368 34635349 
R CGTATGACCTCACCCACTCC 34635168 34635149 
CTAG2 
F TCAGTCGGCTAAATGTGAGG 
510 60º/5%DMSO 
153880553 153880534 
R CAGAGGAAAGTGGGGAATCA 153881042 153881023 
GREB1 
F CTCCCTTTGCCCCTGTGAC 
387 62º/5%DMSO 
11706535 11706549 
R AAACAGAAACAGGGCTGCAT 11706902 11706922 
SEMA4D 
F TTCTTCCTCCCACTCTGACC 
232 59,7º/5%DMSO 
92017971 92017951 
R CCACTCAAGCTGGGCTATGT 92017758 92017738 
USP47 
F TTTTAGGGCCTTCGGTTTT 
218 62º/5%MgCL2 
11941883 11941903 
R AAAACCATGACTGACTAATGTGGA 11942076 11942100 
SSH1 F TCTGAAGACCATCTGCTACACC 202 62,8º 109182169 109182147 
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R CAGCTTGGCAAGAGAGTGTG 109181988 109181968 
GRP 
F CAGCTCACTCTGTTTGCTGAA 
264 59,7º 
56897594 56897614 
R TGCTGCTTGAAAATCACGAA 56897838 56897857 
CYR61 
F AGAGAAATATCACCCCTAACTTTCC 
264 59,7º 
86048378 86048403 
R TTTGCAGGACTGGATCATCA 86048622 86048642 
PLEC 
F CTTCCTCCCTGTCCCTTCC 
381 61º/5%DMSO 
143934802 143934821 
R AGGCCCACCTCAATCTCCT 143935163 143935182 
GYS2 
F GGTTTTTGATGGAACCAAAGAG 
300 56,2º 
21693605 21693583 
R TTTTTAAGTGGTCTGCTGTGTTTA 21693328 21693304 
MAST4_V1 
F CTCGGGCTCAGAAACTCTGT 
272 62º/5%DMSO 
65892609 65892628 
R GAACCCAGAGTGGGCAAG 65892863 65892880 
MAST4_V2 
F GGGGAAACCAAAGGGAAG 
200 62º/5%DMSO 
66462679 66462698 
R TACAAGGCCTTTTTGTGAGG 66462858 66462878 
ODF1 
F CTGCAAAGAGTTCAGCTTGC 
391 65º/5%DMSO 
103572872 103572892 
R CTTTCACACAACACCAGCAGA 103573242 103573263 
SSTR5 
F CTGGGGCTGCCTTTCCTG 
502 60º/10%DMSO 
1129139 1129156 
R CAAACACCAGCACCACCAC 1129632 1129640 
DNAAF1 
F GCCCTGGGAGTAGGAGCTTA 
288 62,6º/5%DMSO 
84188136 84188156 
R TGCTTGCTGGGTACCCTTAC 84188404 84188424 
MAP4_V1 
F AATAGAGGTGGCACAGGCTAA 
196 58,5º 
47958072 47958051 
R TTGAGCCATGTCCTTGACTG 47957896 47957876 
MAP4_V2 
F ATGGCTGACCTCAGTCTTGC 
281 62º 
48040350 48040331 
R GGCATAATCCCTAACCTGCTT 48040090 48040070 
SPZ1 
F CTGAGCCATGACACCTATTCA 
276 65º 
79617216 79617237 
R AAGACAAACATCCAGGCTTCT 79616962 79616983 
HRASLS 
F GCTAGCTCTTCTTTGTATTTGTCA 
243 62º 
192973409 192973433 
R TTTCACCCATGATTACTTCCTG 192973631 192973653 
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PSRC1 
F ATTTCTCCACCCCTCTCCAC 
382 62º/5%DMSO 
109823691 109823671 
R AAGGATGGCAAAAGTGGTCA 109823329 109823309 
GAR1 
F TTTCATCAGGGAGGAGAGAGA 
316 65º 
110737299 110737320 
R TCCCAAACTTGCTGCCTAAC 110737595 110737615 
TAF1L_V3 
F TTCGGACAAGACAGGGTTACT 
451 59º/5%DMSO 
32633227 32633207 
R TTTTCTTCTTCTGGGGCAAA 32632796 32632777 
CYP2C8 
F GCGCTACGTGATGTCCACTA 
379 62º 
96798873 96798853 
R TGTATTGTGAGGGTGGAGCA 96798513 96798493 
SPATA12 
F TCACCTCCAGCTCTCCTGAT 
186 64,9º 
57108041 57108061 
R AAATGTCAGTTGGTTTGAACG 57108206 57108227 
CYP1A1 
F CTACCTGAACGGTTTCTCACC 
223 62,2º 
75013087 75013108 
R AGGCATGCTTCATGGTTAGC 75012885 75012865 
SHQ1 
F TGCCTCAGACTGCCAGAGTA 
222 65º 
72891652 72891632 
R CCTATTTCTTCCACAAGTGGTTT 72891451 72891430 
DDX4 
F TCTTGCTCACTGCAAGCTCT 
472 64º 
55088254 55088273 
R TCTCTAAAAATAGGATATTCACAGTGC 55088725 55088698 
CCDC62 
F CATGCTGCCAGAAAAATGAA 
397 65º/5%DMSO 
123286180 123286200 
R GACTCAACAGTCCATGCTGTG 123286555 123286576 
MAGEE1 
F CACCTCCGTGCTGCCTAC 
590 66º/5%DMSO 
75648909 75648931 
R GCTGCACTAAGGTGCTTGC 75649485 75649504 
APLF 
F CCTCTGGATGCAGAAAGACA 
325 64º 
68804858 68804878 
R GAAAAGGCAAGGCAACAAAA 68805156 68805183 
CYP2C8_V2 
F TCCCAGGAACTCACAACAAA 
193 63º 
96818235 96818215 
R TCACAAAATGGACAAGAAATCAA 96818066 96818042 
GFRA1 
F CTCTGGAGCAAACCCTTGAA 
595 63/10%DMSO 
118030887 118030907 
R CTGGGGAGAAGTGAGTGGAG 118030250 118030230 
FSIP2_V1 F CAAGTGAATCCAAAGAAGTAGTCAA 247 63º 186665099 186665124 
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R GTGCTTGTGCATTCTTCCAA 186665325 186665345 
FSIP2_V2 
F TTTAAACGTTTGGAATCTTTTGC 
204 63º 
186658632 186658657 
R AAGCTCTTGGCTGAGAATGG 186658818 186658838 
TNK2 
F CCAGCTTCCAGTGGTGTTG 
377 63º 
195591162 195591143 
R AGCCCTCAAGCCTGTCTTC 195590804 195590785 
TRIM16 
F GAAACAGCAGCCTGGGTAAA 
788 64º 
15532653 15532633 
R TCACCCTAAAATGCAAATCC 15531885 15531865 
CYP2C8_V3 
F TGGCACTGGAAAGAAGGAGT 
343 58º 
96829019 96829039 
R AACATCTATCTGTAGCATATTTCCAA 96829361 96829381 
SMYD2 
F TGATTCAGAGTGACATAGCTGC 
219 57º/5%MgCL2 
214318892 214318914 
R TCAGAGCTTCGTTGTCAGGA 214319090 214319110 
FANCD2 
F ATGGGAGGATAACTTGGGCC 
362 63,6º/5%MgCL2 
10077938 10077958 
R ACCCAAACACAATGCCAAAGA 10078278 10078299 
NLRP14 
F TGTCTGAAGCAGCAAATGGAG 
396 63,6º/5%MgCL2 
7043158 7043179 
R TTCAAAAGGCTGGCAGGAAG 7043533 7043553 
LRP4 
F CCAGGTGGAATGCCAAGTT 
370 57,1º 
46895724 46895705 
R CCATCTGTGAAATGGGAAGG 46896313 46896293 
PIF1 
F GCCTGGGTGACAGAAAGAGA 
396 65º 
64821223 64821243 
R AGTCCCCACAGATGATGAGC 64821598 64821618 
SERPINB11 
F ATTTAGATGAGAAACAGACAACAGAA 
702 66,2º/5%MgCL2 
63722796 63722822 
R AGGTGTGTGAGGTGTGAACA 63723477 63723497 
HORMAD1 
F GGGAGGAATTCTTGGGGTGA 
396 57,1º/5%MgCL2 
150717004 150717024 
R ACTGTCAGGTACGTGAATTGT 150717378 150717399 
DCLRE1C 
F GCCTGGTGTGGTTCAAATTACT 
451 60º 
14935267 14935289 
R GACCAGCCTGCCCAACAT 14935699 14935717 
ERCC5 
F TTGTTCTTTGTTCCCTGTTGG 
402 65º/5%DMSO 
102861410 102861431 
R TCATTAATATTATCCAGGGGTGCT 102861787 102861811 
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NOTCH3 
F TTTCTGCCTCCCTGACATGG 
176 63,8º 
15162458 15162478 
R GGCTCACCTTGCTATCCTG 15162614 15162633 
TDRD6 
F TCAATTTGCCCTCGGAAGTG 
383 59º/5%DMSO 
46688487 46688507 
R CTGCAGCTGGGGATAGAAGT 46688849 46688869 
YY1 
F GGAGACCATCGAGACCACAG 
225 63º/5%DMSO 
100705680 100705700 
R GTCTGCACCAGGATCACCTC 100705884 100705904 
STARD6 
F AAGCCCTGCTTTTTCCAAAT 
315 63º/5%MgCL2 
51858031 51858051 
R CTTTGAAGCTGTGAATAAAGGGA 51858322 51858345 
DNAH8 
F TGAGGTTGAAATGAGGATGAAA 
353 66º/5%MgCL2 
38738031 38738053 
R CAAAAAGGTGTGGTGTGGAG 38738363 38738383 
STARD6_V2 
F TGGCAGAGACAAGATATGACC 
490 61º 
51880700 51880721 
R GCAGTCCTCCTGTGTTAGCC 51881169 51881189 
TAF1L_V4 
F CGGGAAGAGTTCAGAGAGCA 
262 61º 
32630936 32630956 
R GAAATGGCCAAGAATCTGGA 32631177 32631197 
TAF1L_V5 
F AGCCACAGGCAGTGAAGAAG 
201 61º 
32632382 32632402 
R ATTTACTCATGGGCCCCTCT 32632562 32632582 
TBP 
F TGTCTTTGCACACCTGACCT 
614 66º 
170870784 170870804 
R CCATCTGAAAACAGAGCAGGA 170871376 170871397 
ZP2 
F ATGAACAACCTGTGGGATCA 
565 64º/5%MgCL2/1min ext 
21208697 21208717 
R TGCCTCTACACTGAGGAACAAA 21209239 21209261 
ZPBP2 
F GAGGAGGTGGGGAGGTGT 
R 61º/5%DMSO 
38024524 38024542 
R AGGCGAAGGAGGCAGGAC 38024712 38024730 
BRD4 
F CATAGTCCTGTGGGCTAGGG 
206 61º/5%DMSO 
15350496 15350516 
R ATGCTCTCCGGGTGCTTG 15350683 15350701 
TDRD6_V2 
F ATCCTGGTAAATGCCCACTC 
204 61º 
46657894 46657914 
R TCTTTTCACTTTTTCCTGCACA 46658075 46658097 
PINX1_V2 F TGGAGAGAATCATCAACTCAGAA 476 61º/10%MgCL2 10690137 10690160 
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R TGTTGGCTGCAAAAACTTAGAA 10690590 10690612 
KDM4B 
F TGGGACTCTGGGGAGAATTA 
216 61º 
5047396 5047416 
R AAGGTGGTCTTCCACATGC 5047592 5047611 
PRKDC_V1 
F GGGAAAGTGTTAGCATTTAACATCA 
339 61º/10%MgCL2 
48710703 48710728 
R ACATGCACTGCACACACTAAC 48711020 48711041 
PRKDC_V2 
F TGATTCTTAGCTTTGCCTCAGA 
614 64º/5%MgCL2/1min ext 
48690884 48690906 
R TGCATTCAATGACCATGACA 48691477 48691497 
KAT6B_V1 
F AGAAGGAGGAACAAGAAATCCT 
517 61º5%MgCL2 
76781673 76781695 
R CACCGCACTAACAAACCTGA 76782169 76782189 
KAT6B_V2 
F GTACCCGAATCTGACGAGGA 
195 61º 
76789077 76789097 
R GGCACAATCCTGAAAGGTGT 76789251 76789271 
NEK11 
F TGATTTAAAAGCACATTTTCCTG 
407 61º/5%MgCL2 
131068326 131068349 
R GATGGGAGCTCTGCTTTTGT 131068712 131068732 
EXO5 
F TGCTAGCCTAATCCACCACA 
359 61º 
40980921 40980941 
R TCCACTCACAAATGTCTGCAT 40981258 40981279 
CAPZA3 
F GACCTCATCAGGAGGCTCAG 
413 61º/5%DMSO 
18891035 18891055 
R CGGTAGTCGCCCATTACATT 18891427 18891447 
RECQL4 
F CAGGTACACGTGCTGATGCT 
183 62º 
145739552 145739572 
R CCCAGTTCACATATGGCTCA 145739814 145739834 
POLE2 
F CCGGCCGTTTAGTCAGTTT 
410 61º 
50122388 50122407 
R CCAGCAAACATTATGCGAAG 50122777 50122797 
ERCC4_V1 
F GGGTAAGATGTCTTCCCTTCG 
374 61º/5%MgCL2 
14028903 14028924 
R TGAGTTAAGGTCAACTTCCGTTT 14029253 14029276 
ERCC4_V2 
F GAGGTGCCTTGTTTCAGGAG 
572 66º 
14041768 14041788 
R TCTGGTCCACCGTACAATCA 14042319 14042339 
ATP8B3 
F TCTGCCCCCAGATACACTTC 
487 61º 
1811408 1811428 
R CACCTGCCAGCTCTCTAGC 1811875 1811894 
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KIF18A 
F TCGGCACCTAGGTAATCCTC 
543 64º/1min ext 
28105916 28105936 
R TTAGGGAGAAAGCCACTCAAG 28106437 28106458 
ADAM20 
F GCAAAAGATCCCTGTTGTCTG 
615 64º/1min ext 
70989573 70989594 
R GGCTTGTGACAGATGAACCA 70990167 70990187 
DNAH9 
F GCTAGGGAAACCGATGCAG 
525 62º/10%DMSO/ min ext 
11501781 11501800 
R CTCCGTCCCTTAAGGCTC 11502287 11502305 
ZAN_V1 
F GGTCCTGTTTCCTAGAGAAGAACT 
416 61º 
100352741 100352765 
R AGCTGACCCCTTGGGACTAT 100353136 100353156 
ZAN_V2 
F AGGAGGAAGGGCAGATGCT 
381 61º 
100371245 100371264 
R CACCAGAAGCTCTTGGTTGC 100371605 100371625 
KIF17 
F CACAGTCCAGTGCCATTGTT 
345 61º/5%DMSO 
21041915 21041935 
R GCCACCTGTCAGAAGTGCTC 21042239 21042259 
AKAP3 
F GAAGCTGTGTGTCATCATTGC 
496 61º/5%MgCL2 
4735539 4735560 
R CAAATCCCACTGTTCCCATT 4736014 4736034 
SP100 
F GGGGGAAGGAGAATCTTTGA 
310 61º 
231337975 231337995 
R CCACTTCCTGTTGGTGATCC 231338264 231338284 
LAMA1 
F ACTATGTTGCCCTGGCTTGT 
386 61º 
6961856 6961876 
R ATCCCCACTGGTTTGTTGTG 6962221 6962241 
JAG2 
F AGGATGAGGAGGACGAGGAT 
200 61º/5%DMSO 
105609023 105609043 
R CAGCCGCCCCTACTCCTT 105609204 105609222 
GPRC6A 
F GAATGTCTCCTTGCCCAGAG 
229 64º 
117113662 117113682 
R TTTGCCAAATGTGGTAGCAT 117113870 117113890 
SPAG4 
F TTCCCAAGGTGAAGATCCAG 
212 63º/5%DMSO 
34209028 34209048 
R CCAGAGCTCTCCCAACAGAG 34209008 34209028 
CEP152 
F CTGTGGTCAGTGCTTTTAGGG 
168 63º 
49064801 49064821 
R ACCCAGCAAACGCTGTACTT 49064948 49064968 
H1FNT F AGCTATGGAACAGGCCTTGA 193 63º 48722944 48722964 
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R CAACTGGGACACTCTGAGCA 48723261 48723281 
BCHE 
F TGGAAAAGTCAGAGGGATGAACT 
373 63º/5%MgCL2 
165830548 165830571 
R AGCCAGAAACTTGCCATCATAAA 165830897 165830920 
CCDC33 
F CAAGGCCACATGGTGTTCA 
303 63º/5%DMSO 
74563999 74564017 
R GGAAGCTTACTGGGACCTCA 74564282 74564301 
CDC25B 
F TGCTAATCTGGCCTCAGGAT 
474 61º 
3782352 3782372 
R GCCCTCTGCCACAAACTTAG 3782805 3782825 
FGD2 
F AGGTCCCCATCAGAGGAGAC 
221 57º/5%DMSO 
36978678 36978658 
R GGAAGGCTGAGAAGGGGTG 36978917 36978898 
FOXR1 
F CCCACAACCTTCTCCCAGAG 
427 57º 
118978682 118978662 
R GCTGGCATCTTCCTCCTTCT 118979128 118979108 
GGN 
F CTGCCCTAAACTGCCTTTGG 
418 57º 
38874889 38874909 
R TCTGGTCCAGCTTCACGATT 38875286 38875306 
GOLGA3 
F CCTCTTCTCTCCTACTCCAGC 
474 57º 
133393025 133393046 
R GCACACAACAGCTCAGACAG 133393468 133393488 
HERC2 
F TCTTTGAGGCCAGTTCTTTCT 
404 64º/44 cycles/5%MgCL2 
28391215 28391235 
R GAAAGAGGCAAGCAAACCCA 28391598 28391618 
HIST1H1D 
F AGCAAGGAACCAATCATCACT 
957 63º/2min ext 
26234263 26234284 
R CTGTGGCTGAGACTGAGACG 26235259 26235279 
HSPA4 
F CTCCTCTGCGGCCACTGA 
400 57º/5% 
132387734 132387716 
R GTTCCCCAAGCAGCGAGG 132388151 132388133 
KDM6B 
F GACAGTGGGACTGAGCGAC 
310 63,8º/10% 
7849124 7849143 
R CTGTGGGTGGCTTGGCCTT 7849414 7849433 
KDM1B 
F CATGTAATATGAGAATCGGAAAGG 
228 63º/5%MgCL2 
18208283 18208259 
R AAAGATTTGTCCTTCCCTCCA 18208531 18208510 
TET1 
F AAAATGTGGCATCAGTCAAGAC 
789 66,2º/5%MgCL2/2min ext 
70332202 70332180 
R TGGGGTAGCAATCATGTTCAC 10333011 10332990 
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LRP4 
F CCAGGTGGAATGCCAAGTT 
370 57,1º 
46895724 46895705 
R CCATCTGTGAAATGGGAAGG 46896313 46896293 
NWD1 
F AGTGGTTTAGGATGGCTTGG 
347 64º 
16872681 16872661 
R AAAGGGGAAGGAAGGAGGTG 16873048 16873027 
NGF 
F ACCTCTTCGTGATCCCCTTG 
911 64º/5% DMSO/2min ext 
115828624 115828644 
R ACAGGTTGAGGTAGGGAGGG 115829514 115829534 
PDCL2 
F GTACATGAGAATTTGTTGGCACA 
674 66,2º/5%MgCL2/2min ext 
56435723 56435746 
R TCCCTGAAGCCAATGACTATCA 56436314 56436336 
PINX1 
F AGCCTTGTCTCCTAAGTGCC 
807 64º/5%DMSO/2min ext 
10765261 10765281 
R AGGACTCGGCAGCCCATG 10766048 10766067 
TINF2 
F CCAAATGGCCAGGATTACAGG 
699 67º/5%MgCL2/2min ext 
24709895 24709916 
R CCTAGAGGGGCCAGATTGAA 24710575 24710595 
USP49 
F GGGTTTGGCTCAGGACACTA 
171 57º/10% MgCL 
41798602 41798622 
R TTTTTGATGTATGTAATTTCCCTCT 41798747 41798772 
PLEC_V4 
F AGCAGATCACCATGGAGGAG 
238 61º/5%DMSO 
143917915 143917935 
R GCCTCCAGGAGCTCAAAGG 143918133 143918152 
PLEC_V5 
F CTTTGGTGGGTGATGGGTG 
411 61º/5%DMSO 
143922047 143922066 
R GGTTCTCCTCAGCCAGCA 143922439 143922457 
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Supplementary Table S3. Primers of splicing variants for being validated at cDNA level. (F correspond to Forward and R to Reverse primer) 
      
Gene Primer Sequence cDNA Product (pb) Anneling temperature Position GRCh37  
UBN1 
F CAGGGTCCAGTTCACCTCTC  
373 65º/5%DMSO 
4902933 4902953 
R CCCCATATCGATCAAGTCCT 4908299 4908319 
CCDC33 
F CGGAAGAGCAGCTTCATACC 
217 63º/5%DMSO/40 cycles 
74560746 74560766 
R ACGGGATAGGGAAGGACAGT 74565162 74565182 
CEP152 
F GGTGGCTCAGCTACAGTTCC 
446 61º 
49064704 49064724 
R CATCCTTCTTCACTTGGTGGA 49074394 49074414 
SALL3 
F CAAGGAGAAGTACCCCCACA 
2136 63º/5%DMSO/3min ext 
76753401 76753421 
R ATGGGGTTCTCCACAGACAG 76756944 76756964 
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Supplementary Table S4. Functional role and pathway implication of the WES candidate variants 
    
Gene Function Pathway References 
SPAG1 
Involve in the regulation of the GTP signal transduction pathway of spermatogenesis and fertilization. This 
protein localizes to the plasma membrane of germ cells in the testis and to the post-acrosomal plasma membrane 
of mature spermatozoa. Recombinant polypeptide binds GTP and exhibits GTPase activity. Thus, this protein 
may regulate GTP signal transduction pathways involved in spermatogenesis and fertilization. Moreover, plays a 
role in the cytoplasmic assembly and/or trafficking of the axonemal dynein arms. 
Spermatogenesis 
(Biermann et al., 
2007)(Knowles et 
al., 2013) 
TEX19 
Plays an important role in a specialized mechanism that operates in the germline to repress transposable genetic 
elements and maintain genomic stability through successive generations. Additionally, is a new factor involved 
in the maintenance of self-renewal in pluripotency of stem cells. 
Male germ cell 
development 
(Kuntz et al., 
2008) 
EPHX2 
Regulates the levels of testosterone through cholesterol biosynthesis and metabolism. It has been demonstrate 
that its inhibition reduce the expression of the androgens receptors which means that secondary sex 
characteristics development and spermatogenesis process could be affected. 
Hormonal (Luria et al., 2009) 
NOP10 
It is part of the telomerase complex, associating with GAR1, NHP2 ribonucleoprotein, DKC1 (Dyskerin 
Pseudouridine Synthase 1), TERC and TERT proteins. Particularly DKC1-NOP10-NHP2 form the core trimer 
that specifically recognizes H/ACA box to join with the RNAs. 
Telomerase 
(Wang et al., 
2004)(Trahan et 
al., 2010) 
UBN1 
The assembly of chromatin into senescence-associated heterochromatin foci, transcriptionally-silent 
heterochromatin structures present in senescent cells, containing the condensed chromatin of one chromosome, 
and enriched for histone modifications. Formation of these chromatin structures is thought to repress expression 
of proliferation-promoting genes. Moreover, it is implicated in the assembly of the telomerase complex. 
Microtubule 
assembly & 
Telomerase 
(Ubn et al., 2011) 
(Pchelintsev et al., 
2013) 
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PKN1 
PKC-related serine/threonine-protein kinase involved in various processes such as regulation of the intermediate 
filaments of the actin cytoskeleton, cell migration, tumor cell invasion and transcription regulation. Acts as a key 
coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and 
specifically mediating phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for epigenetic 
transcriptional activation that promotes demethylation of histone H3 'Lys-9' (H3K9me). 
Microtubule 
assembly, 
hormonal & 
epigenetic 
(Metzger et al., 
2003)(Harrison et 
al., 2010) 
MEA1 
Plays an important role in different steps of the male germ cell development, spermatogenesis and testis 
development; cell organization/biogenesis; , reproduction/sex; late stages of spermatogenesis; male gonad 
development. The MEA1 gene is found to be localized in primary and secondary spermatocytes and spermatids, 
but the protein products are detected only in spermatids. Intensive transcription of MEA1 gene and specific 
localization of the gene product suggest that MEA1 may play an important role in the late stage of 
spermatogenesis. 
Male germ cell 
development & 
Spermatogenesis 
(Lau et al., 1989) 
MYCT1 
Is a general transcription factor underscored by recent studies that as much as 10% to 15% of the expressed 
genome may be at least partially c-Myc-responsive. C-Myc overexpressing cells often display morphologic 
abnormalities, cell size differences, aberrant cell cycle control, loss of growth factor responsiveness, inability to 
differentiate, enhanced sensitivity to proapoptotic stimuli, and genomic instability. 
Male germ cell 
development 
(Rothermund et 
al., 2005) 
TAF1L 
The gene is expressed in male germ cells, and make reference to the TAF1L (TAF1 RNA polymerase II, TATA 
box binding protein (TBP)-associated factor, 210kDa-like) protein-coding gene. GO annotations related to this 
gene include TBP-class protein binding and protein serine/threonine kinase activity. It acts as a functional 
substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced. The 
locus of this gene is intron less, and apparently arose in the primate lineage from retrotransposition of the 
transcript from the multi-exon TAF1 locus on the X chromosome. 
Male germ cell 
development 
(Wang et al., 
2002) 
PDE11A 
Phosphodiesterase (PDE) 11A (PDE11A) is a dual-specificity PDE, binding with cAMP. It is expressed in 
several tissues, but its highest expression has been reported in the testis, prostate and adrenal glands. It is an 
essential regulator of cyclic (c) AMP signaling in adrenal and other steroidogenic tissues. 
Hormonal 
(Francis, 
2005)(Horvath et 
al., 2010) 
SH2D4A 
The protein encode of this gene inhibits the estrogen-induced for cell proliferation with phospholipase C-gamma 
for binding to ESR1, blocking the effect of estrogen on PLCG and repressing estrogen-induced proliferation by 
signaling pathway of ERα/PLC-γ/PKC. 
Hormonal (Li et al., 2009) 
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KCNU1 
Testis-specific potassium channel activated by both intracellular pH and membrane voltage that mediates export 
of Potassium (K(+)). Represent the primary spermatozoa potassium channel currently. It is critical for fertility 
process and play an important role in sperm osmoregulation required for the acquisition of normal morphology 
and motility when faced with osmotic challenges, such as those experienced after mixing with seminal fluid and 
entry into the vagina. 
Spermatogenesis 
(Schreiber et al., 
1998) 
INCENP 
Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The 
CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and 
segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. 
Microtubule 
assembly 
(Tang et al., 2006) 
(Parra et al., 2009) 
GREB1 
This gene is an estrogen-responsive gene that act in the early response of the estrogen receptor-regulated pathway 
in the sertoli cells. So, plays an important role in estrogen-stimulated cell proliferation and acts as a regulator of 
hormone-dependent cancer growth not only in testis but also  in breast and prostate cancers. 
Hormonal 
(Rae et al., 
2005)(Gustavsson 
et al., 2008) 
SEMA4D 
It is a cell surface plasma membrane receptor in the human embryonic stem cells and human embryonal 
carcinoma cells for joining the transmembrane plexin partners PLXN1B and PLXNB2, which plays an important 
role in cell-cell signaling, and promotes the reorganization of the actin cytoskeleton. 
Male germ cell 
development 
(Dormeyer et al., 
2008) 
USP47 
Ubiquitin-specific protease that specifically deubiquitinates monoubiquitinated DNA polymerase beta (POLB), 
therefor it plays a role in base-excision repair (BER), and acts as a regulator of cell growth and genome integrity. 
DNA damage 
(Peschiaroli et al., 
2010)(Parsons et 
al., 2011) 
SSH1 
Is a protein phosphatase that regulates actin filament dynamics. Dephosphorylates and activates the actin 
binding/depolymerizing factor cofilin, which subsequently binds to actin filaments and stimulates their 
disassembly. 
Microtubule 
assembly 
(Takahashi et al., 
2014) 
GRP 
Gastrin releasing peptide (GRP) is present in endometrial gland cells, is secreted into the gland lumen and has 
proliferative effects on the endometrium, it may play a paracrine role in uterus. However, in different mammalian 
species, GRP receptor activation results in activation of phospholipase C, which induces an increase of 
phosphoinositides and mobilization of cellular calcium. Interestingly, Ca2+ has been described as an essential 
factor of acrosome reaction and is also implicated in zona binding, which means that GRP is an essential 
component on the parameters involved in the fertilization process like sperm motility, acrosome reaction and 
zona pellucida binding. 
Spermatogenesis 
(Carreau et al., 
2011) 
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ODF1 
Its protein is a component of the outer dense fibers (ODF) of spermatozoa. ODF are filamentous structures 
located  outside of the axoneme in the mid piece and principal piece of the mammalian sperm tail and may help 
to maintain the passive elastic structures and elastic recoil of the sperm tail 
Hormonal 
(Yang et al., 2012) 
(Nozawa et al., 
2014) 
SSTR5 
Sertoli cells have been ascertained as the target for the regulatory peptide somatostatin (SST). Somatostatin 
receptors plays an important role in the control of the proliferation of male germ cells. Its biological functions 
settle down in modulation of testosterone production at the testicular level. The presence of this receptor in 
human testes points to the existence of auto/paracrine loops controlling local testosterone secretion. 
Male germ cell 
development 
(Riaz et al., 2013) 
PSRC1 
It is required for normal progression through mitosis and required for normal congress of chromosomes at the 
metaphase plate, and for normal rate of chromosomal segregation during anaphase. Plays a role in the regulation 
of mitotic spindle dynamics. Increases the rate of turnover of microtubules on metaphase spindles, and 
contributes to the generation of normal tension across sister kinetochores. 
Microtubule 
assembly 
(Samani et al., 
2008) (Jang et al., 
2010) 
GAR1 
Required for ribosome biogenesis and telomere maintenance. It is required for correct processing or intranuclear 
trafficking of TERC, and the RNA component of the telomerase reverse transcriptase (TERT) holoenzyme. 
Telomerase 
(Wang & Meier, 
2004) 
CYP2C8 
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins 
are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, 
steroids and other lipids. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive 
androstane receptor, pregnane X receptor and glucocorticoid receptor. Its interaction with the androgen receptor 
mantain the tstosterone production. 
Hormonal  
(Zaphiropoulos, 
1997) 
SHQ1 
SHQ1 assists in the assembly of H/ACA-box ribonucleoproteins that function in the processing of ribosomal 
RNAs, modification of spliceosomal small nuclear RNAs, and stabilization of telomerase. Required for the 
quantitative accumulation of H/ACA ribonucleoproteins (RNPs), including telomerase, through the stabilization 
of DKC1, from the time of its synthesis until its association with NOP10, NHP2, and NAF1 at the nascent 
H/ACA RNA. 
Telomerase 
(Singh et al., 
2009)(Grozdanov 
et al., 2009) 
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DDX4 
DEAD box proteins, are characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA 
helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure 
such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based 
on their distribution patterns, some members of this family are involved in embryogenesis, spermatogenesis, and 
cellular growth and division. This gene encodes a DEAD box protein, specifically expressed in the germ cell 
lineage in both sexes and functions in germ cell development. 
Male germ cell 
development 
(Heeren et al., 
2016)(Gainetdinov 
et al., 2016) 
CCDC62 
CCDC62 is a novel cancer/testis antigen which works as a coactivator to enhance estrogen receptor beta-
mediated transactivation and target gene expression in prostate cancer cells. Nuclear receptor coactivator that can 
enhance preferentially estrogen receptors ESR1 and ESR2 transactivation. Modulates also progesterone (PGR), 
glucocorticoid (NR3C1) and androgen (AR) receptors transactivation, although at lower level; has little effect on 
vitamin D receptor (VDR). 
Hormonal 
(Chen et al., 
2009)(Domae et 
al., 2009) 
GFRA1 
This gene is implicated in the regulation of spermatogonial stem cell self-renewal and spermatocyte meiosis by 
Sertoli cell signaling. Furthermore, it has been identified as the most important upstream factor that regulate SSC 
self-renewal and spermatocyte meiosis. 
Male germ cell 
development 
(Hammoud et al., 
2015) 
(Tiptanavattana  et 
al., 2016) 
HERC2 
It is an E3 ubiquitin-protein ligase that regulates ubiquitin-dependent retention of repair proteins on damaged 
chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the 
assembly of UBE2N and RNF8 promoting DNA damage-induced formation of Lys-63-linked ubiquitin chains. 
Moreover, E3 ubiquitin-protein ligase promotes the ubiquitination and proteasomal degradation of XPA which 
influences the DNA excision repair activity. 
DNA damage 
(Ji et al., 
1999)(Sánchez-
Tena et al., 2016) 
NGF 
Nerve growth factor (NGF) has been reported to be involved in male reproductive physiology. NGF mediates its 
cellular effects through interactions with two distinct receptors in Leydig cells. Peritubular myoid cells, Sertoli 
cells and germ cells have been identified as potential testicular NGF sources. NGF play an important role during 
Leydig cells regeneration by regulating the proliferation and differentiation of the stem leydig cell at different 
developmental stages, from Stem leydig cells to Progenitor leydig cells,  and from Progenitor leydig cells to 
leydig cells. 
Male germ cell 
development 
(Zhang et al., 
2013) 
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RHBG 
Distinct cell-specific RHBG expression is being identified in the testis and cell-specific expression combined 
with axial heterogeneity in the epididymis and vas deferens, which indicates that RHBG is likely to be involved 
in multiple components of male fertility. RHBG mediated ammonia transport that regulate Leydig cell 
steroidogenesis. Humans with elevated plasma ammonia levels show altered sex steroid hormone levels. 
Hormonal 
(Biver et al., 
2008)(Weiner & 
Verlander, 2010) 
JAG2 
The Notch signaling pathway is an intercellular signaling mechanism that is essential for proper embryonic 
development. Members of the Notch gene family encode transmembrane receptors that are critical for various 
cell fate decisions. The protein encoded by this gene is one of several ligands that activate Notch and related 
receptors.  Notch 1/Jagged 2 signaling system plays an important role for male germ cells to differentiate or at 
least to survive in the rat testis and fails to express in the testis of spermatogenic maturation arrest patients. 
Male germ cell 
development 
(Hayashi et al., 
2001)(Hayashi et 
al., 2004) 
TET1 
Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Additionally It is involved in 
transcription/repression of a subset of genes through recruitment of transcriptional repressors to promoters. 
Involved in the balance between pluripotency and lineage commitment of cells it plays a role in embryonic stem 
cells maintenance and inner cell mass cell specification. 
Epigenetics 
(Meyenn et al., 
2016)(Yang et al., 
2016) 
YY1 
The progression of spermatogenesis involves global changes in chromatin structure and conformation. It has been 
described that YY1 acts in both chromatin modifications and meiotic DSB formation. Depletion of YY1 alter the 
structural integrity of heterochromatin, rendering it more accessible to the DSB machinery. In addition, YY1-
deficient spermatocytes show univalent formation, increased aneuploidy, and pachytene cell death, which are 
likely due to defects in DNA repair. 
DNA damage 
repair 
(Kim et al., 2016) 
LIG3 
The protein encoded by this gene is involved in excision repair, it join the DNA-repair protein XRCC1 in the 
nucleus and can correct defective DNA strand-break repair and sister chromatid exchange following treatment 
with ionizing radiation and alkylating agents. Moreover is has being described that this is implicated in the 
process of meiosis during spermatogenesis and germ cell differentiation. 
male germ cell 
development & 
DNA damage 
(Olesen et al., 
2007) 
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GOLGA3 
GOLGA3 encodes a Golgi autoantigen that is a member of the golgin subfamily A, specifically targets the b1 
adrenergic receptor to the plasma membrane. It has been demonstrate that truncation of the protein produce 
defects in germ cell development that culminate in testicular atrophy, low epididymal sperm concentration, low 
motility and unsuccessful in vitro fertilization. Analysis of the first wave of spermatogenesis revealed that 
spermatogenesis is disrupted primarily in late meiosis, leading to increased cell death and a delay in germ cell 
maturation. Abnormal spermiogenesis, including head and tail defects, is evident among the surviving germ cells 
Spermatogenesis 
(Bentson et al., 
2013) 
SMYD2 
Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 
and RB1. Specifically methylates histone H3 Lys-4 (H3K4me) and dimethylates histone H3 Lys-36 
(H3K36me2). Shows even higher methyltransferase activity on p53/TP53. Monomethylates Lys-370 of 
p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of 
p53/TP53. Monomethylates RB1 at Lys-860. 
Epigenetic 
(Zhang et al., 
2013)(Jiang et al., 
2014) 
FANCD2 
Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, which bound to GDP for free GTP 
exchange. Activates JNK1 via CDC42 but not RAC1, these genes form part of DNA damage repair system. 
Expression in the diploid phase of spermatogenesis facilitate the distribution of gene products from both alleles 
to all haploid sperm cells, a prerequisite for a Distorter. 
DNA damage 
(Brown et al., 
2016)(Tan & 
Deans, 2017) 
NLRP14 
General role for NALPs protein are apoptosis by activation of caspases and in pro-inflammation signaling 
processes. NALP14 is exclusively expressed in human testis and mainly in A dark spermatogonia, mid and late 
spermatocytes and spermatids, but not in mitotically active A pale and B spermatogonia. The expression of 
NALP14 in mid and late pachytene spermatocytes indicates that NALP14 could be involved in the apoptotic 
processes that occur often during the meiotic divisions. 
Spermatogenesis 
(Westerveld et al., 
2006) 
LRP4 
LRP4 is expressed in PGCs in the hindgut and the dorsal mesentery of E9.5 embryos, and in germ cells in the 
genital ridges of male and female E10.5-13.5 embryos. LRP4 is also expressed in spermatogonia of the neonatal 
and adult testes and in the immature oocytes and follicular cells of the adult ovary. The absence of LRP4 
expression in the blastocyst, embryonic stem cells and embryonic germ cells suggests the LRP4 is a molecular 
marker that distinguishes the germ cells from embryo-derived pluripotent stem cells and play a role in the 
differentiation process. 
PGCs & male 
germ cell 
development 
(Yamaguchi et al., 
2006) 
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PIF1 
Is a DNA-dependent ATPase and 5-3 DNA helicase required for the maintenance of both mitochondrial and 
nuclear genome stability. Efficiently unwinds G-quadruplex (G4) DNA structures and forked RNA-DNA 
hybrids, resolves G4 structures, preventing replication pausing and double-strand breaks (DSBs) at G4 motifs. 
Involved in the maintenance of telomeric DNA. Inhibits telomere elongation, de novo telomere formation and 
telomere addition to DSBs via catalytic inhibition of telomerase. Reduces the processivity of telomerase by 
displacing active telomerase from DNA ends. Releases telomerase by unwinding the short telomerase 
RNA/telomeric DNA hybrid that is the intermediate in the telomerase reaction. Possesses an intrinsic strand 
annealing activity. 
Telomeres (Li et al., 2014) 
SERPINB11 
The SERPINB11 protein is localized in the intermediate spermatogonia, B-type spermatogonium, preleptotene 
spermatocyte, leptonema spermatocyte, zygotene spermatocyte, but weakly localized in the pachytene 
spermatocyte, diplotene spermatocyte, sphere sperm, and the apoptotic sperm was positive stained of 
SERPINB11 protein, the localization of cell cycle marker CDK4 and meiosis marker SCP3 were investigated, 
and the SCP3 and SERPINB11 colocalized in the intermediate spermatogonia, B-type spermatogonium, 
preleptotene spermatocyte. Taken together, SerpinB11 is involved in spermatogenesis and apoptosis. 
Spermatogenesis (Yang et al., 2015) 
TDRD6 
Tudor containing protein 6 (TDRD6) is a male germ line-specific protein essential for chromatoid body (ChB) 
structure, elongated spermatid development and male fertility. TDRD6 play a role in the maturation of 
spliceosomal snRNPs during the transcriptionally highly active prophase I of spermatogenesis. This function 
adds to the roles of TDRD6 at later stages of spermatogenesis/spermiogenesis in formation of the ChB type 2 and 
in nonsense-mediated decay. 
Spermiogenesis 
(Akpınar et al., 
2017) 
BRD4 
BRD4 is a novel ring-like structure that is closely associated, both spatially and functionally, with the 
acrosome/acroplaxome. It has been described that in spermatids regulated an interesting mechanism by which 
transcription is attenuated by the progressive removal of BRD4 itself and acetylated histones via the acrosome. 
Spermatogenesis 
(Bryant et al., 
2015) 
PRKDC 
Is a DNA-dependent protein kinase (DNA-PK), which is a nuclear protein serine/threonine kinase, a molecular 
sensor of DNA damage. DNA-PK is involved in the ligation step of the non-homologous end joining (NHEJ) 
pathway of DNA double strand break (DSB) repair. 
DNA damage 
(Ahmed et al., 
2016) 
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AKAP3 
This gene encodes a member of A-kinase anchoring proteins (AKAPs), a family of functionally related proteins 
that target protein kinase A to discrete locations within the cell. The encoded protein is reported to participate in 
protein-protein interactions with the R-subunit of the protein kinase A as well as sperm-associated proteins. This 
protein is expressed in spermatozoa and localized to the acrosomal region of the sperm head as well as the length 
of the principal piece. It may function as a regulator of motility, capacitation, and the acrosome reaction. 
Spermatogenesis 
(Xu et al., 
2014a)(Xu et al., 
2014b) 
RECQL4 
The protein encoded by this gene is a DNA helicase that belongs to the RecQ helicase family. DNA helicases 
unwind double-stranded DNA into single-stranded DNAs and may modulate chromosome segregation. This gene 
is predominantly expressed in thymus and testis. 
DNA damage 
(Shamanna et al., 
2014)(Im et al., 
2015) 
POLE2 
This gene encode the DNA polymerase epsilon, which is involved in DNA repair and replication, is composed of 
a large catalytic subunit and a small accessory subunit. The protein encoded by this gene represents the small 
subunit (B). 
DNA damage 
(Huang et al., 
2001) 
KIF18A 
Is a microtubule-depolymerizing kinesin which plays a role in chromosome congression by reducing the 
amplitude of preanaphase oscillations and slowing poleward movement during anaphase, thus suppressing 
chromosome movements. It is stabilize the CENPE-BUB1B complex at the kinetochores during early mitosis 
and maintains CENPE levels at kinetochores during chromosome congression. 
Microtubule 
assembly 
(Mayr et al., 
2007)(Wordeman 
et al., 2016) 
ADAM20 
Domains of the protein of this gene, are involved in adhesion to egg cells, play a role in sperm–egg fusion or 
(ADAM20) proteolytic processing of other fertilins. Since the only human fertilin α gene is non-functional, is 
speculate that ADAM20 or ADAM21 functionally replace this subunit. 
Spermatogenesis 
& germ cell 
development 
(Inoue et al., 
2011)(Anifandis et 
al., 2014) 
DNAH9 
This gene encodes the heavy chain subunit of axonemal dynein, a large multi-subunit molecular motor. 
Axonemal dynein attaches to microtubules and hydrolyzes ATP to mediate the movement of cilia and flagella. 
The testis-specific pattern expression for this gene involve it in sperm development or motility, and male 
infertility. 
Spermatogenesis 
(Bartoloni et al., 
2001) 
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SYCP2 
The synaptonemal complex is a proteinaceous structure that links homologous chromosomes during the prophase 
of meiosis. The protein encoded by this gene is a major component of the synaptonemal complex and may bind 
DNA at scaffold attachment regions. The encoded protein requires synaptonemal complex protein 3, but not 1, 
for inclusion in the synaptonemal complex, SYCP2 interacts with SYCP3 (associate with the centromere regions 
of male, but not female, metaphase-I chromosomes, suggesting a sex-specific function for the two proteins). 
Microtubule 
assembly 
(Casey et al., 
2015) 
DDX54 
This gene encodes a member of the DEAD box protein family. DEAD box proteins, characterized by the 
conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicase. Based on their distribution patterns, 
some members of this family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth 
and division. The protein encode for this gene interacts in a hormone-dependent manner with the estrogen 
receptor, other nuclear receptors and represses their transcriptional activity. 
Male germ cell 
development & 
Spermatogenesis 
(Rajendran et al., 
2003) 
VNN1 
Vanin-1 play an important role in testis and adrenal function. Is one of the enzymes that regulate indirectly the 
i9nitial steps of cholesterol synthesis which is require for the synthesis of steroids hormones produce by the 
adrenal gland and leydig cells. Moreover VNN1 control the stress response in the surface of sertoli cells which is 
very important because its expression surrounding germ cells within the testis cords act as a protectant against 
reactive oxygen species. 
Male germ cell 
development 
(Grimmond et al., 
2000)(Wilson et 
al., 2005) 
CYP3A43 
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins 
are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, 
steroids and other lipids. The encoded protein has a low level of testosterone hydroxylase activity, which means 
that indirectly maintain testosterone levels. Moreover, this gene has been implicated in aging mechanisms and 
cancer progression, it has been described that variants in this gene increase the risk of developing TGCT. 
Hormonal 
(Lévesque et al., 
2014) 
ABCA1 
The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette 
(ABC) transporters. ABC proteins transport various molecules across extra- and intracellular membranes. 
ABCA1, is a located in the sertoli cells surface, contributing to transport maternal cholesterol to the developing 
fetus. 
Hormonal 
(Cavelier et al., 
2001)(Goedeke et 
al., 2015) 
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SOX30 
This gene is potentially involved in differentiation of male germ cells. This gene encodes a member of the SOX 
(SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development 
and in the determination of the cell fate. The encoded protein may act as a transcriptional regulator after forming 
a protein complex with other proteins. The protein may be involved in the differentiation of developing male 
germ cells. Alternative splicing results in multiple transcript variants 
Male germ cell 
development 
(Petit et al., 2015) 
MLH3 
This gene is a member of the MutL-homolog (MLH) family of DNA mismatch repair (MMR) genes. MLH genes 
are implicated in maintaining genomic integrity during DNA replication and after meiotic recombination. The 
protein encoded by this gene functions as a heterodimer with other family members. Somatic mutations in this 
gene frequently occur in tumors exhibiting microsatellite instability, and germline mutations have been linked to 
hereditary nonpolyposis colorectal cancer type 7 (HNPCC7). 
DNA damage 
(Oliver-Bonet et 
al., 2005)(Terribas 
et al., 2010) 
CCDC33 
The cancer testis antigen 61 has been implicated in the devopment of male germ cells at different stages. The 
expression starts at the primary spermatocyte stage, indicating an important role of this protein during 
spermatogenesis. The protein encoded by CCDC33 contains 3 coiled-coil domains, a C2-domain, 2 ER 
membrane retention signal-like motifs and 2 putative peroxisomal targeting signals type 2 (PTS2). PTS2 
sequence is functional and responsible for the targeting of CCDC33 to peroxisomes, specifically to PXT1. 
Peroxisomes are important cellular organelles indispensable for cell survival, and are responsable for different 
metabolic pathways, specifically in the testis protect germ cells from negative long chain fatty acids and the 
disruption of plasmalogen synthesis leads to germ cell degeneration and apoptosis. 
Male germ cell 
development 
(Kaczmarek et al., 
2010) 
SBF1 
SBF1 (SET-binding factor 1 or MTMr5) is the most extensively characterized of the myotubularin-related 
pseudophosphatases. SBF1 contains several domains (e.g., pleckstrin and Rab3 GEF homology motifs) that are 
conserved in signaling proteins, and in vitro studies shows a role for SBF1 in cellular growth control. SBF1 is 
expressed in Sertoli’s cells where it controls the vacuolization levels of the cells function in response to 
phosphatidylinositol-mediated signaling and is also express in a subset of germ cells, where it has been described 
to be implicated in the premeiotic and meiotic progression of pachytene spermatocytes. 
Male germ cell 
development & 
Spermatogenesis 
(Firestein et al., 
2002) 
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CYR61 
Is a member of the CCN protein family that has been implicated in diverse biological processes such as cell 
adhesion, proliferation, angiogenesis, and tumorigenesis. Altered expression of CYR61 is found to be associated 
with human cancers, such because the functional link between CYR61 and P53 in cancers.  Embryonic 
expression of the cysteine rich protein 61 (CYR61) gene involve it as a candidate for the development of human 
epispadias (genital malformation of the penis) which could end in the development of testicular tumors in 
patients with exstrophy-epispadias complex. 
Hormonal 
(Kireeva et al., 
1996)(Babic et al., 
1998) 
PLEC 
The protein encode by this gene, Plectin, in Sertoli cells is concentrated at the nuclear surface and in junction 
plaques associated with the plasma membrane. The pattern of distribution is consistent with the connection 
between the intermediate filaments centrally (basally) with the nucleus and peripherally to intercellular 
attachment sites. Furthermore, Nesprin-3 connects plectin and vimentin to the nuclear envelope of Sertoli cells 
promoting its function in spermatogenesis. Additionally. Plectin is concentrated at intercellular junctions and at 
the nuclear surface in morphologically differentiated rat Sertoli cells. 
Male germ cell 
development 
(Ketema et al., 
2013)(Williamson 
et al., 2016) 
GYS2 
It is a muscle glycogen synthase responsible for the testicular glycogen synthesis that should be extremely 
regulated because glycogen overproduction induces apoptosis in male germ cells. 
Male germ cell 
development & 
Hormonal 
(Villarroel-
Espíndola et al., 
2013) 
DNAAF1 
DNAAF1 forms a component of the microtubule outer dynein arm, stabilizing microtubule-base cilia. Deleterious 
mutations in this gene has being previously associated with primary ciliary dyskinesia, which is characterize by 
impaired primary cilia function and male infertility. 
Microtubule 
assembly 
(Litchfield et al., 
2016) 
MAP4 
The protein encoded by this gene is a microtubule-associated protein, which contains a domain similar to the 
microtubule-binding domains of neuronal microtubule-associated protein (MAP2) and microtubule-associated 
protein tau (MAPT/TAU). This protein promotes microtubule assembly, and has been shown to counteract 
destabilization of interphase microtubule catastrophe promotion. Cyclin B was found to interact with this protein, 
which targets cell division cycle 2 (CDC2) kinase to microtubules. The phosphorylation of this protein affects 
microtubule properties and cell cycle progression. 
Microtubule 
assembly 
(Chang et al., 
2001) (Semenova 
et al., 2014) 
SPZ1 
This gene encodes a bHLH-zip transcription factor which functions in the mitogen-activate protein kinase 
(MAPK) signaling pathway. Because of its role in the upregulation of cell proliferation and tumorigenesis, this 
gene may serve as a target for Ras-induced tumor treatments. Furthermore, it plays an important role in the 
regulation of cell proliferation and differentiation during spermatogenesis. 
Spermatogenesis 
(Hsu et al., 
2001)(Hrabchak & 
Varmuza, 2004) 
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SPATA12 
In the testis, SPATA12 is specifically expressed in spermatocytes, spermatids and spermatozoa, and is involved in 
the development of testicular maturation. SPATA12 is a stage-specific and germ cell-specific gene, that maintain 
the cell in a differentiated state and/or to suppress cell proliferation during the spermatogenesis process. 
Male germ cell 
development & 
Spermatogenesis 
(Dan, Lifang, & 
Guangxiu, 2007) 
CYP1A1 
This gene, CYP1A1, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 
proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of 
cholesterol, steroids and other lipids. CYP1A1 is one of the enzymes that metabolized Estradiol to 
hydroxyestradiols and methoxyestradiols and changes related with increased intratesticular hydroxyestradiols and 
methoxyestradiols concentrations, cause an impaired Sertoli cell function. Moreover, it has been described that 
polymorphisms in the CYP1A1 gene may contribute to variability of individual susceptibility to testicular cancer. 
Hormonal 
(Kristiansen et al., 
2011) 
APLF 
Is a nuclease involved in single-strand and double-strand DNA break repair, that is recruited to sites of DNA 
damage through interaction with poly (ADP-ribose), a polymeric post-translational modification synthesized 
transiently at sites of chromosomal damage to accelerate DNA strand break repair reactions. 
DNA damage 
(Grundy et al., 
2012)(Mehrotra et 
al., 2011) 
FSIP2 
FSIP2, The fibrous sheath, is a cytoskeletal structure located in the principle piece region of the sperm flagellum. 
Genes encoding most of the fibrous-sheath associated proteins genes are transcribed only during the post meiotic 
period of spermatogenesis. The protein encoded by this gene is specific to spermatogenic cells and copy number 
variation in this gene may be associated with testicular germ cell tumors. 
Microtubule 
assembly 
(Litchfield et al., 
2015) 
TNK2 
Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and 
migration, cell survival, cell growth and proliferation. Confers metastatic properties on cancer cells and promotes 
tumor growth by negatively regulating tumor suppressor such as WWOX (WW Domain Containing 
Oxidoreductase) and positively regulating pro-survival factors such as AKT1 and AR. 
Hormonal 
(Mahajan & 
Mahajan, 2016) 
TRIM16 
This gene is identified as an estrogen and anti-estrogen regulated gene in epithelial cells stably expressing 
estrogen receptor. The proteins of this family have been reported to be involved in a variety of biological 
processes including cell growth, differentiation and pathogenesis. 
Hormonal 
(Beer et al.,  
2002)(Bell et al., 
2013) 
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BCHE 
The widespread expression in early differentiation this gene related it with testicular developmental functions. 
Intact cholinergic functioning appears to be important in germ-line cell development and early embryogenesis, 
various cholinergic elements, and particularly BCHE is expressed early in embryogenesis, cholinergic inhibitors 
block sperm motility, and high levels of BCHE mRNA are already present in developing human oocytes. 
Hormonal 
(Nieto-Cerón et 
al., 2010)(Jallouli 
et al., 2015) 
PINX1 
Microtubule-binding protein essential for faithful chromosome segregation. Mediates TRF1 and TERT 
accumulation in nucleolus and enhances TRF1 binding to telomeres. Inhibits telomerase activity an inhibit cell 
proliferation acting as tumor suppressor. 
Telomerase 
(Zigo et al., 
2013)(Li et al., 
2016) 
NWD1 
NWD1 (NACHT and WD repeat domain-containing protein 1) acts downstream of SRY family transcription 
factors to modulate AR activity by stabilizing AR protein levels and by promoting expression of the AR co-
activator PDEF. 
Hormonal 
(Correa et al., 
2014) 
GPRC6A 
GPRC6A inactivation or sub-function contributes to reduced exposure to androgens, leading to cryptorchidism 
during fetal life and/or low sperm production in adulthood. Mediates the non-genomic effects of androgens in 
multiple tissue and coordinates nutritional and hormonal anabolic signals through the sensing of extracellular 
amino acids, osteocalcin, divalents ions and its responsiveness to anabolic steroids. 
Hormonal 
(Toni et al., 
2014)(Toni et al., 
2016) 
KDM1B 
Histone demethylase that demethylates Lys-4 of histone H3, a specific tag for epigenetic transcriptional 
activation, thereby acting as a corepressor. Required for de novo DNA methylation of a subset of imprinted genes 
during oogenesis. 
Epigenetic 
(Ciccone et al., 
2009)(Feazel et 
al., 2009) 
HIST1H1D 
HIST1H1D protein binds to linker DNA between nucleosomes forming the macromolecular structure known as 
the chromatin fiber. HIST1H1D is necessary for the condensation of nucleosome chains into higher-order 
structured fibers. Acts also as a regulator of individual gene transcription through chromatin remodeling, 
nucleosome spacing and DNA methylation. 
Epigenetic 
(Maselli et al., 
2012) 
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FOXR1 
Foxr1 belongs to the forkhead-box family of DNA-binding proteins involved in development, somatic cancer, 
and reproduction. Mammalian Foxr1 is predominantly transcribed in mitotic spermatogonia and meiotic 
spermatocytes but that the mouse protein peaks in post meiotic elongated spermatids. Foxr1 encodes a putative 
transcription factor that belongs to a conserved family of regulators involved in chromatin remodeling, including 
some that are important for reproduction, such as Foxo1 that is required for spermatogonial stem cells. 
Spermatogenesis (Petit et al., 2015) 
GGN 
This gene is a germ cell-specific gene that encodes proteins that interact with POG (proliferation of germ cells). 
Alternatively spliced transcript variants of a similar mouse gene encode at least three different proteins, namely 
gametogenetin protein 1a, gametogenetin protein 2, and gametogenetin protein 3, which show a perinuclear, 
cytoplasmic, and nucleolar localization, respectively. These proteins regulate the localization of POG and may 
play a role in spermatogenesis. 
Male germ cell 
development 
(Lu & Bishop, 
2003)(Jamsai et 
al., 2008) 
PDCL2 
Is a new member of the phosducin-like (PhLP) protein family that is predominantly, if not exclusively, expressed 
in male and female germ cells. In situ analysis on testis sections and analysis of purified spermatogenic cell 
fractions evidenced a stage-specific expression with high levels of RNA and protein in pachytene spermatocytes 
and round spermatids. 
Male germ cell 
development 
(Horvath et al., 
2009) 
FGD2 
FGD2 encodes a guanine nucleotide exchange factor (GEF) for Rho small G proteins. GEFs promote the active 
state of small G proteins by catalyzing the exchange of GDP for GTP. This GEFs) controls cytoskeleton-
dependent membrane rearrangements by activating the cell division cycle 42 (CDC42) protein. Moreover, it has 
been described FGD2 is transcribed at 7 d post-partum, which corresponds to early meiotic stages of the first 
cycle of spermatogenesis and that FGD2ranscription is down-regulated during spermiogenesis, the haploid phase 
of spermatogenesis. 
Spermatogenesis 
(Bauer et al., 
2007) 
TINF2 
Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and 
protection. Shelterin associates with arrays of double-stranded TTAGGG repeats added by telomerase and 
protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage 
surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Plays a role in 
shelterin complex assembly. Isoform 1 may have additional role in tethering telomeres to the nuclear matrix. 
DNA replication 
(Kim et al., 1999) 
(O’Connor et al., 
2006) 
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HSPA4 
Down-regulation of transcription levels of this gene is known to be expressed in spermatocytes at late stages of 
prophase I and post-meiotic spermatids which leads to most spermatogenic cells are arrested at late stages of 
meiotic prophase I. Is component of mTORC2 which is required for proper assembly and activity of the kinase 
both constitutively. 
Spermatogenesis 
& epigenetica 
(Held et al., 2011) 
USP49 
Specifically deubiquitinates histone H2B at Lys-120 (H2BK120Ub). H2BK120Ub is a specific tag for epigenetic 
transcriptional activation and acts as a regulator of mRNA splicing. Deubiquitination is required for efficient 
cotranscriptional splicing of a large set of exons. USP49 tDMRs showed that these two markers could be used 
successfully to identify semen samples including sperm cells 
Epigenetic 
(Zhang et al., 
2013) 
KDM6B 
JMJD3 (KDM6B), regulates the fragmentation of spermatogonial cysts Down-regulation of Jmjd3 in 
Spermatogonial Stem cells promotes an increase in undifferentiated spermatogonia but does not affect their 
differentiation. Germ cell-specific Jmjd3 null male mice have larger testes and sire offspring for a longer period 
compared to controls, likely secondary to increased and prolonged maintenance of the spermatogonial 
compartment. Moreover, JMJD3 deficiency induces frequent fragmentation of spermatogonial cysts by 
abscission of intercellular bridges. So, JMJD3 controls the spermatogonial compartment through the regulation of 
fragmentation of spermatogonial cysts and this mechanism may be involved in maintenance of diverse stem cell 
niches 
Male germ cell 
development & 
methylation 
pathway 
(Iwamori et al., 
2013) 
HORMAD1 
HORMAD1 is a critical component of the synaptonemal complex that affects recombination and meiotic sex 
chromosome inactivation by transcriptional silencing. 
Male germ cell 
development & 
and microtubule 
assembly 
(Shin et al., 2010) 
DCLRE1C 
This gene encodes a nuclear protein that is involved in V(D)J recombination and DNA repair. The encoded 
protein has single-strand-specific 5'-3' exonuclease activity; it also exhibits endonuclease activity on 5' and 3' 
overhangs and hairpins. So, the protein functions in the regulation of the cell cycle in response to DNA damage. 
DNA damage 
repair 
(Moshous et al., 
2001) 
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ERCC5 
Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3incision in 
DNA nucleotide excision repair (NER). Acts as a cofactor for a DNA glycosylase that removes oxidized 
pyrimidines from DNA. May also be involved in transcription-coupled repair of this kind of damage, in 
transcription by RNA polymerase II, and perhaps in other processes too. 
DNA damage 
repair 
(Cheng et al., 
1999)(Soltys et al., 
2013) 
STARD6 
START-domain-containing 6 (STARD6) is exclusively expressed in germ cells during spermatogenesis. STARD6 
is a functional gene, which play a pivotal role in the process of spermatogenesis in adult testis and in the 
steroidogenesis of Leydig cells, such because regulate cholesterol homeostasis, at least in part, by the sterol 
regulatory element (SRE)-binding protein it present. 
Hormonal (Gomes, 2005) 
NOTCH3 
The expression pattern of Notch family receptors during mouse spermatogenesis is located entire in the 
cytoplasm of spermatogonia, spermatocytes and spermatids. In contrast, the nuclei of spermatogonia showed 
staining of the intracellular domain of Notch3 specifically. During regeneration of spermatogonia, the nuclei of 
all proliferating cells showed high levels of intracellular domain of Notch3. Take all the information together, the 
intracellular domain of Notch was cleaved in the cytoplasm and translocated to the nucleus, which means that, 
Notch signals are sequentially activated during spermatogenesis and control the proliferation and differentiation 
of spermatogenic stem cells. 
Spermatogenesis 
& germ cell 
development 
(Mori et al., 
2003)(Brown et 
al., 2016) 
SPAG4 
SPAG4, which, like ODF1, is exclusively transcribed in round spermatids and translated in elongating 
spermatids. However, in contrast to ODF1, SPAG4 protein appears to be associated with the axonemal and 
manchette microtubules during sperm tail formation. Spag4 protein assists during the organization and assembly 
of ODFs in the elongating spermatids. 
Spermatogenesis 
& germ cell 
devopment 
(Shao et al., 1999) 
DNAH8 
Is a dynein with ATPase activity that produce a release of ADP. This protein is involved in sperm motility and 
implicated in sperm flagellar assembly because of its implication in the cilia respiratory cilia. 
Microtule 
assembly 
(Wang et al., 
2016) 
ZP2 
The zona pellucida is an extracellular matrix that surrounds the oocyte and early embryo. It is composed of three 
glycoproteins with various functions during fertilization and preimplantation development. The glycosylated 
mature peptide is one of the structural components of the zona pellucida and functions in secondary binding and 
penetration of acrosome-reacted spermatozoa. Mediates species-specific sperm binding, induction of the 
acrosome reaction and prevents post-fertilization polyspermy. 
Spermatogenesis 
(Suzuki et al., 
2015)(Gupta, 
2015) 
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TBP 
General transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID. Binding of 
TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex (PIC), playing a role in the 
activation of eukaryotic genes transcribed by RNA polymerase II. Component of the transcription factor 
SL1/TIF-IB complex, which is involved in the assembly of the PIC during RNA polymerase I-dependent 
transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with 
the rDNA promoter. SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. 
DNA replication 
(Kimmins et al., 
2004)(Martianov 
et al., 2016) 
ZPBP2 
The ZP is responsible for the initial sperm binding and the subsequent induction of the acrosome reaction that 
allows sperm penetration. The ZP also functions as a physical barrier to select for functional spermatozoa capable 
of successful penetration, to prevent polyspermy, and to protect early embryos. However, the molecular details of 
sperm binding and zona penetration are mostly unresolved. 
Male germ cell 
development 
(Lin, et al., 2007) 
KDM4B 
Histone demethylase that specifically demethylates Lys-9 of histone H3, thereby playing a role in histone code. 
Does not demethylate histone H3 Lys-4, H3 Lys-27, H3 Lys-36 nor H4 Lys-20. Only able to demethylate 
trimethylated H3 Lys-9, with a weaker activity than KDM4A, KDM4C and KDM4D. Demethylation of Lys 
residue generates formaldehyde and succinate. 
Epigenetic 
(Iwamori et al., 
2011) 
EXO5 
Single-stranded DNA (ssDNA) bidirectional exonuclease involved in DNA repair. Probably involved in DNA 
repair following ultraviolet (UV) irradiation and interstrand cross-links (ICLs) damage. Has both 5-3 and 3-5 
exonuclease activities with a strong preference for 5-ends. Acts as a sliding exonuclease that loads at ssDNA 
ends and then slides along the ssDNA prior to cutting; however the sliding and the 3-5 exonuclease activities are 
abolished upon binding to the replication protein A (RPA) complex that enforces 5-directionality activity. 
DNA damage 
(Sparks et al., 
2012) 
CAPZA3 
This gene encodes an actin capping protein, one of the F-actin capping protein alpha subunit family. The encoded 
protein is predominantly localized to the neck region of ejaculated sperm, other immunohistochemical signals 
were found in the tail and postacrosomal regions. The encoded protein may also form heterodimers of alpha and 
beta subunits. This protein may be important in determining sperm architecture and male fertility. 
Male germ cell 
development 
(Tokuhiro et al., 
2008) 
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ATP8B3 
P4-ATPase is a flippase that catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids 
from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution 
of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of 
lipid signaling molecules. Moreover it is responsible for the maintenance of asymmetric distribution of 
phosphatidylserine (PS) in spermatozoa membranes and involved in acrosome reactions and binding of 
spermatozoa to zona pellucida 
Spermatogenesis (Gong et al., 2009) 
HRASLS 
RASLS (HRAS Like Suppressor) protein contains an NC domain, with unknown function at the N-terminus, and 
a hydrophobic membrane-anchoring domain at the C-terminus. The family proteins exhibit activities that regulate 
cellular growth, differentiation, and apoptosis, and the membrane-anchoring domain is indispensable for this 
activity. Specifically HRASLS has been shown to express at high levels in differentiated tissues of post-meiotic 
testicular germ cells.H-rev107 regulates prostaglandin D2 synthase (PTGDS)-mediated suppression of cellular 
invasion in testicular cancer cells. 
Male germ cell 
development 
(Shyu et al., 2013) 
NEK11 
Is a protein kinase that plays an important role in the G2/M checkpoint response to DNA damage. Controls 
degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-
mediated polyubiquitination and degradation 
DNA damage (Fry et al., 2012) 
H1FNT 
Essential for normal spermatogenesis and male fertility. Required for proper cell restructuring and DNA 
condensation during the elongation phase of spermiogenesis. Involved in the histone-protamine transition of 
sperm chromatin and the subsequent production of functional sperm and binds both double-stranded and single-
stranded DNA, ATP and protamine. 
Spermatogenesis 
& germ cell 
devopment 
(Catena et al., 
2009) 
CEP152 
Necessary for centrosome duplication. Acts as a molecular scaffold facilitating the interaction of PLK4 and 
CENPJ, 2 molecules involved in centriole formation. Also plays a key role in deuterosome-mediated centriole 
amplification in multiciliated that can generate more than 100 centrioles. Overexpression of CEP152 can drive 
amplification of centrioles 
Telomerase 
(Sonnen et al., 
2013) 
SP100 
SP100 is a constitutive component of promyelocytic leukemia nuclear bodies, suppresses ALT-associated PML 
bodies formation, causes progressive telomere shortening, and inhibits the rapid changes in telomere length that 
are characteristic of alternative lengthening of telomere cells. These effects were associated with Sp100-mediated 
sequestration of the DNA repair and recombination. 
Telomerase (Jiang et al., 2005) 
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LAMA1 
Laminin alpha 1 (LAMA1) is a trophectoderm specific gene development, that plays an important role during 
early human embryo development, especially in compartmentalization via the basement membrane and in 
orienting the direction and quality of trophoblast invasion. It binds to cells via a high affinity receptor, and 
mediate the attachment, migration and organization of cells into tissues during embryonic development by 
interacting with other extracellular matrix components. 
Male germ cell 
development 
(Bai et al., 2012) 
CDC25B 
CDC25 is a dual specificity phosphatase with three isoforms in mammalian cells - CDC25A, B and C. CDC25 
activates cdk complexes that drive the cell cycle and is involved in the DNA damage checkpoints and is known 
as a key mediator of cell cycle progression. 
DNA damage 
(Donzelli et al., 
2003) 
MAST4 Is a new member of the microtubule associated serine-threonine kinase family. 
Microtubule 
assembly 
(Garland et al., 
2008) 
KAT6B 
The protein encode by this gene is a histone acetyltransferase and component of the MOZ/MORF protein 
complex that contribute to important and specific acetylation events occurring during gametes and embryo 
development. Also known as MYST4, is the only HAT to be described in cells (elongating spermatids, oocyte, 
granulosa and theca cells) related to gamete formation in both male and female. Moreover it has been 
demonstrate that KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic 
Loss in Small Cell Lung Cancer. 
Epigenetic 
(McGraw et al., 
2007) 
ERCC4 
Catalytic component of the structure-specific DNA repair endonuclease responsible for the 5-prime incision 
during DNA repair. Involved in homologous recombination that assists in removing interstrand cross-link. 
DNA damage 
(Welsh et al., 
2004)(Park et al., 
2011) 
ZAN 
This gene encodes a protein that functions in the species specificity of sperm adhesion to the egg zona pellucida. 
The encoded protein is located in the acrosome and may be involved in signaling or gamete recognition. 
Spermatogenesis 
(Olson et al., 
2004)(Herlyn et 
al., 2005) 
YLPM1 
Plays a role in the reduction of telomerase activity during differentiation of embryonic stem cells by binding to 
the core promoter of TERT and controlling its down-regulation 
Telomerase 
(Armstrong et al., 
2004) 
KIF17 
KIF17 gene mediates microtubule-independent delivery of ACT from the nucleus to the cytoplasm and 
microtubule-dependent transport of Spatial-ε, both are presumably involved in spermatogenesis 
Microtubule 
assembly 
(Wong-Rileyet al., 
2012) 
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CTAG2 
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis 
antigens. CTAs have unique subcellular distribution patterns and interacting partners, with SPANX-A/C/D 
forming protein complexes in the inner nuclear membrane and CTAG2 being recruited to the centrosome. CTAG2 
interacts with a protein complex containing Pericentrin (a microtubule organizing center gene (MTOC)) 
necessary for invasive behavior. CTAG2 could accomplish influence the stability of protein-protein complexes 
found at centrosomes, and recruit proteins that are not normally found at the centrosomes of somatic cells. 
Male germ cell 
development 
(Maine et al., 
2016) 
MAGEE1 
CT-X antigens are expressed likely in germ cell differentiation of the neoplastic cells (in seminomas) or aberrant 
gene activation as cancer antigens (in non-seminomatous tumors). MAGE-A proteins are established regulators 
of certain cancer-associated transcription factors, including P53, and are activators of several RING finger-
dependent ubiquitin E3 ligasesCancer/testis (CT) genes are expressed only in the germ line and certain tumors 
and are most frequently located on the X-chromosome (the CT-X genes). The function of MAGE proteins is not 
well understood, but several have been shown to potentially influence the tumorigenic phenotype. 
Male germ cell 
development 
(Barker & Salehi, 
2002)(Marcar et 
al., 2010) 
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Supplementary Table S5. Pathogenicity results from the Predict SNP analysis. Dark red correspond to deleterious effect, light red to probably 
deleterious and Green to Neutral effect. 
 
Gene Existing variant Predict Snp MAPP Phd-snp Polyphen-1 Polyphen-2 SIFT SNAP nsSNPAnalyzer Panther 
SPAG1 rs56246127 - - - - - - - - - 
TEX19 rs147220016 61 65 72 74 63 46 81 - 76 
EPHX2 rs71553864 - - - - - - - - - 
NOP10 rs146261631 65 81 78 74 41 53 56 - 67 
UBN1 - - - - - - - - - - 
PKN1 - 64 - 78 74 65 79 62 63 69 
MEA1 rs375030293 - - - - - - - - - 
MYCT1 rs41292880 79 86 45 74 81 79 85 - 65 
TAF1L_V1 rs140558556 72 43 66 74 68 79 89 63 74 
PDE11A TMP_ESP_2_178936993 - - - - - - - - - 
SH2D4A rs150534166 72 43 66 74 68 79 62 - 74 
KCNU1 rs374327006 87 86 58 74 81 79 89 - 57 
INCENP rs149820986 76 62 66 74 81 79 72 - 77 
GREB1 rs142882892 63 46 58 67 60 68 61 - - 
SEMA4D rs13284404 74 70 72 67 - 45 58 - 56 
USP47 COSM1604203 87 84 82 59 65 79 81 63 - 
SSH1 COSM1358541 72 70 59 74 81 79 72 - - 
GRP rs149962068 64 85 68 74 65 43 56 - 51 
ODF1_V1 COSM330203 - - - - - - - - - 
SSTR5 - 51 70 68 59 70 79 72 - - 
PSRC1 rs76057315 83 66 89 67 68 76 55 - 67 
GAR1 rs150273267 60 59 66 - - 77 72 - 75 
TAF1L_V3 rs141368669 60 77 72 68 59 79 56 - 48 
CYP2C8_V1 rs143386810 65 73 73 59 47 53 72 63 69 
SHQ1 rs78491606 87 48 73 59 55 79 56 - 74 
CYP2C8_V3 rs142470035 - - - - - - - - - 
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DDX4 rs201103498 65 57 59 74 70 53 62 - 52 
CCDC62 rs141689290 55 48 72 59 55 43 50 - - 
GFRA1 rs8192662 51 64 55 67 40 79 81 - - 
CYP2C8_V2 rs1058930 75 77 68 67 73 68 61 65 65 
HERC2 - 51 - 59 67 43 68 62 - 67 
NGF rs11466111 51 74 51 67 47 79 72 - 56 
RHBG rs71591938 - - - - - - - - - 
JAG2 - 61 70 77 74 81 79 61 - - 
TET1 rs142008363 51 - 78 74 55 53 55 - 69 
YY1 COSM949287 - - - - - - - - - 
LIG3 - - - - - - - - - - 
GOLGA3 rs76213047 72 48 55 74 59 53 56 - 61 
SMYD2 rs61755311 60 71 45 59 43 45 58 - 55 
FANCD2 rs372574627 52 74 78 74 55 43 62 - - 
NLRP14 rs76670455 87 77 82 74 81 79 72 - - 
LRP4 rs118009068 65 - 51 59 40 46 81 - 84 
PIF1 rs118062397 51 62 58 67 61 79 61 - 57 
SERPINB11 - 87 92 88 74 81 79 81 63 66 
TDRD6 - 63 57 66 67 63 76 62 - 56 
BRD4 rs35676845 52 - 68 74 65 53 55 - - 
TDRD6_V2 rs144670071 - - - - - - - - - 
PRKDC_V1 - 60 63 83 74 56 45 58 - 70 
AKAP3 rs2041291 64 43 78 74 55 53 62 - 56 
RECQL4 rs199654783 65 48 68 67 61 43 55 - 52 
POLE2 rs141483427 63 70 66 67 55 79 55 - 65 
KIF18A rs34913484 61 41 58 67 59 79 62 63 74 
ADAM20 rs45554935 76 64 82 75 68 79 56 - 73 
DNAH9 - 87 - 77 74 81 53 89 - - 
SYCP2 rs6071006 55 - 66 74 60 79 58 - 52 
DDX54 rs201635496 63 70 66 67 43 79 50 - - 
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VNN1 rs189034822 87 78 68 59 55 45 62 - - 
CYP3A43 rs143991326 87 84 77 74 81 79 56 63 74 
ABCA1 COSM273811 74 - 72 67 43 73 61 - 48 
SOX30 rs184421438 87 92 68 74 47 79 72 - - 
MLH3 rs28756990 51 73 78 74 47 45 56 - - 
CCDC33 rs369047254 - - - - - - - - - 
SBF1 rs199972466 61 74 51 74 68 79 72 - 61 
CYR61 rs148330006 64 85 68 74 65 43 56 - 51 
PLEC_2 rs138924815 55 80 82 97 81 43 56 - - 
GYS2 rs202136674 60 65 61 67 41 79 58 - - 
DNAAF1 rs144018942 63 57 55 67 68 79 55 - - 
MAP4_V1 rs2230169 63 77 72 67 81 53 71 - 61 
MAP4_V2 rs11711953 60 77 58 67 81 46 56 - - 
SPZ1 rs111595904 61 65 58 74 68 79 56 - - 
SPATA12 rs76587478 72 77 72 59 50 79 81 - - 
CYP1A1 rs41279188 61 70 51 59 45 79 62 63 61 
APLF rs149897324 62 57 89 59 56 46 56 - 62 
FSIP2_v2 rs76311269 64 51 - 59 43 79 - - - 
FSIP2_v1 rs11892184 61 - 89 59 45 73 - - - 
TNK2 rs13433937 65 - 78 74 65 79 81 - - 
TRIM16 rs3174720 72 64 86 74 81 43 56 - 57 
BCHE rs1799807 61 73 82 59 56 79 55 65 74 
PINX1 rs17855458 60 77 78 74 60 66 72 - 48 
NWD1 rs777897918 - - - - - - - - - 
GPRC6A - - - - - - - - - - 
KDM1B rs72840622 60 64 77 67 41 53 50 - - 
HIST1H1D rs202225825 60 59 83 - - 79 58 - 72 
FOXR1 rs45602538 87 81 59 74 68 53 72 - 66 
GGN rs62123481 - - - - - - - - - 
PDCL2 COSM1430232 87 77 88 74 81 79 85 - 87 
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FGD2 - 83 63 89 67 61 70 71 - - 
PLEC_4 rs78461695 65 - 61 67 81 46 81 63 - 
TINF2 rs17102311 61 51 78 74 81 53 55 - 69 
HSPA4 rs61745470 83 85 78 67 70 67 55 - 64 
USP49 rs201338884 - - - - - - - - - 
KDM6B rs61764072 75 79 89 67 79 79 71 - 70 
HORMAD1 - 55 82 83 59 60 68 62 - - 
DCLRE1C rs41297018 72 56 82 67 56 53 81 - 69 
PLEC_5 rs201569045 55 - 78 74 81 79 50 - - 
ERCC5 rs1047769 63 63 45 67 61 53 81 - 56 
STARD6 rs374944431 61 62 51 67 50 45 72 65 48 
NOTCH3 rs115582213 61 78 73 74 81 79 55 63 47 
SPAG4 - 87 91 88 74 81 79 89 - - 
DNAH8 rs367805228 75 75 72 67 64 79 50 - 65 
TAF1L_V4 - 61 77 58 74 63 79 62 63 69 
TAF1L_V5 rs35905429 61 56 55 74 81 79 50 - 78 
ZP2 - - - - - - - - - - 
TBP - - - - - - - - - - 
ZPBP2 - 87 78 77 74 81 79 85 - 69 
PINX1_v2 rs189959562 71 63 83 67 43 43 67 - 70 
STARD6 rs17292725 - - - - - - - - - 
KDM4B - 61 65 77 74 60 53 55 - - 
EXO5 rs150018949 72 72 55 59 47 53 72 - - 
CAPZA3 rs61912355 65 84 78 74 45 53 56 - 68 
ATP8B3 - 63 - 89 67 45 79 58 - - 
HRASLS rs116653160 - - - - - - - - - 
NEK11 rs140471991 - - - - - - - - - 
H1FNT rs117292373 61 88 78 59 59 79 50 - 72 
PRKDC_V2 rs201214138 74 65 51 67 41 68 55 - 65 
CEP152 rs199773611 - - - - - - - - - 
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SP100 rs150147150 - - - - - - - - - 
LAMA1 - 87 - 82 74 81 79 72 63 - 
CDC25B rs141314132 76 48 86 59 56 79 50 - 72 
MAST4_v1 - 51 - 78 59 70 43 81 - - 
MAST4_v2 - 51 - 83 59 45 73 62 - - 
KAT6B_V1 rs71929101 - - - - - - - - - 
KAT6B_V2 rs145158232 60 - 68 67 65 79 58 - - 
ERCC4_V1 rs1800067 60 74 58 67 40 53 56 - 55 
ERCC4_V2 rs1800124 74 65 55 67 69 46 58 - 49 
ZAN_v1 rs201422303 - - - - - - - - - 
ZAN_v2 rs314299 61 76 73 74 81 43 58 - 68 
YLPM1 rs45617140 65 63 78 0 0 79 70 - 74 
KIF17 rs35835983 55 73 61 67 45 79 72 63 - 
CTAG2 rs113459988 61 63 83 74 68 79 89 - - 
MAGEE1 rs41298484 60 76 78 59 55 79 50 - - 
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Supplementary Table S6. Gene tissue expression determine by Gtex Platform 
 
Gene Tissue1 
Media 
RPKM 
Tissue2 
Media 
RPKM 
Tissue3 
Media 
RPKM 
Tissue4 
Media 
RPKM 
Tissue5 
Media 
RPKM 
Testis 
SPAG1 testis 6.871 
Transformed 
lymphocytes 
6.777 
Colon 
Transverse 
4.399 
Esophagus-
Mucosa 
2.824 Bladder 2.653  
TEX19 testis 29.77 
Transformed 
lymphocytes 
0.31        
EPHX2 liver 45.661 Adrenal gland 29.702 
Small 
Intestine 
Terminal 
Ilenium 
28.178 Prostate 21.492 
Colon 
Transverse 
20.398 5.518 
NOP10 Whole blood 126.197 
Transformed 
lymphocytes 
130.109 
Transforme 
fibroblast 
107.376 Spleen 92.1 
Espphagus 
mucosa 
76.518 24.995 
UBN1 testis 27.256 Spleen 13.134 
Esophagus 
mucosa 
12.586 Whole blood 12.801 Vagina 9.819  
PKN1 Spleen 67.121 Lung 48.999 Testis 44.862 Whole blood 44.851 
Colon 
Transverse 
44.512  
MEA1 Testis 234.892 
Brain-Frontal 
Cortex 
52.641 Brain Cortex 51.27 Pituitary 50.064 
Brain-
Anterior 
Cingulate 
Cortex 
49.933  
MYCT1 
Adipose 
Subcutaneous 
15.421 Spleen 14.991 
Adipose 
Visceral 
14.472 Breast 11.758 Lung 10945 1.292 
TAF1L Testis 14 Vagina 2 
Skin (lower 
leg) 
2 
Esophagus-
Mucosa 
2 
Adipose 
visceral 
2  
PDE11A Prostate 1.917 
Brain Spinal 
Cord 
1.203 Pituitary 0.683 Testis 0.668 Liver 0.648  
SH2D4A Ovary 10.513 
Esophagus 
mucosa 
10.226 Stomach 8.493 
Minor 
Salivary gland 
7.584 
Transformed 
fibroblast 
7.54 1.4988 
KCNU1 testis 5.231 Prostate 0.028        
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INCENP 
Transformed 
lymphocytes 
15.852 
Esophagus 
mucosa 
9.76 
Brain 
Cerebellar 
hemisphere 
7.917 Testis 6.399 Vagina 4.287  
GREB1 Ovary 84.993 Prostate 18.834 Uterus 14.757 Testis 5.982 Vagina 5.938  
SEMA4D 
Brain Spinal 
cord 
41.011 
Brain substantia 
nigra 
15.414 
Transformed 
lymphocytes 
15.299 Whole blood 15.22 Spleen 15.102 4.089 
USP47 
Brain 
Cerebellar 
Hemisphere 
23.815 
Brain 
Cerebellum 
21.486 
Muscle-
Skeletal 
17.508 
Heart Atrial 
Appendage 
17.081 Artery Tibial 16.091 13.436 
SSH1 
Transformed 
fibroblasts 
13.824 
Transformed 
lymphocytes 
12.506 
Brain 
Cerebellar 
Hemisphere 
12.154 Nerve Tibial 10.52 
Brain 
Cerebellum 
10.324 4.656 
GRP Testis 2.178 
Brain 
Hippocampus 
2.108 
Brain-
Anterior 
Cingulate 
Cortex 
1.789 
Brain 
Hyphotalamus 
1.737 
Colon 
Sigmoid 
0.995  
ODF1 Testis 303.039 
Brain Nucleous 
Accumbens 
0.239        
SSTR5 Pituitary 9.547 
Heart Atrial 
Appendage 
3.651 
Heart left 
ventricle 
1.772 
Adrenal 
Gland 
1.648 Artery Aorta 1.309 0.166 
PSRC1 
Brain Spinal 
Cord 
37.33 
Brain 
Hippocampus 
25.218 
Brain 
Subtantia 
nigra 
24.244 Brain Cortex 21.395 
Brain-Frontal 
Cortex 
17.261 10.954 
GAR1 
Transformed 
lymphocytes 
16.962 
Skin 
(suprapubic) 
13 
Skin (lower 
leg) 
12.786 Testis 12.609 
Transformed 
fibroblast 
12.061  
CYP2C8 Liver 368.753 Testis 6.505 Pituitary 4.331 Stomach 3.776 
Brain 
Hypothalamus 
2.269  
SHQ1 
Transformed 
lymphocytes 
4.141 
Transformed 
fibroblast 
3.912 Testis 3.843 Thyroid 2.862 
Adrenal 
Gland 
2.802  
DDX4 Testis 82.503 
Brain Nucleous 
Accumbens 
0.159        
  
 
2
2
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CCDC62 Testis 26.44 
Brain Cerebelar 
Hemisphere 
0.44        
GFRA1 Nerve tibial 13.684 Colon sigmoid 12.868 Breast 8.683 
Brain 
Nucleous 
Accumbens 
7.281 Brain Caudate 7.803 2.023 
HERC2 
Brain 
Cerebellum 
12.608 
Brain Cerebelar 
Hemisphere 
11.391 Ovary 9.747 Pitutary 9.669 
Colon 
sigmoid 
9.515 7.601 
NGF Ovary 11.848 Artery Aorta 9.537 
Heart Atrial 
Appendage 
8.05 
Adipose 
visceral 
7.802 Uterus 7.435 0.748 
RHBG 
Brain 
Cerebelar 
Hemisphere 
19.095 
Brain 
Cerebellum 
18.202 Kidney cortex 14.21 Ovary 11.963 
Skin (lower 
leg) 
4.305 1.986 
JAG2 Pituitary 27.196 
Skin 
(suprapubic) 
20.13 
Skin (lower 
leg) 
17.473 Prostate 12.533 Breast 12.092 5.774 
TET1 Nerve tibial 0.884 Ovary 0.706 
Minor 
salivary gland 
0.553 
Brain 
Cerebellum 
0.524 
Brain 
Cerebelar 
Hemisphere 
0.504 0.166 
YY1 Thyroid 23.755 
Brain Cerebellar 
Hemisphere 
18.258 
Transformed 
lymphocytes 
17.483 Artery Tibial 17.008 
Colon 
sigmoid 
16.476 12.916 
LIG3 Testis 15.732 Uterus 9.314 Prostate 8.046 
Transformed 
Lymphocytes 
7.994 Ovary 7.759  
GOLGA3 Pituitary 20.619 
Transformed 
fibroblast 
13.313 Artery Aorta 12.033 
Brain 
Cerebelar 
Hemisphere 
11.54 
Brain 
Cerebellum 
11.476 10.13 
SMYD2 
Heart left 
ventricle 
46.319 
Brain-Frontal 
Cortex 
14.48 Testis 13.573 
Muscle 
Skeletal 
13.293 Pitutary 11.775  
FANCD2 
Transformed 
lymphocytes 
11.867 Testis 9.366 Spleen 3.223 
Small 
Intestine 
1.96 
Esophagus 
mucosa 
1.552  
NLRP14 Testis 0.592 Brain spinal cord 0.107 Nerve tibial 0.089 Ovary 0.06    
LRP4 
Skin 
(suprapubic) 
21.88 Skin (lower leg) 21.803 Brain Caudete 21.661 
Brain 
Putamen 
17.026 
Brain 
Nucleous 
Accumbens 
15.136 1.132 
PIF1 
Transformed 
lymphocytes 
16.26 Spleen 3.21 Testis 2.708 
Transformed 
fibroblasts 
2.576 
Small 
Intestine 
1.898  
  
 
2
3
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SERPINB11 Prostate 7.623 
Esophagus 
mucosa 
6.133 Vagina 3.686 Testis 0.126 
Minor Saivary 
Gland 
0.053  
TDRD6 Testis 12.402 Brain cerebellum 5.906 
Brain 
Cerebelar 
Hemisphere 
5.325 Pituitary 1.762 Thyroid 1.043  
BRD4 Testis 15.039 Skin (lower leg) 14.904 
Skin 
(suprapubic) 
14.527 Ovary 14.3 Spleen 14.068  
PRKDC 
Transformed 
lymphocytes 
24.991 
Transformed 
fibroblasts 
22.24 Testis 12.855 Bladder 10.713 Ovary 10.52  
AKAP3 Testis 77.93 
Heart Atrial 
Appendage 
1.45 
Brain Spinal 
cord 
1.078 Pituitary 0.931 
Brain 
substantia 
nigra 
0.737  
RECQL4 Testis 22.61 
Transformed 
lymphocytes 
11.639 
Brain 
Cerebellum 
10.129 
Brain 
Cerebelar 
Hemisphere 
8.868 
Esophagus 
mucosa 
5.642  
POLE2 
Transformed 
lymphocytes 
5.2 Testis 2.013 
Esophagus 
mucosa 
1.823 
Small 
Intestine 
1.142 Vagina 1.141  
KIF18A Testis 8.183 
Transformed 
lymphocytes 
7.717 
Transformed 
fibroblasts 
1.232 
Esophagus-
Mucosa 
0.912 Thyroid 0.569  
ADAM20 Testis 4.2 
Brain 
Cerebellum 
0.306 
Brain 
Cerebelar 
Hemisphere 
0.248 Nerve Tibial 0.161 Vagina 0.138  
DNAH9 Testis 2.002 
Brain 
Hyphotalamus 
0.847 
Brain 
Nucleous 
Accumbens 
0.696 
Brain 
Hippocampus 
0.631 Brain Caudete 0.599  
SYCP2 Testis 18.227 Breast 2.288 Nerve tibial 1.953 
Minor 
Salivary gland 
1.78 Prostate 1.673  
DDX54 
Transformed 
lymphocytes 
22.449 Muscle skeletal 15.355 Spleen 15.216 
Skin (lower 
leg) 
15.18 Uterus 14.915 8.516 
VNN1 Whole blood 47.862 Liver 29.483 
Small 
Intestine 
Terminal 
Ilenium 
9.84 Spleen 6.588 Kidney 3.03 0.087 
CYP3A43 Liver 1.927 Pancreas 1.202 Testis 0.768 Prostate 0.336 Nerve tibial 0.106  
ABCA1 
Adrenal 
gland 
26.504 
Adipose 
subcutaneous 
12.997 Nerve tibial 11.242 
Colon 
sigmoid 
11.203 
Adipose 
Visceral 
11.165 2.378 
  
 
2
3
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SOX30 Testis 59.992 Colon Transverse 0.158 Bladder 0.137 
Colon 
sigmoid 
0.119 
Small 
Intestine 
0.108  
MLH3 Thyroid 6.007 Nerve tibial 5.085 
Transformed 
lymphocytes 
4.583 Testis 4.451 Prostate 4.433  
CCDC33 Testis 12.189 Pituitary 0.165 Lung 0.127 
Brain 
Hippocampus 
0.111 
Brain 
Hypothalamus 
0.088  
SBF1 Testis 68.098 
Brain 
Cerebellum 
50.077 Thyroid 47.97 
Brain 
Cerebellar 
Hemisphere 
42.838 Brain Cortex 39.417  
CYR61 
Transformed 
fibroblasts 
543.677 Artery Aorta 307.746 
Adipose 
Visceral 
305.326 
Adipose 
subcutaneous 
276.469 
Artery 
Coronary 
276.458 15.655 
PLEC Nerve tibial 79.219 
Transformed 
fibroblast 
62.516 
Muscle-
Skeletal 
61.894 Artery aorta 46.592 
Skin 
(suprapubic) 
46.377 12.688 
GYS2 liver 25.154 
Esophagus 
mucosa 
2.701 
Adipose 
Subcutaneous 
1.524 Vagina 0.683 Breast 0.214 0.066 
DNAAF1 Testis 45.677 Pituitary 5.86 
Brain 
Hypothalamus 
4.142 Thyroid 3.21 
Brain 
Hyppocampus 
2.055  
MAP4 
Brain Spinal 
cord 
150.885 Muscle skeletal 87.989 
Brain 
Subtantia 
nigra 
82.989 Nerve Tibial 61.201 
Brain 
Hippocampus 
57.293 27.94 
SPZ1 Testis 26.195          
SPATA12 Testis 21.952 Adrenal Gland 0.248 
Minor 
salivary gland 
0.114 
Adipose 
subcutaneous 
0.058 
Esophagus 
mucosa 
0.055  
CYP1A1 
Skin (lower 
leg) 
2.674 
Adipose 
subcutaneous 
2.325 Liver 2.278 Breast 1.659 
Skin 
(suprapubic) 
1.123 0.2 
APLF Testis 2.262 
Skin 
(suprapubic) 
1.449 
Skin (lower 
leg) 
1.379 Vagina 1.235 
Transformed 
fibroblast 
1.063  
FSIP2 Testis 5.42 Colon Transverse 1.466 Stomach 0.606 Pituitary 0.342 
Small 
Intestine 
0.24  
TNK2 Brain cortex 51.707 
Brain 
Cerebellum 
50.293 Pituitary 48.588 
Brain 
Anterior 
Cingulate 
cortex 
47.992 
Brain Frontal 
Cortex 
45.421 16.613 
TRIM16 
Esophagus 
mucosa 
40.831 Vagina 19.364 
Skin (lower 
leg) 
13.425 
Skin 
(suprapubic) 
12.587 
Adrenal 
Gland 
10.69 5.44 
  
 
2
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BCHE 
Esophagus 
mucosa 
14.173 
Esophagus 
Gastresophageal 
Junction 
13.154 
Colon 
sigmoid 
11.96 Liver 11.591 Uterus 7.617 0.953 
PINX1 
Transformed 
lymphocytes 
7.023 Testis 5.601 Nerve tibial 5.594 
Skin 
(suprapubic) 
5.101 
Skin (lower 
leg) 
4.78  
NWD1 
Brain 
Nucleous 
Accumbens 
3.81 Brain Caudate 3.757 
Brain-
Anterior 
Cingulate 
Cortex 
3.446 
Brain 
Amigdala 
2.719 Prostate 2.445 1.72 
GPRC6A 
Minor 
salivary gland 
0.286 Kidney cortex 0.06 Adrenal gland 0.053 Prostate 0.013   0 
KDM1B Thyroid 10.899 
Transformed 
lymphocytes 
7.473 Testis 6.484 
Skin 
(suprapubic) 
6.052 
Skin (lower 
leg) 
5.896  
HIST1H1D Whole blood 1.288 Vagina 1.092 
Transformed 
lymphocytes 
0.968 Prostate 0.682 
Small 
Intestine 
0.51 0.247 
FOXR1 Testis 4.027 Vagina 0        
GGN Testis 82.584 Artery Aorta 1.343 Brain Cortex 0.976 
Small 
Intestine 
0.828 Pitutary 0.786  
PDCL2 Testis 62.507 
Esophagus 
mucosa 
0.218 Pituitary 0.149 
Skin (lower 
leg) 
0.078 
Skin 
(suprapubic) 
0.054  
FGD2 Spleen 87.999 
Transformed 
lymphocytes 
23.132 Whole blood 17.652 Lung 15.203 
Small 
Intestine 
12.869 1.262 
TINF2 
Adrenal 
gland 
39.596 Spleen 37.628 Whole blood 32.537 
Esophagus-
Mucosa 
32.248 Lung 30.695 13.777 
HSPA4 
Transformed 
lymphocytes 
40.437 Testis 39.317 
Transformed 
fibroblasts 
31.041 
Esophagus-
Mucosa 
27.455 
Adrenal 
Gland 
24.305  
USP49 Thyroid 3.866 
Brain 
Cerebellum 
3.337 
Brain 
Cerebelar 
Hemisphere 
3.175 Testis 2.748 
Transformed 
lymphocytes 
2.228  
KDM6B Whole blood 30.998 Ovary 19.895 Spleen 16.609 Pitutary 16.406 Testis 16.324  
HORMAD1 Testis 42.206 
Esophagus 
mucosa 
1.346 
Skin (lower 
leg) 
0.991 Nerve Tibial 0.737 
Skin 
(suprapubic) 
0.718  
DCLRE1C 
Transformed 
lymphocytes 
3.812 Spleen 2.641 Bladder 2.483 
Esophagus-
Mucosa 
2.157 Nerve tibial 1.909 0.72 
  
 
2
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ERCC5 Spleen 15.445 Small Intestine 14.345 
Transformed 
lymphocytes 
13.604 
Skin (lower 
leg) 
13.039 Nerve tibial 12.791 10.581 
STARD6 Testis 7.341 
Brain Spinal 
Cord 
0.145 Nerve tibial 0.11 
Brain 
Subtantia 
nigra 
0.09    
NOTCH3 Artery Tibial 140.088 Artery aorta 78.692 
Artery 
coronary 
77.652 
Skin (lower 
leg) 
60.283 
Adipose 
subcutaneous 
59.678 3.385 
SPAG4 Testis 32.968 Pancreas 13.587 Spleen 6.322 Pituitary 6.29 
Transformed 
lymphocytes 
5.122  
DNAH8 Testis 5.255 Spleen 0.554 
Transformed 
lymphocytes 
0.338 Prostate 0.056    
ZP2 
Brain 
Cerebellum 
23.703 
Brain cerebellar 
Hemisphere 
23.028 
Small 
Intestine 
0.145 Testis 1.141 
Brain Spinal 
Cord 
0.031  
TBP Testis 25.597 
Transformed 
lymphocytes 
12.171 Spleen 10.208 Ovary 9.413 Uterus 8.781  
ZPBP2 Testis 65.254 
Transformed 
lymphocytes 
0.887 Spleen 0.092 
Small 
Intestine 
0.036    
KDM4B 
Transformed 
lymphocytes 
16.61 Thyroid 15.016 Prostate 13.6 
Brain 
Cerebellum 
11.601 Whole blood 11.011 10.271 
EXO5 Spleen 2.843 
Transformed 
lymphocytes 
2.601 
Brain 
cerebellar 
Hemisphere 
2.554 
Brain 
Cerebellum 
2.333 Testis 1.945  
CAPZA3 Testis 175.897 
Skin 
(suprapubic) 
0.768 Stomach 0.718 
Skin (lower 
leg) 
0.611 Kidney 0.318  
ATP8B3 Testis 28.133 Spleen 3.416 Adrenal gland 1.367 Vagina 0.674 Uterus 0.522  
HRASLS Testis 67.627 Muscle skeletal 10.149 
Heart Atrial 
Appendage 
4.114 
Brain 
Amygdala 
4.478 
Brain-Frontal 
Cortex 
3.457  
NEK11 Testis 9.846 Thyroid 4.172 Pituitary 3.566 
Brain 
Nucleous 
Accumbens 
3.14 
Brain 
Hypothalamus 
3.094  
H1FNT Testis 211.149 Ovary 0.599 
Brain 
Cerebellum 
0.539 
Brain 
cerebellar 
Hemisphere 
0.411 Brain Cortex 0.368  
  
 
2
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CEP152 
Transformed 
lymphocytes 
7.073 Testis 6.043 Nerve tibial 2.308 Thyroid 1.773 
Small 
Intestine 
1.407  
SP100 
Transformed 
lymphocytes 
36.656 Spleen 20.023 Lung 16.258 
Adipose 
subcutaneous 
15.33 Whole blood 15.205 1.915 
LAMA1 Testis 8.794 
Transformed 
fibroblasts 
5.636 Thyroid 2.415 Kidney cortex 1.979 Pitutary 1.685  
CDC25B 
Brain 
Cerebellum 
56.236 
Brain cerebellar 
Hemisphere 
52.231 Lung 49.462 Spleen 37.85 Pitutary 33.024 10.565 
MAST4 
Esophagus 
mucosa 
12.966 Vagina 10.802 
Skin 
(suprapubic) 
6.373 Ovary 5.897 
Skin (lower 
leg) 
5.879 2.7 
KAT6B Ovary 5.958 
Transforme 
Lymphocytes 
5.442 Bladder 5.355 Uterus 5.191 Testis 4.947  
ERCC4 Testis 5.591 Adrenal Gland 2.338 
Transforme 
Lymphocytes 
2.042 
Transformed 
fibroblasts 
1.97 Bladder 1.877  
ZAN Testis 1.922 Skin (lower leg) 0.043 
Skin 
(suprapubic) 
0.037 Liver 0.027    
YLPM1 Testis 16.556 Ovary 14.379 
Transformed 
lymphocytes 
13.088 Bladder 11.94 
Transformed 
fibroblast 
11.896  
KIF17 Testis 28.68 Spleen 9.099 Brain Cortex 6.537 
Adrenal 
Gland 
5.631 
Brain-Frontal 
Cortex 
5.546  
CTAG2 Testis 6.28 Spleen 0.045        
MAGEE1 
Brain-Frontal 
Cortex 
19.83 
Brain cerebellar 
Hemisphere 
17.197 
Brain 
Cerebellum 
14.98 
Brain 
Hypothalamus 
13.479 Brain Cortex 13.441 0.4 
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Supplementary Table S7. Pathogenicity results from the Predict SNP analysis. Dark red correspond to deleterious effect, light red to probably 
deleterious and Green to Neutral effect. 
 
Gene Existing variant Predict Snp MAPP Phd-snp Polyphen-1 Polyphen-2 SIFT SNAP nsSNPAnalyzer Panther 
DNAH7_V1 rs146463525 72 74 82 74 71 79 62 - - 
DNAH7_V2 - 87 63 88 74 68 79 81 - - 
DNAH7_V3 rs62623377 87 51 88 74 56 79 72 - - 
DNAH7_V4 rs144390858 63 74 51 59 63 79 50 - - 
LRP2_v1 rs34291900 61 - 61 - 68 81 - - - 
LRP2_v2 rs766473797 - - - - - - - - - 
PKDREJ 
rs538611590 - - - - - - - - - 
TMP_ESP_22_466533
99_46653402 - - - - - - - - - 
BZRAP1_v1 rs376971639 74 - 78 67 70 46 55 - - 
BZRAP1_v2 rs3744098 - - - - - - - - - 
SIRT1 - 83 63 78 - - 73 58 - 48 
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Supplementary Table S8. Candidate variants characteristics of the FB-Burden analysis 
 
Gene Function Pathway References 
DNAH7 
Is a component of the inner dynein arm of ciliary axonemes, forcing the generation of the protein of 
respiratory cilia. Additionally, it produces force towards the minus ends of microtubules, it has dynein 
ATPase activity. 
Microtubule 
assembly 
(Zhang et al., 2002) 
LRP2 
The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, 
vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular 
ligands include parathyroid hormones and the morphogen sonic hedgehog while cytosolic ligands 
include MAP kinase scaffold proteins and JNK interacting proteins. May participate in regulation of 
parathyroid-hormone and para-thyroid-hormone-related protein release. 
Hormonal 
(Holt et al., 2008)(Marzolo 
et al., 2011) 
PKDREJ 
The protein encode by this gene has a central role in fertilization. Its generate a Ca(2+) transporting 
channel directly involved in initiating the acrosome reaction of the sperm. 
Hormonal 
(Hamm et al., 2007)(Zigo 
et al., 2013) 
BZRAP1 
The first of these proteins to be identified is the peripheral benzodiazepine receptor (PBR), now also 
called the mitochondrial transporter protein (TSPO). It was initially proposed that PBR/TSPO was the 
‘acute trigger’ of steroidogenesis, but it is now clear that BZRAP1 plays that role, and that PBR/TSPO 
is part of the molecular machine. Their ligands stimulate steroidogenesis and neurosteroidogenesis and 
act by facilitating mitochondrial cholesterol delivery (cholesterol translocation from the OMM to the 
IMM); this results in increased cholesterol metabolism to pregnenolone by cytochrome P450 
cholesterol side-chain cleavage enzyme (P450scc, also known as CYP11A1), which is the rate-
determining step in steroid synthesis during the sex determination. 
Hormonal & 
male germ 
cell 
development 
(Miller et al., 2011)(Chung 
et al., 2013) 
SIRT1 
Human SIRT1 is an NAD+-dependent deacetylase protein that plays a role in cell death/survival, 
senescence, and endocrine signaling. SIRT1 deacetylates non histone proteins and allows mammalian 
cell survival under oxidative stress and DNA damage through at least three mechanisms. 
DNA 
damage and 
epigenetics 
(Kim et al., 
2007)(Ramachandran et 
al., 2017) 
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Supplementary Table S9. Pathogenicity results from the Predict SNP analysis. Dark red correspond to deleterious effect, light red to probably deleterious 
and Green to Neutral effect. 
 
Gene Existing variant Predict Snp MAPP Phd-snp Polyphen-1 Polyphen-2 SIFT SNAP nsSNPAnalyzer Panther 
ADAM8 rs36054052 60 74 66 59 43 79 55 - - 
APLF rs36021078 51 86 51 67 56 53 61 - 56 
CCR5_v1 rs145061115 72 64 68 59 81 79 56 - - 
CCR5_v2 rs1799863 72 46 68 59 81 79 62 - - 
CCR5_v3 rs34418657 87 59 82 74 81 79 56 - - 
DHX34_v1 rs143911542 68 66 66 67 45 46 71 - - 
DHX34_v2 rs12984558 83 65 83 67 68 74 61 - - 
DHX34_v3 rs151213663 74 - 83 67 73 46 55 - 74 
GREB1 rs145454387 63 76 78 59 68 71 50 - - 
HERC2_v1 - 65 - 78 67 40 45 71 - 61 
HERC2_v2 - 87 - 68 74 45 79 62 - 74 
HERC2_v3 - 51 - 59 67 43 68 62 - 67 
HERC2_v4 - 51 - 89 67 56 79 56 - 71 
KAT6B rs71929101 - - - - - - - - - 
KAT6B_v3 rs145158232 60 - 68 67 65 79 58 - - 
MAP3K1 - - - - - - - - - - 
MYH14_v1 - 72 74 61 74 68 79 72 65 74 
MYH14_v2 - 61 78 77 59 56 79 55 63 61 
NF1_v1 - 55 76 51 59 65 53 56 - - 
NF1_v2 - 65 70 58 67 40 53 67 - 56 
SALL3_v1 rs 7233194 - - - - - - - - - 
SALL3_v2 COSM196185 64 64 68 - - 79 85  71 
SLC22A16_v1 rs75035916 83 78 83 67 79 90 83 - 71 
SLC22A16_v2 rs41288594 87 86 82 59 81 79 72 - - 
TNXB - 63 - 68 67 40 71 81 - - 
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Supplementary Table S10. Candidate variants characteristics of the FB-SKAT analysis. APLF; GREB1; HERC2; KAT6B information in Supplementary 
Table S3 
 
Gene Function Pathway References 
ADAM8 
Encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. ADAM8 is expressed 
in a stage-specific manner and is hormonally regulated in ovulating follicles by the coordinate actions of 
LH and PGR involve in the hormonal regulation of the testicles. 
Cell cycle 
(Sriraman et al., 
2008) 
CCR5 
Sperm capacitation, involve significant changes in the membrane architecture produce by an intensive 
trafficking processes of CCR5. CCR5 protein is present on the surface of spermatozoa, and has its receptor 
on the periacrosomal region of the sperm head. As spermatozoa are both transcriptionally and 
translationally inactive cells, a CCR5 recycling could provide a subtle and dynamic control for its 
membrane expression. 
Spermatogenesis 
(Barbonetti et al., 
2009) 
DHX34 
DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA 
helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary 
structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome 
assembly, implicated in Non-mediated Decay activation process. 
DNA damage 
repair system 
(Hug & Cáceres, 
2014) 
MAP3K1 
The protein encoded by this gene is a serine/threonine kinase and is part of some signal transduction 
cascades, including the ERK and JNK kinase pathways as well as the NF-kappa-B pathway. Members of 
the MAP kinase gene family could mediate the balance between the male and female sex-determining 
pathways by affecting the activities of the testis-promotingSOX9 and FGF9 (MIM 600921) and ovarian-
promoting WNT4 and CTNNB1 (β-catenin) (MIM 116806). 
Cell cycle & 
spermatogenesis 
(Pearlman et al., 
2010)(Pham et al., 
2014) 
MYH14 
Myosins are actin-dependent motor proteins with diverse functions including regulation of cytokinesis, cell 
motility, and cell polarity. MYH14 is part of NMII family that is required for meiotic cytokinesis in male 
but not female. Specifically, NMIIB-deficient spermatocytes exhibit cytokinetic failure in meiosis I, 
resulting in bi-nucleated secondary spermatocytes. Additionally, cytokinetic failure at meiosis II gives rise 
to bi-nucleated or even tetra-nucleated spermatids, these multi-nucleated spermatids fail to undergo normal 
differentiation, leading to male infertility. 
Microtubule 
assembly 
(Yang et al., 2012) 
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NF1 
Has different biochemical functions, including association to microtubules and participation in several 
signaling pathways. NF1 is a tumor-suppressor gene whose product acts upstream of the RAS proteins, 
moreover, is thought to restrict cell proliferation by functioning as a Ras-specific guanosine 
triphosphatase-activating protein. 
Cell cycle 
(Nasir-ud-Din et al., 
2009) 
SALL3 
This protein binds to DNA methyltransferase 3 alpha (DNMT3A), and reduces DNMT3A-mediated CpG 
island methylation. It is suggested that silencing of this gene, resulting in acceleration of DNA 
methylation, may have a role in oncogenesis. Mutations in some of these genes are associated with 
congenital disorders in human, suggesting their importance in embryonic development 
epigenetics (Ohgane et al., 2004) 
SLC22A16 
High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-
carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the 
maturation of spermatozoa. Also transports organic cations such as tetraethylammonium (TEA) and 
doxorubicin. The uptake of TEA is inhibited by various organic cations. The uptake of doxorubicin is 
sodium-independent. 
Spermatogenesis (Jeulin et al., 1996) 
TNXB 
The tenascins are a growing family of extracellular matrix proteins. The first member termed tenascin 
attracted attention due to its prominent expression during tissue interactions in embryogenesis and its 
overexpression in many tumors. Thus, tenascin have play an important role in regulating cell-extracellular 
matrix interactions in a way to promote cell rounding, migration and/or differentiation, especially in the 
tissue interactions during organogenesis and cell movements in embryogenesis 
Cell cycle 
(Chiquet-Ehrismann, 
et al., 1986)(Endo et 
al., 2009) 
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Supplementary Table S11. Pathogenicity results from the Predict SNP analysis. Dark red correspond to deleterious effect, light red to probably deleterious 
and Green to Neutral effect. 
 
Gene Existing variant Predict Snp MAPP Phd-snp Polyphen-1 Polyphen-2 SIFT SNAP nsSNPAnalyzer Panther 
ABCA1 rs9282537 - - - - - - - - - 
ABCA1 - - - - - - - - - - 
DACT1 rs34015825 60 74 89 59 55 79 61 - 67 
IRX1 rs3596328 55 71 58 74 65 76 56 - 52 
LBP rs2232607 87 43 82 59 50 53 72 63 47 
MAGI2_v1 - 75 - 78 67 61 53 58 - - 
MAGI2_v2 - 55 - 58 59 50 79 50 - - 
PGRMC2 - 61 78 68 67 54 79 50 - - 
RYR2 rs72549414 - - - - - - - - - 
SYT8 rs138428155 51 - 83 - - 53 62 - - 
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Supplementary Table S12. Candidate variants characteristics of the SKAT analysis. ABCA1 information is in Supplementary Table S3 
    
Gene Function Pathway References 
DACT1 
Involved in regulation of intracellular signaling pathways during development. Specifically thought to play a role 
in canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family 
proteins. The activation/inhibition of Wnt signaling may depend on the phosphorylation status, implicated in the 
the process of sex determination and differentiation. 
Cell cycle (An et al., 2013) 
IRX1 
Is a member of the iroquois homeobox gene family and plays a role during pattern formation of vertebrate 
embryos. It present high expression in seminomas and is reported as one of the master regulators of pluripotency, 
with increased expression controlling embryonic differentiation into primitive endoderm and mesoderm. 
Male germ cell 
development 
(Anifandis et al., 
2014) 
LBP 
Prostasomes can fuse with sperm cells and LBP seems to attach to heads and tails of spermatozoa originates from 
prostasomes. The fusion would protect the spermatozoa from an attack by the female immune system and a way to 
associate antimicrobial proteins, reach in the uterus. 
Reproduction (Malm et al., 2005) 
MAGI2 
The protein encoded by this gene interacts with atrophin-1 (ATN1). This encoded protein is characterized by two 
WW domains, a guanylate kinase-like domain, and multiple PDZ domains. Morevoer it mediates actin disassembly 
which is required for postnatal germ cell migration and spermatogonial stem cell niche establishment 
microtubule 
assembly 
(Xu et al., 2015) 
PGRMC2 
Progesterone receptor membrane component (PGRMC1) and PGRMC2 belong to the hemebinding protein family 
and may serve as universal non classical P4 receptors in the uterous. The functional importance of PGRMC1/2 in 
the uterus is related to the inhibition of the cell migration in the stromal. A significant increase in PGRMC2 was 
observed in the human choriodecidua of term and pre-term pregnancies and in human spermatozoa. 
Hormonal 
(Lösel et al., 
2005)(Sueldo et al., 
2015) 
RYR2 
This gene comes from the Ryanodine receptor family which are expressed in male germ cells where they can be 
activated by caffeine and a high ryanodine concentration can affect spermatogonial proliferation and 
differentiation, transients RyRdependent Ca2+ appear to interfere with spermatogonial differentiation. 
Spermatogenesis 
(Chiarella et al., 
2004) 
SYT8 
This gene encodes a member of the synaptotagmin protein family. Synaptotagmins are membrane proteins that are 
important in neurotransmission and hormone secretion, both of which involve regulated exocytosis. SYT8 play a 
role in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues, mediates Calcium Ca (2+)-
regulation of exocytosis acrosomal reaction in sperm. 
Hormonal 
(Hutt et al., 
2002)(Hutt et al., 
2005) 
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Supplementary Table S13. Gene tissue expression determine by Gtex Platform 
 
Gene Tissue1 
Media 
RPKM 
Tissue2 
Media 
RPKM 
Tissue3 
Media 
RPKM 
Tissue4 
Media 
RPKM 
Tissue5 
Media 
RPKM 
Testis 
DNAH7 Testis 2.971 Pituitary 1.754 
Brain 
Caudate 
1.257 
Brain Nucleous 
Accumbens 
1.025 Brain Cortex 0.926  
LRP2 Thyroid 10.127 Kidney cortex 8.146 
Brain Spinal 
Cord 
5.623 
Brain Subtantia 
nigra 
2.601 
Brain 
Hippocampus 
1.402 0.253 
PKDREJ Testis 2.998 Small Intestine 0.191 Nerve tibial 0.182 Ovary 0.174 
Colon 
Transverse 
0.146  
BZRAP1 Brain Cortex 40.694 
Brain-Anterior 
Cingulate 
Cortex 
39.451 
Brain-
Frontal 
Cortex 
32.831 
Brain 
Amygdala 
32.623 
Brain 
Cerebellum 
27.44 1.264 
SIRT1 Testis 14.409 Uterus 9.239 Ovary 9.156 
Brain Cerebelar 
Hemisphere 
8.793 Adrenal Gland 8.561  
ADAM8 Whole Blood 138.021 Spleen 37.97 
Transforme
d 
Lymphocyte
s 
35.793 Lung 13.312 Bladder 6.595 2.711 
CCR5 Spleen 3.793 Small Intestine 1.655 Lung 1.599 Whole Blood 1.315 Stomach 0.607 0.056 
DHX34 Whole Blood 42.203 Testis 29.285 Spleen 13.555 Ovary 10.311 Pituitary 10.231  
MAP3K1 
Skin 
(suprapubic) 
14.087 
Skin (lower 
leg) 
13.35 Spleen 11.469 Thyroid 10.688 
Minor salivary 
gland 
8.801 5.05 
MYH14 Muscle skeletal 45.756 
Skin (lower 
leg) 
41.954 
Small 
Intestine 
38.686 
Colon 
Transverse 
37.14 
Skin 
(suprapubic) 
36.999 1.835 
NF1 
Brain 
Cerebelar 
Hemisphere 
6.649 
Brain 
Cerebellum 
6.144 
Transforme
d fibroblasts 
5.828 Thyroid 5.409 Testis 5.339  
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SALL3 Vagina 2.925 Prostate 1.809 
Brain 
Caudate 
1.654 
Brain Spinal 
Cord 
1.531 
Brain Nucleous 
Accumbens 
1.228 0.641 
SLC22A16 Testis 7.881 Whole blood 0.485 Uterus 0.207 Spleen 0.142 Lung 0.132  
TNXB Ovary 26.292 Uterus 26.03 
Adipose 
subcutaneou
s 
24.073 Nerve tibial 21.75 
Heart Atrial 
Appendage 
20.265 4.022 
DACT1 
Brain 
Cerebelar 
Hemisphere 
13.737 Artery Aorta 12.5 Nerve tibial 12.463 
Artery 
Coronary 
11.442 
Brain 
Cerebellum 
10.89  
IRX1 
Minor salivary 
gland 
11.085 Breast 8.544 
Skin (lower 
leg) 
6.143 Kidney 5.761 
Adipose 
subcutaneous 
4.552 0.104 
LBP Liver 396.734 
Adipose 
visceral 
6.761 
Adipose 
subcutaneou
s 
4.704 Muscle skeletal 2.631 Kidney cortex 2.003 0.782 
MAGI2 
Brain-Frontal 
Cortex 
8.907 Brain Caudate 8.654 
Brain 
Putamen 
7.744 
Brain Nucleous 
Accumbens 
7.761 Brain Cortex 7.327 1.559 
PGRMC2 
Transformed 
fibroblasts 
35.211 
Skin (lower 
leg) 
29.412 
Skin 
(suprapubic) 
29.038 
Adipose 
subcutaneous 
27.39 Breast 26.096 15.595 
RYR2 
Heart left 
ventricle 
59.672 
Heart Atrial 
Appendage 
41.144 
Brain 
Cerebellum 
10.354 
Brain Cerebelar 
Hemisphere 
9.958 Artery Tibial 5.87 1.079 
SYT8 
Skin (lower 
leg) 
37.917 
Skin 
(suprapubic) 
31.356 Bladder 23.449 
Esophagus 
mucosa 
14.949 
Minor salivary 
gland 
4.765 0.252 
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Supplementary Table S14. Mutational spectrum of somatic alterations of TGCT in TCGA 
    
Gene Nº Samples Impact effect Somatic mutations identified 
ERCC4 0 0           
PLEC 
10 
Missense (9) & 
1Truncating A2519D W4315C L3517M P3538T E1295G L3934Q R3981H G3572S R571W E1609Rfs*50 
GRP 
2 
Missense & 
frameshift 
deletion A23S R22Efs*13          
LRP4 2 Missense T43N R281H         
TNXB 4 Missense M2636V V451F L43M S2751L      
TAF1L 1 Missense R873C          
KIF18A 0 0           
BRD4 2 Missense R453C I1008T         
LBP 0 0           
EXO5 0 0           
DHX34 0 0           
PSRC1 0 0           
H1FNT 1 Missense R185G          
CCR5 0 0           
BZRAP1 1 Nonsense S1255*         
GPRC6A 0 0           
BCHE 0 0           
SLC22A16 1 Missense T207N          
SBF1 1 Missense T96K          
DNAH7 1 Missense T3106N         
NOTCH3 4 Missense R1893Q R1014H T445R Q1552R      
ADAM8 0 0           
RECQL4 2 Missense S750R P419L         
VNN1 1 Missense L380I          
DCLRE1C 2 
Missense/ 
inframe deletion K494R V202del         
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Supplementary Table S15. Representation of the variants in the different subtypes of TGCT in the TGCA. 
 
Gene Existing variant 
Presence of alternative allele Absence of alternative allele 
Seminoma Mixed Non seminoma Seminoma Mixed No seminoma 
ERCC4_V1 rs1800067 38 10 25 147 33 86 
ERCC4_V2 rs1800124 10 4 8 184 44 104 
PLEC rs138924815 13 - 10 165 46 98 
GRP rs149962068 24 3 12 179 47 103 
LRP4 rs118009068 15 2 8 176 46 103 
TNXB - 14 3 12 189 47 106 
TAF1L_V5 rs35905429 10 2 5 158 39 89 
KIF18A rs34913484 11 3 4 174 45 108 
BRD4 rs35676845 9 1 3 167 40 101 
LBP rs2232607 8 4 5 189 45 109 
EXO5 rs150018949 10 1 6 185 48 107 
DHX34 rs151213663 12 4 9 188 46 108 
PSRC1 rs76057315 4 2 1 181 44 107 
H1FNT rs117292373 10 1 6 167 40 95 
CCR5 rs1799863 8 3 7 177 41 101 
BZRAP1 rs3744098 3 2 3 187 48 109 
GPRC6A - 16 5 9 169 36 97 
BCHE rs1799807 8 3 4 178 44 106 
SLC22A16 rs75035916 4 1 1 200 49 113 
SBF1 rs199972466 2 4 1 180 40 107 
DNAH7 rs144390858 6 1 3 163 39 90 
SLC22A16 rs41288594 1 2 5 196 48 109 
NOTCH3 rs115582213 4 0 5 189 47 106 
ADAM8 rs36054052 2 1 2 178 43 101 
RECQL4 rs199654783 2 1 1 202 49 113 
VNN1 rs189034822 1 2 1 192 46 108 
DCLRE1C rs41297018 6 0 2 179 45 109 
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Supplementary Table S16. Variants of our WES approach located in the already describe loci (Table1) 
     
Families Gene Chromosome Existing variant Allele frequency 
4 
ATP1B3 chr3 - 0,203 
CLPTM1L chr5 rs5865369 0,232 
3 
ZFPM1 chr16 rs35613341 0,261 
CATSPER3 chr5 rs299364 0,145 
2 
ATF7IP chr12 rs2231909 0,145 
ATP1B3 chr3 rs72988233 0,101 
DMRT1 chr9 rs55905583 0,087 
HNF1B chr17 rs2269842 0,145 
HNF1B chr17 rs3216929 0,217 
RAD51C chr17 rs12946397 0,072 
TERT chr5 rs79662648 0,087 
1 
ATP1B3 chr3 rs11844 0,072 
CENPE chr4 rs4698879 0,087 
DAZL chr3 rs149243225 0,043 
DAZL chr3 rs148790587 0,043 
DMRT1 chr9 rs200423545 0,043 
DMRT1 chr9 rs79358387 0,043 
GAB2 chr11 - 0,043 
GSPT1 chr16 TMP_ESP_16_12009531_12009539 0,087 
HEATR3 chr16 rs7192665 0,058 
HEATR3 chr16 rs6500280 0,087 
HEATR3 chr16 rs7191384 0,072 
HNF1B chr17 rs2107133 0,145 
HNF1B chr17 rs8068014 0,043 
HPGDS chr4 rs77546017 0,043 
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1 
HPGDS chr4 rs34124298 0,043 
PPM1E chr17 rs16943326 0,072 
RFWD3 chr16 rs78219119 0,087 
SSR3 chr3 rs144621829 0,029 
SSR3 chr3 rs6764265 0,043 
SSR3 chr3 rs6764992 0,043 
SSR3 chr3 rs71141714 0,043 
SSR3 chr3 rs71310479 0,043 
SSR3 chr3 rs201862950 0,058 
SSR3 chr3 - 0,043 
TERT chr5 rs35311994 0,058 
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